



Cochrane
Library

Cochrane Database of Systematic Reviews

Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse (Review)

Temmingh HS, Williams T, Siegfried N, Stein DJ

Temmingh HS, Williams T, Siegfried N, Stein DJ.

Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse.

Cochrane Database of Systematic Reviews 2018, Issue 1. Art. No.: CD011057.

DOI: [10.1002/14651858.CD011057.pub2](https://doi.org/10.1002/14651858.CD011057.pub2).

www.cochranelibrary.com

Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse (Review)

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

TABLE OF CONTENTS

ABSTRACT	1
PLAIN LANGUAGE SUMMARY	2
SUMMARY OF FINDINGS	4
BACKGROUND	11
Figure 1.	12
Figure 2.	13
OBJECTIVES	14
METHODS	14
RESULTS	20
Figure 3.	21
Figure 4.	25
Figure 5.	26
DISCUSSION	30
AUTHORS' CONCLUSIONS	32
ACKNOWLEDGEMENTS	32
REFERENCES	34
CHARACTERISTICS OF STUDIES	43
DATA AND ANALYSES	60
Analysis 1.1. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 1 Mental state: 1. General: average endpoint scores (PANSS subscale, lower=better).	63
Analysis 1.2. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 2 Mental state: 2. General: any change in general symptoms:.	63
Analysis 1.3. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 3 Mental state: 3. Specific: positive, negative symptoms - average endpoint scores (PANSS subscales, lower = better):.	64
Analysis 1.4. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 4 Mental state: 4. Specific: anxiety symptoms.	64
Analysis 1.5. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 5 Substance use.	64
Analysis 1.6. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 6 Subjective Well-being: average endpoint scores (Subjective Well-being under Neuroleptics scale, SWN scale, higher=better).	65
Analysis 1.7. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 7 Craving for substances.	65
Analysis 1.8. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 8 Adherence to antipsychotic medication: discontinued medication.	66
Analysis 1.9. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 9 Adverse effects: 1. Movement disorders.	66
Analysis 1.10. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 10 Adverse effects: 2. Non-movement disorder related side-effects.	66
Analysis 1.11. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 11 Leaving the study early.	69
Analysis 2.1. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 1 Mental state: 1. Specific: Depression- change scores (HAM-D, higher = better), short term (up to 6 months).	72
Analysis 2.2. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 2 Mental state: 2. Specific: Positive symptoms, total score- average endpoint scores (SADS-C-PD scale, lower=better), short term (up to 6 months).	72
Analysis 2.3. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 3 Mental state: 3. Specific: Positive symptom subscales- average endpoint scores (SADS-C-PD subscores, lower=better), short term (up to 6 months)- skewed data.	72
Analysis 2.4. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 4 Mental state: 4. Specific: Negative symptoms, subscales- average endpoint scores (SANS subscales, lower=better), short term (up to 6 months).	72
Analysis 2.5. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 5 Substance use: 1. Reduction of cannabis use-change data (number of joints smoked/week, LOCF data, higher =better)- short term data (up to 6 months).	73
Analysis 2.6. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 6 Substance use: 2. Discontinued substance use, short term (up to 6 months).	73
Analysis 2.7. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 7 Craving for substances: 1. Obsessive Compulsive Drug Use Scale- average endpoint score (OCDUS, lower=better)-short term (up to 6 months).	74

Analysis 2.8. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 8 Craving for substances: 2. Desires for Drug Questionnaire- average endpoint scores (DDQ, LOCF data, lower=better), short term (up to 6 months).	74
Analysis 2.9. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 9 Adverse effects.	74
Analysis 2.10. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 10 Leaving study early: 1. Various reasons.	75
Analysis 2.11. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 11 Leaving study early: 2. Weeks in the study- average endpoint data (high=good), short term (up to 6 months).	76
Analysis 2.12. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 12 Leaving study early: 3. Weeks in study- average endpoint data (high=good), short term (up to 6 months)- skewed data.	76
Analysis 3.1. Comparison 3 RISPERIDONE versus PERPHENAZINE, Outcome 1 Leaving the study early: all cause discontinuation, long term (>12 months).	76
Analysis 4.1. Comparison 4 RISPERIDONE versus QUETIAPINE, Outcome 1 Leaving the study early: all cause discontinuation, long term (>12 months).	77
Analysis 5.1. Comparison 5 RISPERIDONE versus ZIPRASIDONE, Outcome 1 Leaving the study early: all cause discontinuation, long term (>12 months).	77
ADDITIONAL TABLES	77
APPENDICES	84
WHAT'S NEW	84
CONTRIBUTIONS OF AUTHORS	84
DECLARATIONS OF INTEREST	85
SOURCES OF SUPPORT	85
DIFFERENCES BETWEEN PROTOCOL AND REVIEW	85
INDEX TERMS	86

[Intervention Review]

Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse

Henk S Temmingh¹, Taryn Williams¹, Nandi Siegfried^{1,2}, Dan J Stein¹

¹Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. ²Alcohol, Tobacco and Other Drug Research Unit, South African Medical Research Council, Tygerberg, South Africa

Contact: Henk S Temmingh, Department of Psychiatry and Mental Health, University of Cape Town, Valkenberg Hospital, Private Bage X1, Cape Town, Western Cape, 7935, South Africa. henk.temmingh@gmail.com, henk.temmingh@uct.ac.za.

Editorial group: Cochrane Schizophrenia Group.

Publication status and date: Edited (no change to conclusions), published in Issue 2, 2018.

Citation: Temmingh HS, Williams T, Siegfried N, Stein DJ. Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse. *Cochrane Database of Systematic Reviews* 2018, Issue 1. Art. No.: CD011057. DOI: [10.1002/14651858.CD011057.pub2](https://doi.org/10.1002/14651858.CD011057.pub2).

Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

ABSTRACT

Background

Up to 75% of people with serious mental illness (SMI) such as schizophrenia and bipolar disorder have co-occurring substance use disorders (dual diagnosis). Dual diagnosis can have an adverse effect on treatment and prognosis of SMI.

Objectives

To evaluate the effects of risperidone compared to treatment with other antipsychotics (first-generation and other second-generation antipsychotics) used in people with serious mental illness and co-occurring substance misuse.

Search methods

On 6 January 2016 and 9 October 2017, we searched the Cochrane Schizophrenia Group's Study-Based Register of Trials (including trial registers).

Selection criteria

We selected randomised trials of risperidone versus any other antipsychotic in people with SMI and substance abuse (dual diagnosis). We included trials meeting our inclusion criteria and reporting useable data. We excluded trials that either did not meet our inclusion criteria or met our inclusion criteria but did not report any useable data.

Data collection and analysis

We independently inspected citations and selected studies. For included studies, we independently extracted data and appraised study quality. For binary outcomes we calculated the risk ratios (RRs) and their 95% confidence intervals. For continuous outcomes we calculated the mean differences (MDs) and their 95% confidence intervals. We pooled data using random-effects meta-analyses and assessed the quality of evidence, creating a 'Summary of findings' table using the GRADE approach.

Main results

We identified eight randomised trials containing a total of 1073 participants with SMI and co-occurring substance misuse. Seven of these contributed useable data to the review. There was heterogeneity in trial design and measurement. Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone. Few trials compared risperidone with first-generation agents. Few trials examined participants with a dual diagnosis from the outset and most trials only contained separate analyses of subgroups with a dual diagnosis or were secondary data analyses of subgroups of people with a dual diagnosis from existing larger trials.

For risperidone versus clozapine we found no clear differences between these two antipsychotics in the reduction of positive psychotic symptoms (1 randomised controlled trial (RCT), $n = 36$, mean difference (MD) 0.90, 95% CI -2.21 to 4.01, *very low quality evidence*), or reduction in cannabis use (1 RCT, $n = 14$, risk ratio (RR) 1.00, 95% CI 0.30 to 3.35, *very low quality evidence*), improvement in subjective well-being (1 RCT, $n = 36$, MD -6.00, 95% CI -14.82 to 2.82, *very low quality evidence*), numbers discontinuing medication (1 RCT, $n = 36$, RR 4.05, 95% CI 0.21 to 78.76, *very low quality evidence*), extrapyramidal side-effects (2 RCTs, $n = 50$, RR 2.71, 95% CI 0.30 to 24.08; $I^2 = 0\%$, *very low quality evidence*), or leaving the study early (2 RCTs, $n = 45$, RR 0.49, 95% CI 0.10 to 2.51; $I^2 = 34\%$, *very low quality evidence*). Clozapine was associated with lower levels of craving for cannabis (1 RCT, $n = 28$, MD 7.00, 95% CI 2.37 to 11.63, *very low quality evidence*).

For risperidone versus olanzapine we found no clear differences in the reduction of positive psychotic symptoms (1 RCT, $n = 37$, MD -1.50, 95% CI -3.82 to 0.82, *very low quality evidence*), reduction in cannabis use (1 RCT, $n = 41$, MD 0.40, 95% CI -4.72 to 5.52, *very low quality evidence*), craving for cannabis (1 RCT, $n = 41$, MD 5.00, 95% CI -4.86 to 14.86, *very low quality evidence*), parkinsonism (1 RCT, $n = 16$, MD -0.08, 95% CI -1.21 to 1.05, *very low quality evidence*), or leaving the study early (2 RCT, $n = 77$, RR 0.68, 95% CI 0.34 to 1.35; $I^2 = 0\%$, *very low quality evidence*).

For risperidone versus perphenazine, we found no clear differences in the number of participants leaving the study early (1 RCT, $n = 281$, RR 1.05, 95% CI 0.92 to 1.20, *low-quality evidence*).

For risperidone versus quetiapine, we found no clear differences in the number of participants leaving the study early (1 RCT, $n = 294$, RR 0.96, 95% CI 0.86 to 1.07, *low-quality evidence*).

For risperidone versus ziprasidone, we found no clear differences in the number of participants leaving the study early (1 RCT, $n = 240$, RR 0.96, 95% CI 0.85 to 1.10, *low-quality evidence*).

For many comparisons, important outcomes were missing; and no data were reported in any study for metabolic disturbances, global impression of illness severity, quality of life or mortality.

Authors' conclusions

There is not sufficient good-quality evidence available to determine the effects of risperidone compared with other antipsychotics in people with a dual diagnosis. Few trials compared risperidone with first-generation agents, leading to limited applicability to settings where access to second-generation agents is limited, such as in low- and middle-income countries. Moreover, heterogeneity in trial design and measurement of outcomes precluded the use of many trials in our analyses. Future trials in this area need to be sufficiently powered but also need to conform to consistent methods in study population selection, use of measurement scales, definition of outcomes, and measures to counter risk of bias. Investigators should adhere to CONSORT guidelines in the reporting of results.

PLAIN LANGUAGE SUMMARY

Risperidone versus other antipsychotics for people with dual diagnosis of a psychiatric disorder and an alcohol or drug use disorder

What is dual diagnosis?

Dual diagnosis is a term used to describe people who have both a psychiatric disorder and an alcohol or drug use disorder. Up to 75% of people with a serious mental illness (SMI) are dual diagnosis. It has been suggested that one of the reasons behind the high levels of substance use in people with SMI is due to 'self-medication', with patients taking additional drugs in order to counter their distressing symptoms. People with a dual diagnosis have been shown to have more complications in their treatment, including higher rates of relapse and re-hospitalisation, more contact with legal and forensic services, higher levels of psychotic symptoms, more risk-taking behaviour, greater levels of side-effects to antipsychotics and lower medication adherence. Antipsychotics are the main treatment for SMI. It has been suggested that second-generation antipsychotics (SGAs) such as risperidone may be superior to older, first-generation antipsychotics (FGAs) in improving negative affective states, reducing drug craving, improving subjective well-being, and may lead to fewer side-effects and hence greater medication adherence. Such improvements in symptoms may lead to less self-medication with alcohol and drugs, and improved overall mental states. However it remains unclear to what extent risperidone, one of the first atypical antipsychotics to be manufactured, is superior to other antipsychotics for dual diagnosis.

Who may be interested in this review?

Mental health care practitioners who treat people with SMI and dual diagnosis, and who prescribe antipsychotics for these conditions. People who use mental health services and their families who may be involved in their treatment and care.

What does this review aim to answer?

How effective and safe is risperidone compared to other antipsychotics for treating people with a dual diagnosis?

Which studies were included in the review?

We conducted searches for relevant randomised studies in January 2016 and October 2017. We found eight randomised controlled trials with 1073 participants who had a dual diagnosis. The majority of participants were adults over 18 years (4 participants were 17 years). Risperidone was compared to clozapine, olanzapine, perphenazine, quetiapine and ziprasidone.

What does the evidence from the review tell us?

We found no great effect favouring risperidone over any of the other comparison medications. Very limited data were available for side-effects; and again, we found no real differences between risperidone and other antipsychotics. Overall the quality of the evidence available was graded as low to very low, and currently there is not sufficient evidence to indicate risperidone is superior or inferior to other antipsychotics in the treatment of people with severe mental illness and co-occurring substance misuse.

What should happen next?

More high-quality research is needed. Future research should include samples sufficiently large to detect meaningful clinical differences in outcomes.

SUMMARY OF FINDINGS

Summary of findings for the main comparison. RISPERIDONE versus CLOZAPINE - all data short term for people with severe mental illness and co-occurring substance misuse

RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months) for people with severe mental illness and co-occurring substance misuse

Patient or population: for people with serious mental illness and co-occurring substance misuse

Setting:

Intervention: Risperidone

Comparison: Clozapine

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	N° of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with Clozapine	Risk with Risperidone				
Mental state: positive symptoms – average endpoint score (PANSS positive subscale, lower = better)		The mean positive symptoms (PANSS positive subscale, lower = better) in the intervention group was 0.9 higher (2.21 lower to 4.01 higher)	-	36 (1 RCT)	⊕⊕⊕⊕ very low ^{1 2}	No trial reported "improvement in symptoms of severe mental illness" – this continuous measure is the nearest proxy for this.
Substance use: improvement – (at least 20% reduction in use, TLFB scale)	Study population		RR 1.00 (0.30 to 3.35)	14 (1 RCT)	⊕⊕⊕⊕ very low ^{3 4}	
	429 per 1000	429 per 1000 (129 to 1000)				
	Moderate					
	429 per 1000	429 per 1000 (129 to 1000)				
Subjective well-being: Subjective well-being under neuroleptics scale – average endpoint scores (SWN scale, higher = better)		The mean subjective well-being under neuroleptics scale score (SWN scale, higher = better) in the intervention group was 6 lower (14.82 lower to 2.82 higher)	-	36 (1 RCT)	⊕⊕⊕⊕ very low ^{1 2}	

Craving for substances: Marijuana Craving Questionnaire – average endpoint scores (MCQ, lower = better)	The mean craving for substances score on the Marijuana Craving Questionnaire (MCQ, lower = better) in the intervention group was 7 higher (2.37 higher to 11.63 higher)		-	28 (1 RCT)	⊕○○○ very low ^{1 2}		
Adherence to antipsychotic medication: discontinued medication	Study population		RR 4.05 (0.21 to 78.76)	36 (1 RCT)	⊕○○○ very low ^{1 2}		
	0 per 1000	0 per 1,000 (0 to 0)					
	Moderate						
	0 per 1,000	0 per 1,000 (0 to 0)					
Adverse effects. 1. Movement disorders - any extrapyramidal	Study population		RR 2.71 (0.30 to 24.08)	50 (2 RCTs)	⊕○○○ very low ^{5 6}	Many adverse effects reported – none designated 'clinically important' (extrapyramidal used as proxy).	
	0 per 1000	0 per 1000 (0 to 0)					
	Moderate						
	0 per 1000	0 per 1000 (0 to 0)					
Leaving the study early – any reason	Study population		RR 0.49 (0.10 to 2.51)	45 (2 RCTs)	⊕○○○ very low ^{5 6}		
	318 per 1000	156 per 1000 (32 to 799)					
	Moderate						
	386 per 1000	189 per 1000 (39 to 968)					

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; **RR:** Risk ratio; **OR:** Odds ratio

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

- 1 High risk of performance bias and detection bias
- 2 Sample size is very small, optimal information size (OIS) not met to detect 25% difference
- 3 Performance bias, attrition bias, selective outcome reporting
- 4 Sample size is very small (n = 14)
- 5 High risk of performance bias, detection bias, attrition bias and selective outcomes reporting
- 6 Total sample size is very small (n<300), total event rate is very low and optimum information size (OIS) is not met

Summary of findings 2. RISPERIDONE versus OLANZAPINE – short- and long-term data for people with severe mental illness and co-occurring substance misuse

RISPERIDONE versus OLANZAPINE- all data short term (up to 6 months) for people with severe mental illness and co-occurring substance misuse

Patient or population: people with serious mental illness and co-occurring substance misuse

Setting: In and outpatients, United States

Intervention: Risperidone

Comparison: Olanzapine

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with Olanzapine	Risk with Risperidone				
Mental state: 2. Specific-Positive symptoms, total score- average endpoint scores (SADS-C-PD scale, lower = better)		The mean positive symptoms total score at endpoint (SADS-C-PD scale, lower = better) in the intervention group was 1.5 lower (3.82 lower to 0.82 higher)	-	37 (1 RCT)	⊕⊕⊕⊕ very low ^{1 2}	
Substance use: 1. Reduction of cannabis use-change data (number of joints smoked/ week)		The reduction of cannabis joints smoked (number of joints smoked/week-short term data, up to 6 months) in the intervention group was 0.4 higher (4.72 lower to 5.52 higher)	-	41 (1 RCT)	⊕⊕⊕⊕ very low ^{3 4}	
Subjective well-being			-	-	-	No trial reported on this important outcome for par-

					participants with a co-occurring substance use disorder
Craving for substances: 2. Drug Desires Questionnaire- average endpoint scores (DDQ, lower = better)	The mean endpoint. Drug Desires Questionnaire- endpoint scores (DDQ, lower = better), short term, up to 6 months-in the intervention group was 5 higher (4.86 lower to 14.86 higher)	-	41 (1 RCT)	⊕⊕⊕⊕ very low ^{2 3}	
Adherence to antipsychotic medication: number of missed doses, average endpoint data, short term (up to 6 months)	-	-	-	-	no useable data available for this outcome
Adverse effects: Parkinsonism - average endpoint score (SAS, high = worse)	The mean adverse effects: - Parkinsonism- average endpoint score (SAS, high = worse)- short-term- up to 6 months in the intervention group was 0.08 lower (1.21 lower to 1.05 higher)	-	16 (1 RCT)	⊕⊕⊕⊕ very low ^{2 5}	
Leaving study early: any reason	Study population	RR 0.68	77 (2 RCTs)	⊕⊕⊕⊕ very low ^{4 6}	
	357 per 1000 243 per 1000 (121 to 482)				
	Moderate				
	411 per 1000 279 per 1000 (140 to 554)				

***The risk in the intervention group** (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; **RR:** Risk ratio; **OR:** Odds ratio;

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect

- 1 High risk for performance bias, allocation concealment, unknown risk for attrition and selective reporting
- 2 Very low sample size, optimal information size (OIS) not met
- 3 High risk of attrition bias, study sponsored by pharmaceutical industry
- 4 Very low sample size, optimal information criterion not met, CI crosses both appreciable harm and benefit
- 5 High attrition risk, high other risk of funding by pharmaceutical industry, all other risk items unclear risk of bias
- 6 High risk of performance, attrition and funding bias. Several domains with unclear risk of bias

Summary of findings 3. RISPERIDONE versus PERPHENAZINE – long-term data for people with severe mental illness and co-occurring substance misuse

RISPERIDONE versus PERPHENAZINE-long term data (>12 months) for people with severe mental illness and co-occurring substance misuse

Patient or population: people with severe mental illness and co-occurring substance misuse

Setting: Outpatients, United States

Intervention: RISPERIDONE

Comparison: PERPHENAZINE

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with PERPHENAZINE	Risk with RISPERIDONE				
Leaving the study early: any reason	Study population		RR 1.05 (0.92 to 1.20)	281 (1 RCT)	⊕⊕○○ low 1 2	
	750 per 1000	788 per 1000 (690 to 900)				
	Moderate					
	750 per 1000	788 per 1000 (690 to 900)				

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

- 1 High risk of attrition bias, but this does not affect this particular outcomes
2 Optimal information size criterion is met but the estimate includes no effect with both appreciable harm and benefit

Summary of findings 4. RISPERIDONE versus QUETIAPINE – short- and long-term data for people with severe mental illness and co-occurring substance misuse

RISPERIDONE versus QUETIAPINE- short and long term data (up to 6months and > 12 months) for people with severe mental illness and co-occurring substance misuse

Patient or population: people with severe mental illness and co-occurring substance misuse
Setting: Outpatients, United States
Intervention: RISPERIDONE
Comparison: QUETIAPINE

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	Nº of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with QUETIAPINE	Risk with RISPERIDONE				
Leaving the study early: 1. any reason, long term (>12 months)	Study population		RR 0.96 (0.86 to 1.07)	294 (1 RCT)	⊕⊕○○ low ^{3 4}	
	825 per 1000	792 per 1000 (709 to 883)				
	Moderate					
	825 per 1000	792 per 1000 (709 to 883)				

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

- 1 Risk of bias unclear across all groups and with high risk of funding bias
2 Sample size meets optimal information threshold/ required sample size to detect 25% difference from control group in in PANSS score; at alpha of 0.05 and power of 80%.
3 Outcome not affected by risk of attrition bias

4 Optimal information criterion not met, estimate includes both appreciable harm and benefit

Summary of findings 5. RISPERIDONE versus ZIPRASIDONE – long-term data (> 12 months) for people with severe mental illness and co-occurring substance misuse

RISPERIDONE versus ZIPRASIDONE- all data long term data (>12 months) for people with severe mental illness and co-occurring substance misuse

Patient or population: people with severe mental illness and co-occurring substance misuse

Setting: Outpatients, United States

Intervention: RISPERIDONE

Comparison: ZIPRASIDONE

Outcomes	Anticipated absolute effects* (95% CI)		Relative effect (95% CI)	N° of participants (studies)	Quality of the evidence (GRADE)	Comments
	Risk with ZIPRASIDONE	Risk with RISPERIDONE				
Leaving the study early: any reason	Study population		RR 0.96 (0.85 to 1.10)	240 (1 RCT)	⊕⊕⊕⊖ low 1 2	
	819 per 1000	787 per 1000 (696 to 901)				
	Moderate					
	819 per 1000	787 per 1000 (696 to 901)				

*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the **relative effect** of the intervention (and its 95% CI).

CI: Confidence interval; RR: Risk ratio; OR: Odds ratio;

GRADE Working Group grades of evidence

High quality: We are very confident that the true effect lies close to that of the estimate of the effect

Moderate quality: We are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different

Low quality: Our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect

Very low quality: We have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect

1 Risk of attrition bias high but this does not affect this outcome

2 Optimal information size criterion met but estimate includes both appreciable harm and benefit. Total sample size small

BACKGROUND

Description of the condition

Serious mental illness is characterised by severe and persisting psychiatric disorder associated with significant functional impairment, and includes disorders such as schizophrenia and bipolar disorder, but is not limited to these conditions (Ruggeri 2000). The prevalence of serious mental illness varies according to survey methods and has been reported to range from 0.4% to 7.7% between different countries (Demyttenaere 2004).


Comorbid substance use frequently occurs in people with severe mental illness such as schizophrenia and major affective disorders. The terms 'dual diagnosis' and more recently 'co-occurring disorders' have been used to describe persons who have a diagnosis of both a severe mental illness and a drug or alcohol use disorder (Buckley 2006). Depending on the sample, population and assessment method, prevalence rates of drug and alcohol use disorders in persons with serious mental illness have been reported to vary from 25% to 74% in developed countries (Barnett 2007; Fioritti 1997; Fowler 1998; Jablensky 2000; Kessler 2004; Lambert 2005; Menezes 1996; Modestin 1997; Regier 1990; Soyka 1993; van Mastrigt 2004). The prevalence of co-occurring substance use disorders in persons with severe mental illness from low- and middle-income countries has been found to be in a similar range, with some studies reporting prevalence rates of 51% and up to 68% (Hauli 2011; Weich 2009). Patients participating in studies investigating the use of atypical antipsychotics such as risperidone in the treatment of dual diagnosis have a variety of substance use disorder diagnoses including cocaine, cannabis, opioid and

alcohol use disorders; and most have a mental illness diagnosis of schizophrenia or schizoaffective disorder (Kelly 2012; Stuyt 2006). Comorbidity adversely affects the treatment and prognosis of both drug use disorders and mental illness. In comparison to people without substance use disorders, persons with a dual diagnosis have been reported to have higher levels of positive psychotic symptoms (Katz 2010), shorter time to relapse, higher rates of readmission to hospital, lower remission rates (Lambert 2005; Swofford 1996; Wade 2006), higher levels of medication non-compliance (Ascher-Svanum 2006; Lacro 2002; Owen 1996), and worse clinical outcomes (Lambert 2005). In addition, dual diagnosis patients with psychotic or manic symptoms treated with antipsychotics are more susceptible to extrapyramidal side-effects such as akathisia (Salyers 2001).

Description of the intervention

Risperidone is an antipsychotic medication described as a serotonergic and dopaminergic antagonist (SDA) (Horacek 2006, Figure 1). It was the first medication in the second-generation class of antipsychotics (SGAs), also described as 'atypical' antipsychotics, to be synthesised (Moller 2005). Risperidone is an antagonist on dopamine type 2 (D₂) receptors, and has an even higher affinity for serotonin type 2A receptors, where it also acts as an antagonist (Janssen 1988). These properties result in a relatively low propensity to induce extrapyramidal side-effects when compared with first-generation antipsychotics (FGAs) or 'typical' antipsychotics such as haloperidol (Hunter 2003). Important non-neurological side-effects include a higher risk of weight gain compared with certain typical and other atypical antipsychotics (Newcomer 2007).

Figure 1. Risperidone



Risperidone is available in an oral as well as a long-acting injectable formulation (Fleischhacker 2003; Moller 2007). There are no specific recommendations for any particular type of antipsychotic medication to be used preferentially in the dual diagnosis population, and it has been recommended that the same guidance for persons with only a single severe mental illness diagnosis be used in persons with a dual diagnosis (NICE 2011). Accordingly, some treatment guidelines recommend that second-generation — or 'atypical' — antipsychotics such as risperidone be considered as potential first-line treatment for persons with a first episode of psychosis and schizophrenia, following discussion with patients and their caregivers (Hasan 2012; Hasan 2013; Lehman 2004; NICE 2009).

How the intervention might work

A number of findings from pre-clinical and clinical studies have suggested various mechanisms and effects through which second-generation antipsychotics may result in improved outcomes in the treatment of dual diagnosis.

1. Preclinical studies have shown that risperidone blocks cocaine-induced dopamine and serotonin release in the nucleus accumbens in the rat brain, and reduces locomotion and stereotypical behaviour in rats (Broderick 2003; Tsibulsky 1998). In turn, treatment of humans with atypical antipsychotics such as risperidone, which act antagonistically on both serotonergic and dopaminergic receptors, may translate to a


reduction of conditioned responses such as cue-elicited craving mediated via dopamine release. This may consequently lead to lower levels of drug use (Drevets 2001; Smelson 1997; Volkow 2006). In addition, research in rats has demonstrated increased sensitivity to cocaine-induced hyper-locomotion and increased conditioned place preference following withdrawal from haloperidol, but not from the atypical agent ziprasidone. This serves as a model of dopamine supersensitivity and induced craving which is potentially analogous to situations of non-compliance with antipsychotic medication in humans (Fukushiro 2007; Fukushiro 2008). Treatment non-compliance is a phenomenon that can occur in up to three-quarters of people treated with antipsychotics (Lieberman 2005).

2. Despite the acute reinforcing effects of drug use via increased dopamine release during the early phases of addiction, neuro-imaging studies in persons with drug dependence have demonstrated lower concentrations of dopaminergic receptors following chronic use (Volkow 1997; Volkow 2007). Lower dopamine receptor concentration may be due to persistently increased dopamine release in the nucleus accumbens induced by drugs of abuse (Kuhar 1996). In turn, increased craving has been associated with lower dopamine receptor levels during protracted withdrawal (Volkow 2011). Consequently, in comparison to drugs with a lower affinity for D₂ receptors such as risperidone, drugs with a high affinity for dopamine receptors, such as the first-generation antipsychotics, may exacerbate or

- prolong hypodopaminergic states leading to increased drug craving (Siris 1990).
- Craving has been shown to be an important predictor of relapse into substance use (Sinha 2006; Sinha 2011). Uncontrolled trials have demonstrated a decrease in craving and drug use in persons treated with risperidone (Smelson 2002). Consequently, the use of risperidone may result in lower scores on craving measures (Rosenberg 2009), and consequently decreased drug use.
 - Results from uncontrolled clinical trials have shown lower levels of psychotic symptoms and depression in persons treated with risperidone when compared to first-generation antipsychotics (Smelson 1997; Smelson 2002). Risperidone also acts on the serotonergic system by means of 5HT_{2A} receptor antagonism, which may in turn mediate its antidepressant effect (McIntyre 2007; Sajatovic 2002; Yatham 2005). This may affect the 5HT_{1A} system resulting in fewer depressive symptoms and improved cognitive symptoms in persons with serious mental illness such as schizophrenia (Kuroki 2008; Sajatovic 2002). Altogether, these effects may translate into improved ratings on measures of psychosis, mood and quality of life in persons treated with risperidone (Smelson 2002).
 - Clinical studies have demonstrated comparatively lower rates of extrapyramidal side-effects in participants treated with risperidone (Hunter 2003). As people with dual diagnosis have been shown to be more sensitive to the neurological side-effects of neuroleptic drugs (Potvin 2009; Salyers 2001), the low propensity of risperidone to induce extrapyramidal side-effects offers a potentially favourable side-effect profile. This may result in improved adherence (Perkins 2002; Perkins 2006); and consequently lower rates of symptom re-emergence and of relapse into illness (Sun 2007).
 - It has been postulated that one of the properties that differentiate atypical antipsychotics from typical antipsychotics may be their lower affinity for D₂ receptors and higher affinity for 5HT_{2A} receptors (Seeman 2002). However, it remains uncertain to what extent potent 5HT_{2A} receptor-antagonism is responsible for the 'atypical features' of SGAs, given alternative theories of D₂ receptor binding profiles and dissociation rates conferring "atypicality" (Kapur 1995; Kapur 1996; Kapur 2001; Seeman 2002; Tort 2006). In addition, higher levels of D₂ receptor occupancy in the context of neuroleptic treatment has also been associated with lower levels of subjective well-being (de Haan 2000). Second-generation agents such as risperidone that have lower D₂ receptor occupancy rates (and higher dissociation rates), therefore have a more favourable profile in that they have been demonstrated to produce higher levels of subjective well-being, and are associated with less negative affective states and anhedonia compared to first-generation, typical medications (Smelson 2002; Vothknecht 2011). Therefore, the degree of D₂ binding and D₂ receptor dissociation of antipsychotics may have a differential impact on measures used to assess subjective well-being. However, within the class of serotonin dopamine antagonists various agents differ in their degree of D₂ receptor affinity and dissociation, with clozapine and olanzapine having the lowest affinities (and highest dissociation rates) and risperidone having higher D₂ affinity. Therefore uncertainty remains as to how medications such as risperidone, that differ only marginally from FGAs with regards to D₂ receptor-binding profiles (Seeman 2002), offer additional benefit over typical agents.

Figure 2 contains a diagram of a model within a Baxter 2010 logic framework, outlining the relationship between antipsychotic treatment with risperidone, potential effect modifiers and the final target clinical outcomes in a complex causal pathway.

Figure 2. Logic framework model with potential causal pathways: risperidone treatment in persons with dual diagnosis.



Why it is important to do this review

Despite preclinical animal studies and observational research in humans, there remains a paucity of randomised trials on the efficacy of risperidone compared with other antipsychotics in the treatment of people with a dual diagnosis. In fact, most randomised controlled trials that investigate the efficacy of risperidone in the treatment of serious mental disorders such as schizophrenia have excluded people with comorbid drug or alcohol use disorders (Hunter 2003). As comorbid drug and alcohol use disorders occur commonly in people with severe mental illness, it is important to evaluate the impact of risperidone on drug use and symptom control, as well as on other functional outcomes in people with dual diagnosis. Moreover other atypical medications such as olanzapine and clozapine, that have higher D₂ receptor dissociation rates and greater activity on D₁ receptors (Seeman 2002; Tort 2006), have been postulated to reduce drug use to a greater extent compared to risperidone (Akerele 2007). This review aims to assess whether risperidone offers any additional advantage over FGAs or other SGAs in the treatment of people with serious mental illness and co-occurring substance misuse.

OBJECTIVES

To evaluate the effects of risperidone compared to treatment with other antipsychotics (first-generation and other second-generation antipsychotics) used in people with serious mental illness and co-occurring substance misuse.

METHODS

Criteria for considering studies for this review

Types of studies

We included randomised controlled trials (RCTs), in which risperidone was the antipsychotic treatment that was randomised. If a trial was described as 'double blind' but randomisation was implied, we included such trials after confirming randomisation with the study investigators. We excluded quasi-randomised studies, such as those allocating by alternate days of the week.

Types of participants

Adults, aged 17 to 65 years, with a severe mental illness and a co-occurring substance use disorder, where severe mental illness is defined to include the following disorders as diagnosed according to the method specified in each individual trial.

1. Schizophrenia, schizoaffective disorder, schizophreniform disorder.
2. Major affective disorders such as bipolar disorder and major depressive disorder with psychotic features.

Severe mental illness is defined to exclude the following disorders.

1. Organic mental disorders.
2. Moderate to severe intellectual disability.
3. Drug-induced mental disorders.
4. Personality disorders.
5. Non-severe mental disorders such as anxiety disorders, mild depression, and somatoform disorders.
6. Factitious disorders or malingering.

Co-occurring substance use disorder is diagnosed by any means or scale and includes:

1. alcohol or drug abuse or dependence.

Co-occurring substance use disorder is defined to exclude:

1. nicotine dependence, volatile solvent abuse or dependence, and caffeine use disorders, where the trial has been designed to primarily measure the impact of risperidone on these substance use disorders and related outcomes;
2. studies in which drug use was not classified as either abuse or dependence.

We included RCTs that compared treatment with risperidone with another antipsychotic in people with a dual diagnosis of severe mental disorder and a co-occurring substance use disorder.

We placed no restrictions on co-morbid conditions such as anxiety and depressive disorders.

As indicated in the description of the condition, the phenomenon of dual diagnosis is prevalent across various settings as reflected in data from a variety of studies. Therefore we included all settings, embracing those from both the developed and the developing world, as well as where dual diagnosis treatments were delivered in various models of care (such as integrated or parallel service models).

We included studies with participants in any clinical state or stage of illness.

Types of interventions

1. Experimental interventions

Treatment with risperidone in any formulation and any dose.

2. Comparator interventions

Any other antipsychotic, divided into first-generation ('typical') and second-generation ('atypical').

In addition to antipsychotic treatment, we included studies in which co-administration with a mood stabiliser (lithium, valproate, lamotrigine, carbamazepine, topiramate) or antidepressant (serotonin re-uptake inhibitors, tricyclic, tetracyclic or new generation anti-depressants) occurred in both treatment arms. Furthermore, studies comparing risperidone with another antipsychotic, where both treatment arms receive the same additional psychosocial intervention, were also included. Studies where only one treatment arm received an additional psychopharmacological or psychosocial intervention were excluded. Where imbalances exist between the treatment arms in terms of the dose, timing or duration of the additional treatments, we intended to note and discuss the impact of such imbalances in the section on assessment of risk of bias (Table 1).

Types of outcome measures

We categorised outcomes into short-term, medium-term and long-term outcomes. Short-term outcomes included outcomes measured in the first six months, medium-term outcomes include outcomes from six months to one year, and long-term outcomes include outcomes beyond one year.

Primary outcomes

1. Mental state

1.1 General

1.1.1 Clinically important change in general mental state – as defined by trial authors.

1.2 Specific symptoms

1.2.1 Clinically important change in positive symptoms – as defined by trial authors.

1.2.2 Clinically important change in negative symptoms – as defined by trial authors.

1.2.3 Clinically important change in anxiety symptoms – as defined by trial authors.

2. Substance use (determined according to how it was assessed, i.e. whether by means of self-report, or determined biochemically, either by positive urine or blood tests, or gas chromatography mass spectroscopy on hair follicles)

2.1 A reduction in substance use (drug or alcohol).

2.2 The presence or absence of drug or alcohol use at the end of the study follow-up period.

3. Adverse effects *

3.1 Clinically important adverse effect – as defined by trial authors.

* see [Differences between protocol and review](#)

Secondary outcomes

1. Mental state

1.1 General

1.1.1 Any change in general mental state – as defined by trial authors.

1.1.2 Average change/endpoint scores mental state scale.

1.1.3 Change in co-morbid psychopathology.

1.2 Specific symptoms

1.2.1 Any change in positive symptoms – as defined by trial authors.

1.2.2 Average change/endpoint scores positive mental state scale.

1.2.3 Any change in negative symptoms – as defined by trial authors.

1.2.4 Average change/endpoint scores negative mental state scale.

1.2.5 Average change/endpoint scores anxiety scale.

2. Substance use (determined according to how it was assessed, i.e. whether by means of self-report, or determined biochemically, either by positive urine or blood tests, or gas chromatography mass spectroscopy on hair follicles)

2.1 Time to relapse into drug or alcohol use.

2.2 Frequency of use over the study period.

3. Subjective well-being as measured by validated rating scales

3.1 Average endpoint/change scores on subjective well-being scales.

4. Craving for substances

4.1 Average endpoint/change scores on craving scales.

5. Adherence to antipsychotic medication

5.1 Average endpoint/change scores on medication adherence rating scales.

5.2 An improvement in adherence to antipsychotics – as defined by trial authors.

6. Adverse effects

6.1 Any general adverse effects.

6.2 Specific adverse effects.

6.2.1 Allergic reactions.

6.2.2 Blood dyscrasia such as agranulocytosis.

6.2.3 Central nervous system (ataxia, nystagmus, drowsiness, fits, diplopia, tremor).

6.2.4 Metabolic adverse events (weight changes, serum glucose measures, serum triglyceride measures, serum high density lipoprotein (HDL) measures).

6.2.5 Endocrinological dysfunction (hyperprolactinaemia, disturbance of reproductive organ and sexual performance functioning).

6.2.6 Gastrointestinal (nausea, vomiting, diarrhoea).

6.2.7 Kidney dysfunction.

6.2.8 Movement disorders (extrapyramidal side-effects, including neuroleptic malignant syndrome and tardive dyskinesia).

7. Leaving the study early

7.1 A reduction in numbers leaving study early: any reason.

7.2 A reduction in the proportion of participants lost to follow-up at the study end-point.

7.3 An increase in the proportion of participants attending the first follow-up visit.

7.4 An increase in time to attrition.

7.5 An increase in the mean number of clinic visits.

8. Mortality

8.1 Due to natural causes.

8.2 Due to drug overdose.

8.3 Due to suicide.

8.4 Due to any other unnatural cause.

9. Quality of life

9.1 General quality of life

9.1.1 Clinically important change in general quality of life – as defined by trial authors.

9.1.2 Any change in quality of life – as defined by trial authors.

9.1.3 Average change/endpoint scores quality of life scale.

9.2 Physical health

9.2.1 Clinically important change in physical health – as defined by trial authors.

9.2.2 Any change in physical health – as defined by trial authors.

9.2.3 Average change/endpoint scores physical health. scale

10. 'Summary of findings' table

We used the GRADE approach to interpret findings ([Guyatt 2011](#); [Schünemann 2011](#)); and used [GRADEpro](#) to export data from our review to create 'Summary of findings' tables. These tables provide outcome-specific information concerning the overall quality of evidence from each included study in the comparison, the magnitude of effect of the interventions examined, and the sum of available data on all outcomes we rated as important to

patient care and decision making. We selected the following main outcomes for inclusion in the 'Summary of findings' table.

1. Mental state: General — clinically important change – at study endpoint.
2. Substance use: a reduction in substance use – at study endpoint.
3. Subjective well-being – improvement in measures of subjective well-being.
4. Craving for substances – improvement in measures of substance craving.
5. Adherence to antipsychotic medication – improvement in measures of medication adherence.
6. Adverse effects – clinically important adverse effect.
7. Leaving the study early – a reduction in the proportion of participants leaving the study early: any reason.

Search methods for identification of studies

Electronic searches

1. Cochrane Schizophrenia Group's Study-Based Register of Trials

On 6 January 2016 and 9 October 2017, the Information Specialist searched the register using the following search strategy:

Risperidone in Intervention AND *Substance Abuse* in Healthcare Condition Fields of STUDY

In such study-based registers, searching the major concept retrieves all the synonyms and relevant studies because all the studies have already been organised based on their interventions and linked to the relevant topics (Shokraneh 2017).

This register is compiled by systematic searches of major resources (AMED, BIOSIS, CINAHL, ClinicalTrials.gov, Embase, MEDLINE, PsycINFO, PubMed, WHO ICTRP) and their monthly updates; ProQuest Dissertations and Theses A&I and its quarterly update; Chinese databases (CBM, CNKI, and Wanfang) and their annual updates; handsearches; grey literature; and conference proceedings (see [Group's Module](#)). There are no language, date, document type, or publication status limitations for inclusion of records into the register.

2. Cochrane Common Mental Disorders Group's Trials Register

On 8 January 2016 and 10 October 2017, the Information Specialist of Cochrane's Common Mental Disorders Group searched the trials register of their group using the following search strategy:

Search 1:

#1. (*Risp* AND (*Substance* OR *Cannabis* OR *Amphetamine* OR *Alcohol* OR *Cocaine* OR *Opioid* OR *Drug Dependence* OR *Addict*)) [in Register]

Search 2:

#2. (*Risp*)

#3. ("substance use disorder*" or SUD or SUDs)

#4. "drug abuse"

#5. (abuser* or abusing or addict* or depend* or habit* or misuse or user*)

#6. (abuse not (child* or sex*))

#7. (adinazolam or aerosol* or alcohol* or alprazolam or amphetamin* or anthramycin* or anxiolytic* or ativan or barbituat* or benzazepam or benzodiazepin* or bromazepam or brotizolam or buprenorphin* or camazepam or cannabi* or chlordiazepoxid* or cinolazepam or clobazam or clonazepam or clorazepam or clotiazepam or cloxazolam or cocaine* or codeine or crack or crystal or cyprazepam or depressant* or diacetylmorphin* or diazepam* or doxefazepam or ecstasy or estazolam or etizolam or fentanyl or flunitrazepam or flurazepam or flutazoram or flutoprazepam or fosazepam or gases or GHB or girisopam or halazepam or hallucinogen* or haloxazepam or heroin* or hydromorphone or hydroquinone or hypnotic* or inhalant* or ketamin* or ketazolam or librium or loflazepate or lopraxolam or lorazepam or lormetazepam or LSD or marihuana* or marijuana* or MDMA or meclonazepam or medazepam or meperidine or mephedrone or mescaline* or metaclazepam or methadone or methamphetamine* or methaqualone or mexazolam or midazepam or midazolam or morphine* or narcotic* or nerisopam or nimetazepam or nitrazepam or nitrites or "nitrous oxide" or "n-methyl-3,4-methylenedioxyamphetamine" or nordazepam or opiate* or opioid* or opium or oxazepam or oxazolam or oxazepam or oxycodone or oxepam or painkiller* or "pain killer*" or PCP or pethidin* or phenacyclidin* or pinasepam or prazepam or propazepam or propoxyphene or psilocybin or psychedelic* or psychoactive* or psychostimulant* or quinazolinone or ripazepam or ritalin or sedative* or serazepin* or solvent* or steroid* or stimulant* or substance* or temazepam or tetrazepam or tofisopam or tramadol or triazolam or triflubazam or valium or vicodin)

#8. (drug* and (recreational or street))

#9. #2 and (#3 or #4 or #5 or #6 or #7 or #8)

#10. #9 not #1 [in Register]

For previous searches, please see [Appendix 1](#).

Searching other resources

1. Reference searching

We inspected reference lists of all included studies for further relevant studies.

2. Personal contact

We contacted the first author of each included study for information regarding unpublished trials. In addition we contacted pharmaceutical companies regarding unpublished trials.

Data collection and analysis

Selection of studies

HT and TW independently inspected citations from the searches and identified relevant abstracts. NS independently re-inspected included abstracts to ensure reliability. HT and TW obtained and inspected full reports of the abstracts meeting the review criteria. Where disputes arose, NS re-inspected reports in order to ensure reliable selection. Where it was not possible to resolve

disagreement by discussion, we attempted to contact the authors of the study for clarification.

Data extraction and management

1. Extraction

Review authors HT and TW extracted data from all included studies. Again, any disagreements were discussed; decisions documented; and, if necessary, authors of studies were contacted for clarification. NS helped to clarify issues with remaining problems and we documented these final decisions. If data had been presented only in graphs we would have used data in analyses only when both reviewers derived similar results from extraction. One study reported data in graphs only, but we were unable to extract as data were reported for subgroups and the total number of participants at study endpoint for each subgroup was not known, precluding a calculation of standard deviations (SDs) (Akerele 2007). In case of multi-centre studies we attempted to get information from authors so as to extract data from each component centre separately. In one multi-centre study, authors were unable to provide this level of data and the data across all participating centres were reported.

2. Management

2.1 Forms

We extracted data onto a standardised form and piloted it on one study prior to use.

2.2 Scale-derived data

We included continuous data from rating scales only if:

1. the psychometric properties of the measuring instrument have been described in a peer-reviewed journal (Marshall 2000); and
2. the measuring instrument had not been written or modified by one of the trial investigators for that particular trial.

Ideally the measuring instrument should either be i) a self-report or ii) completed by an independent rater or relative (not the therapist). We realise that this is not often reported clearly and recorded if this was the case or not.

2.3 Endpoint versus change data

There are advantages of both endpoint and change data. Change data can remove a component of between-person variability from the analysis. On the other hand calculation of change needs two assessments (baseline and endpoint) which can be difficult to measure in unstable conditions such as schizophrenia. We decided to primarily use endpoint data, and only used change data if the former were not available. We decided that in cases where change data had been used, endpoint and change data would be combined in the analysis. If this had occurred we would have used mean differences (MD) rather than standardised mean differences (Higgins 2011). As pooling of continuous data in a meta-analysis was not possible for this review we did not use this method.

2.4 Skewed data

Continuous data on clinical and social outcomes are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data, we aimed to apply the following standards to all data before inclusion.

1. Standard deviations and means are reported in the paper or obtainable from the authors.
2. When a scale starts from the finite number zero, the standard deviation, when multiplied by two, is less than the mean (as otherwise the mean is unlikely to be an appropriate measure of the centre of the distribution (Altman 1996).
3. If a scale started from a positive value (such as the Positive and Negative Syndrome Scale (PANSS) which can have values from 30 to 210) we modified the calculation described above to take the scale starting point into account. In these cases skew is present if $2\text{SD} > (S - S_{\text{min}})$, where S is the mean score and S_{min} is the minimum score.

Endpoint scores on scales often have a finite start and end point, and the above rules can be applied. Had we found skewed data from studies of fewer than 200 participants we would have entered such data in additional tables rather than into an analysis. Skewed data pose less of a problem when looking at means if the sample size is large, and had we found such studies we would have entered them into syntheses.

When continuous data are presented on a scale that includes a possibility of negative values (such as change data), it is difficult to tell whether data are skewed or not. We included change data in statistical analyses regardless of the size of the study.

2.5 Common measure

To facilitate comparisons between trials, we converted variables that can be reported in different metrics, such as days in hospital (mean days per year, per week or per month) to a common metric (e.g. mean days per month).

2.6 Conversion of continuous to binary data

Where possible, we converted outcome measures to dichotomous data. This can be done by identifying cut-off points on rating scales and dividing participants accordingly into 'clinically improved' or 'not clinically improved'. It is generally assumed that if there is a 50% reduction in a scale-derived score such as the Brief Psychiatric Rating Scale (BPRS, Overall 1962) or the PANSS, Kay 1986, this could be considered as a clinically significant response (Leucht 2005a; Leucht 2005b). If data based on these thresholds were not available, we used the primary cut-off presented by the original authors. As the definition of a clinically significant treatment response may differ across various patient populations, we accepted a 50% symptom reduction as an adequate response in acute, non-refractory schizophrenia and a 25% reduction in chronic, refractory patients (Leucht 2009), and used these different definitions depending on the population studied. Where possible we also attempted to analyse continuous data.

2.7 Direction of graphs

Where possible, we entered data in such a way that the area to the left of the line of no effect indicates a favourable outcome for risperidone. Where keeping to this makes it impossible to avoid outcome titles with clumsy double-negatives (e.g. 'Not unimproved') we reported data where the left of the line indicates an unfavourable outcome. This was noted in the relevant graphs.

Assessment of risk of bias in included studies

Review authors HT and TW worked independently to assess risk of bias by using criteria described in the *Cochrane Handbook for*

Systematic Reviews of Interventions (Higgins 2011). This set of criteria is based on evidence of associations between overestimate of effect and high risk of bias of the article, and includes assessment of sequence generation, allocation concealment, blinding, incomplete outcome data, selective reporting and other forms of bias. Measures to prevent risk of bias were assessed as either 'high', 'low' or 'unclear', according to the definitions of these ratings in the *Cochrane Handbook for Systematic Reviews of Interventions* (Table 1).

If the raters disagreed, they came to a consensus over the final rating by involving another review author (NS). Where inadequate details of randomisation and other characteristics of trials were provided, we contacted authors of the studies in order to obtain further information.

We noted the level of risk of bias for each included study in both the text of the review and within 'Risk of bias' tables and incorporated them in the judgement of overall quality across studies in the 'Summary of findings' tables.

Measures of treatment effect

1. Binary data

For binary outcomes we calculated a standard estimation of the risk ratio (RR) and its 95% confidence interval (CI). It has been shown that RR is more intuitive than odds ratios (Boissel 1999); and that odds ratios tend to be interpreted as RR by clinicians (Deeks 2000).

2. Continuous data

For continuous outcomes we estimated the mean difference (MD) and the standard deviation (SD) between groups. However, if scales of very considerable similarity were used, we presumed there was a small difference in measurement, and we calculated the standardised mean difference (SMD) and transformed the effect back to the units of one or more of the specific instruments.

Unit of analysis issues

1. Cluster randomised control trials

Analysis of multi-level data may pose problems and failure to account for clustering in data may result in unit of analysis errors (Divine 1992), whereby P values are spuriously low, confidence intervals unduly narrow and statistical significance overestimated. This causes type I errors (Bland 1997; Gulliford 1999).

Where clustering was not accounted for in primary studies, we would have presented data in a table, with a (*) symbol to indicate the presence of a probable unit of analysis error. In subsequent versions of this review we will seek to contact first authors of studies to obtain intra-class correlation coefficients (ICCs) for their clustered data and to adjust for this by using accepted methods (Gulliford 1999).

We have sought statistical advice and have been advised that the binary data as presented in a report should be divided by a 'design effect'. This is calculated using the mean number of participants per cluster (m) and the ICC (Design effect = $1 + (m - 1) * ICC$) (Donner 2002). If the ICC is not reported it will be assumed to be 0.1 (Ukoumunne 1999).

If we had found cluster randomised trials in this review and had been able to analyse them appropriately, taking into account

ICCs and relevant data documented in the report, we could then have included them in a synthesis with other studies using the generic inverse variance technique. However, we found no cluster randomised trials.

2. Repeated measurements

Multi-level data may also arise where multiple measurements are conducted on one participant, i.e. counts of the number of urine tests over a period of time per participant that screen positive for drug use. In such cases, unit of analysis issues may also occur. Outcomes could also be reported as the percentage of participants per treatment group with positive urine drug tests, which represents another form of count data that is not compatible with Cochrane Review Manager 5 (RevMan 5) software, that analyses data derived at an individual participant level. In such cases, we contacted the authors to provide actual count data on the number of individual urine tests that screened positive or negative per participant over the study period. In accordance with methods previously described by Mattick 2014, we asked authors to derive a mean and SD of positive urine tests per treatment group over the study period. We would have then analysed differences between treatment groups as continuous data. In cases where the denominator differed for individual participants due to missed study visits and missing data for urine testing, we would have omitted studies where missing data occurred in more than 50% visits per individual participant and for more than 50% of overall participants in either treatment arm. In studies where no data on number of urine tests were obtained, we would have dealt with missing outcome data by the methods described under *Dealing with missing data* for continuous outcomes. We found one such study where urine tests were measured over time, generating longitudinal data (Akerele 2007). No information was provided by study authors despite attempts to contact them. In a second study authors did report means and standard deviations (van Nimwegen 2008).

3. Cross-over trials

A major concern of cross-over trials is the carry-over effect. It occurs if an effect (pharmacological, physiological or psychological) of the treatment in the first phase is carried over to the second phase. As a consequence, on entry to the second phase the participants can differ systematically from their initial state despite a wash-out phase. For the same reason, cross-over trials are not appropriate if the condition of interest is unstable (Elbourne 2002). As both effects are very likely in severe mental illness, if we obtained data from cross-over trials we would have only used data from the first phase of such studies. However, we included no cross-over studies in this review.

4. Studies with multiple treatment groups

When a study involved more than two treatment arms, if relevant we presented the additional treatment arms in comparisons. If data were binary these would have simply been added and combined within a two-by-two table, in order to avoid double counting a common comparison group in the same meta-analysis. If data had been continuous we would have combined data following the formula in section 7.7.3.8 (Combining groups) of the *Cochrane Handbook of Systematic Reviews of Interventions* (Higgins 2011). If the additional treatment arms were not relevant, these data would not have been reproduced.

Dealing with missing data

1. Overall loss of credibility

At some degree of loss to follow-up, data must lose credibility (Xia 2009). We chose that, for any particular outcome, if more than 50% of data were unaccounted for, we did not reproduce these data or use them within analyses (except for the outcome 'leaving the study early'). If, however, more than 50% of those in one arm of a study were lost, but the total loss was less than 50%, we marked such data with (*) to indicate that such a result may well be prone to bias.

2. Binary

In cases where attrition for a binary outcome was between 0% and 50% and where these data were not clearly described, we presented data on a 'once randomised always analyse' basis (an intention-to-treat analysis). Those leaving the study early were all assumed to have had the same rates of negative outcome as those who completed, with the exception of the outcomes of death and adverse effects. For these outcomes, the rate of those who stayed in the study — in that particular arm of the trial — was used for those who did not. However, due to the small study sample sizes we were not able to conduct such a sensitivity analysis in order to test how prone the primary outcomes are to change when 'completer' data only are compared to the intention-to-treat analysis using the above assumptions.

3. Continuous

3.1 Attrition

Where attrition for a continuous outcome is between 0% and 50%, and completer-only data were reported, we reproduced these.

3.2 Standard deviations

If standard deviations (SDs) were not reported, we first tried to obtain the missing values from the study authors. If not available, where there were missing measures of variance for continuous data, but an exact standard error and CIs available for group means, and either P value or t value available for differences in mean, we calculated them according to the rules described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). When only the standard error (SE) is reported, SDs are calculated by the formula $SD = SE * \sqrt{n}$. Chapters 7.7.3 and 16.1.3 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011) present detailed formula for estimating SDs from P values, t or F values, CIs, ranges or other statistics. If these formulae did not apply, we would have calculated the SDs according to a validated imputation method which is based on the SDs of the other included studies (Furukawa 2006). Although some of these imputation strategies can introduce error, the alternative would be to exclude a given study's outcome, and thus to lose information. We nevertheless would have examined the validity of the imputations in a sensitivity analysis excluding imputed values. However, as our search only yielded two studies with two different comparisons, we were unable to use this method of imputation.

3.3 Last observation carried forward

We anticipated that in some studies the method of last observation carried forward (LOCF) would have been employed in the study report. As with all methods of imputation to deal with missing data, LOCF introduces uncertainty about the reliability of the results (Leucht 2007). Therefore, when LOCF data had been used in the trial

and if less than 50% of the data had been assumed, we would have reproduced these data and indicated that they were the product of LOCF assumptions.

Assessment of heterogeneity

1. Clinical heterogeneity

We inspected all studies to determine whether the studies were similar enough in terms of participant profile and intervention comparisons to combine them, and discussed such differences if any were found.

2. Methodological heterogeneity

We simply inspected all studies for clearly outlying methods and discussed any outlying methods in full.

3. Statistical heterogeneity

3.1 Visual inspection

Where possible we visually inspected graphs to investigate the possibility of statistical heterogeneity.

3.2 Employing the I² statistic

We investigated heterogeneity between studies by considering the I² statistic alongside the Chi² test P value. The I² statistic provides an estimate of the percentage of inconsistency thought to be due to chance (Higgins 2003). The importance of the observed value of I² depends on i) magnitude and direction of effects and ii) strength of evidence for heterogeneity (e.g. P value from Chi² test, or a CI for I²). I² values between 0% to 40% were interpreted as possibly unimportant, 30% to 60% as possibly significant, 50% to 90% as possibly substantial, and 75% to 100% as possibly considerable (Deeks 2011). Had substantial levels of heterogeneity been found in the primary outcome, we would have explored reasons for heterogeneity (see [Subgroup analysis and investigation of heterogeneity](#)). As no study data was combined in a meta-analysis for any primary outcomes, we did not conduct any exploration of heterogeneity.

Assessment of reporting biases

1. Protocol versus full study

Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results. These are described in section 10.1 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). We tried to locate protocols of included RCTs by searching clinical trials registries and contacting authors. If the trial protocol was available, outcomes in the protocol and in the published report were compared. If the protocol was not available, outcomes listed in the Methods section of the trial report were compared with actual reported results.

2. Funnel plot

Reporting biases arise when the dissemination of research findings is influenced by the nature and direction of results (Egger 1997). These are again described in section 10 of the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011). We are aware that funnel plots may be useful in investigating reporting biases but are of limited power to detect small-study effects. However, we were not able to generate funnel plots as there were no outcomes

including more than two studies. Should more studies become available in future, and funnel plots become possible, we will seek statistical advice in their interpretation.

Data synthesis

As we anticipated clinical and methodological heterogeneity we used random-effects models for all analyses.

Subgroup analysis and investigation of heterogeneity

1. Subgroup analyses

We planned to conduct subgroup analyses based on a number of factors (substance abuse versus dependence, the type and formulation of risperidone, and the presence of additional pharmacological or psychosocial treatment in some studies), but due to the small number of studies included were unable to carry out such subgroup analyses.

Sensitivity analysis

We would have applied the following sensitivity analyses in our review to primary outcome data. However, due to the small number of studies, the low sample size within included studies and single studies within each comparison, none of these sensitivity analyses were possible.

1. Risk of bias

We would have analysed the effects of excluding trials that were judged to be at high risk of bias across one or more of the domains of randomisation (implied as randomised with no further details available), allocation concealment, blinding and outcome reporting for the meta-analysis of the primary outcome. In case the exclusion of trials at high risk of bias would have not substantially altered the direction of effect or the precision of the effect estimates, then we would have included data from these trials in the analysis.

2. Assumptions for lost binary data

Where we would have had to make assumptions regarding people lost to follow-up (see [Dealing with missing data](#)), we would have compared the findings of the primary outcomes when we used our assumption with completer data only. If there had been substantial difference, we would have reported results and discussed them but would have continued to employ our assumption.

3. Assumptions for lost continuous data

If we had to make assumptions, such those used in imputation methods, regarding missing SD data (see [Dealing with missing data](#)), we intended to compare the findings on primary outcomes when we applied these assumptions with completer data only. We intended to conduct a sensitivity analysis to test how prone results were to change when 'completer' data only were compared to the imputed data using different assumptions (LOCF, imputation from other studies). If there had been a substantial difference, we

would have reported results and discussed them but would have continued to employ our assumption.

4. Imputed values

We would have also undertaken a sensitivity analysis to assess the effects of including data from trials where we used imputed values for ICC in calculating the design effect in cluster randomised trials.

If substantial differences had been noted in the direction or precision of effect estimates in any of the sensitivity analyses listed above, we would not have pooled data from the excluded trials with the other trials contributing to the outcome, but would have presented them separately.

5. Fixed effect and random effects

We expected substantial clinical and methodological heterogeneity in the studies included in the review. We therefore used a random-effects model to combine data in a meta-analysis. We intended to carefully inspect the results of our meta-analysis and if it turned out that smaller studies received a higher weighting, we did intend to conduct a sensitivity analysis using a fixed-effect model. If a fixed-effect meta-analysis did not show a similar beneficial effect compared to the random-effects analysis, we would have carefully considered whether the conclusions of the random-effects model were justified in light of the methodological rigour and risk of bias assessments of the larger compared to the smaller studies. If it had turned out that larger studies were indeed more rigorous, we would have restricted our report to the results of the meta-analysis of the larger studies.

RESULTS


Description of studies

For description of studies please see [Characteristics of included studies](#) and [Characteristics of excluded studies](#) tables.

Results of the search

We identified 197 records from the searches of the Cochrane Schizophrenia Group's Study-Based Register of Trials (including trial registers) and the Cochrane Common Mental Disorders' database ([Figure 3](#)). In addition we obtained four records from other sources (two through searches of a clinical trials register, one from communication with an author and one from search of reference lists). After removal of 145 abstracts that did not meet eligibility criteria, a total of 56 full text records containing 37 studies that appeared to meet eligibility criteria were inspected in detail. After excluding 23 studies which did not meet our inclusion criteria (see [Characteristics of excluded studies](#)) and a further six studies either awaiting classification or ongoing ([Characteristics of studies awaiting classification](#); [Characteristics of ongoing studies](#)), we were left with eight studies meeting our inclusion criteria (see [Characteristics of included studies](#)).

Figure 3. PRISMA flow diagram of study selection from 2016 and 2017 searches



Included studies

A total of eight studies met criteria for inclusion (Akerle 2007; Brunette 2011; Machielsen 2014; Noordsy 2010; Sevy 2011; Smelson 2006; Swartz 2008; van Nimwegen 2008); however, Brunette 2011 did not provide any useable data for analyses.

1. Design and duration

Four of the included studies were parallel-group superiority trials that randomised participants to risperidone and a comparator drug. These studies all had pre-specified hypotheses about the comparator drugs. In the study by Akerle 2007 the authors hypothesised that olanzapine would be superior to risperidone in reducing cocaine and cannabis use in people with schizophrenia in a 14-week trial. In Noordsy 2010 the authors hypothesised that clozapine would be superior to risperidone in reducing substance use and psychiatric symptoms over 24 weeks of study. In a 4-week trial, Machielsen 2014 hypothesised that clozapine would be superior to risperidone in reducing brain activation in regions associated with attentional bias on fMRI, reduce craving and increase subjective well-being in people with first episode schizophrenia with comorbid cannabis use disorders. In a 12-week trial Brunette 2011 randomised participants to either continue their treatment with their treatment as usual (TAU) or to switch participants to clozapine, with the hypothesis that clozapine would reduce cannabis use. In this study five participants in the TAU group were taking risperidone.

Three trials were post-hoc, secondary data analyses of existing larger parent randomised trials (Sevy 2011; Smelson 2006; Swartz 2008). In Sevy 2011 the authors studied a group of 49 participants from a larger randomised trial of 120 participants (Robinson 2006) over 16 weeks who were randomised to risperidone and olanzapine. Smelson 2006 analysed data on 236 out of 632 substance users from a parent study (Tunis 2006) randomised to risperidone, olanzapine and conventional agents (including perphenazine, loxapine, haloperidol, fluphenazine, thiothixene) over a 12-month study period. Swartz 2008 studied 643 out of 1432 participants from the CATIE study (Stroup 2003) randomised to risperidone, olanzapine, quetiapine, perphenazine, and ziprasidone, continued over 18 months of study.

One study was a randomised parallel-group superiority trial comparing risperidone to a comparator drug and reported outcomes on a subgroup of participants with co-occurring substance use disorders (van Nimwegen 2008).

2. Participants

Participants in all of the included studies had a diagnosis of either schizophreniform disorder, schizophrenia or schizoaffective disorder and co-occurring substance misuse. In Noordsy 2010 and Sevy 2011, participants were experiencing their first episode of psychosis (schizophrenia or schizoaffective disorder). In Swartz 2008, participants were multi-episode.

Five studies exclusively randomised participants with a co-occurring cannabis use disorder (Brunette 2011; Machielsen 2014; Noordsy 2010; Sevy 2011; van Nimwegen 2008). The other three studies included participants with other substance use disorders such as alcohol, amphetamine, cocaine and opioid use disorders (Akerle 2007; Smelson 2006; Swartz 2008).

In Akerle 2007, Smelson 2006 and Swartz 2008, participants were adults of mixed ethnicity and in Noordsy 2010 all participants were Caucasian (understood to be white participants). Brunette 2011 had 83.9% Caucasian participants; and in Machielsen 2014, van Nimwegen 2008 and Sevy 2011 ethnicity was not stated. Seven of the studies included adults over the age of 18 years. In the study by Noordsy 2010 four participants (28% of the total sample) were reported to be 17 years; the age range for this study was 17 to 45 years. Both males and females were included in studies but male participants predominated and all participants were male in the Machielsen 2014 study.

3. Settings

Studies were conducted either in the USA or the Netherlands. Most studies included outpatients from single or a small number of sites (1 to 4), and a few recruited from inpatient sites. One study was a large, multi-centre trial conducted over 57 sites (Swartz 2008).

4. Study size

A total of 2466 people were randomised after giving informed consent to participate in the trials. Of these 1073 had a dual diagnosis. The number of participants with SMI and co-occurring substance misuse varied from study to study: six studies randomised fewer than 50 dual diagnosis participants (Akerle 2007; Brunette 2011; Machielsen 2014; Noordsy 2010; Sevy 2011; van Nimwegen 2008); one study randomised between 100 and 300 (Smelson 2006); and Swartz 2008 randomised 643 dual diagnosis participants.

5. Interventions

Risperidone (dose range: 1 mg to 9 mg) was compared to olanzapine (dose range: 2.5 mg to 30 mg) in five different studies (Akerle 2007; Sevy 2011; Smelson 2006; Swartz 2008; van Nimwegen 2008). Three studies compared risperidone (dose range: 3.5 mg to 5 mg daily) to clozapine (dose range: 12.5 mg to 400 mg daily) (Brunette 2011; Machielsen 2014; Noordsy 2010). One study compared risperidone (dose range: 1.5 mg to 6 mg) to quetiapine (dose range: 200 mg to 800 mg) (Swartz 2008). Two studies compared risperidone (dose range: 1 mg to 6 mg daily) with first-generation antipsychotics (perphenazine, loxapine, haloperidol, fluphenazine, thiothixene, various dosages) (Smelson 2006; Swartz 2008). One study compared risperidone (dose range: 1.5 mg to 6 mg) to ziprasidone (dose range: 40 mg to 160 mg daily) (Swartz 2008).

Concomitant psychosocial interventions were delivered in a number of studies. In the trial by Akerle 2007 all participants received weekly psychotherapy over the study period and were asked to nominate a "significant other" to assist with attendance and follow-up. In Brunette 2011 all participants received weekly individual substance abuse and mental health counselling and attended weekly Alcoholics Anonymous meetings. In Machielsen 2014 it is reported that participants had "supportive treatment as usual". In the trial by Noordsy 2010 participants also received a "Lifestyle Intervention" to help prevent metabolic side-effects and assist with recovery. In the trial by Sevy 2011 all participants received psychoeducation about schizophrenia, were seen on a regular basis by allocated social workers and also had access to the ancillary treatment service available from two large departments of psychiatry. In Smelson 2006 it is unclear what psychosocial interventions participants received. In Swartz 2008

the investigators did not account for substance abuse treatments received, but they noted that very few were actively engaged in such treatments.

6. Sources of funding

The study by [Akerle 2007](#) received funding from the National Institute on Drug Abuse (NIDA), the National Alliance for Research on Schizophrenia and Depression (NARSAD) and Eli Lilly, the pharmaceutical company. The study by [Brunette 2011](#) was sponsored by Novartis and Janssen; and [Machielsen 2014](#) by the Dutch health research council. Sponsors and collaborators for the study by [Noordsy 2010](#) included the National Institute of Mental Health and the Dartmouth-Hitchcock Medical Centre; no funding was received from the pharmaceutical industry and the investigators were not employed by the sponsors. In [Sevy 2011](#) several authors declared ties with the pharmaceutical industry but it is stated that the study was sponsored by the NIMH. Funding for [Smelson 2006](#) and [van Nimwegen 2008](#) was received from Eli Lilly; and in [Swartz 2008](#), study medications were provided by several pharmaceutical companies.

7. Outcomes

Scales reported to have been used in the included studies are summarised in [Table 2](#). A description of the scales for which results have been reported is included below.

7.1 Mental state scales

a. Hamilton Depression Rating Scale (HAM-D)

This scale has a 17-item and 21-item version. The severity of depression is rated for the past week on separate items with 2- to 5-point severity scales. A total of eight items are scored on a 5-point scale ranging from 0 "absent" to 4 "severe" and 9-items on a 2-point scale. Scoring ranges from 0 to 50, with scores on the first 17 items contributing to the final score. A further four items (items 18 to 21) provide additional information on the characteristics of the depressive symptoms ([Hamilton 1960](#)). This scale was used by [Akerle 2007](#).

b. Positive and Negative Syndrome Scale (PANSS)

This scale was used in [Akerle 2007](#), [Machielsen 2014](#) and [Swartz 2008](#) and measures positive psychotic symptoms (delusions, thought disorganization, hallucinations, excitement, grandiosity, hostility, persecutory ideation) and negative symptoms (affective blunting, poor rapport, social and emotional withdrawal, stereotypical thinking, poverty of speech, difficulty in abstract thinking) and a range of general psychopathology symptoms. The scale includes seven items measuring positive psychotic symptoms, seven items measuring negative symptoms and 14 items measuring general psychopathology on a 1 to 7 point scale ranging from "absent" to "extreme". It has a range of 30 to 210 ([Kay 1986](#); [Kay 1987](#)).

c. Schedule for Affective Disorders and Schizophrenia—Change Version with psychosis and disorganization items (SADS-C+PD) (Endicott 1978)

This instrument was used to measure positive psychotic symptoms (delusions, hallucinations, thought disorder, and bizarre behaviour) and negative symptoms (affective flattening/blunting, alogia, avolition-apathy, asociality-anhedonia) in the trial by [Sevy 2011](#).

7.2 Substance use scales

a. Timeline Follow-back (TLFB)

This scale is a calendar-based method that assesses the frequency of drug use over a period of time (usually the past week) ([Sobell 1992](#)). This scale can either be self-administered by participants or clinician-completed. In the [Noordsy 2010](#) study this scale was used together with other sources of information such as urine tests and reports from collateral sources of information to determine cannabis use. At the end of the study graphs were plotted showing days of cannabis use per week as rated by the TLFB method and were then rated as "Improved", "Unchanged", or "Worse" by a pair of expert judges ([Noordsy 2010](#)). Raters were instructed to rate the graph "Improved" or "Worsened" if it appeared to be more than 20% better or worse and to rate it "Unchanged" if there was little or no change (less than ~20%) (See under "Other measures: categorical and time to event data").

b. Substance Use Questionnaire:

This instrument was used in conjunction with urine testing to derive best estimate of substance discontinuation in [Sevy 2011](#).

7.3 Subjective well-being scales

a. *Subjective Well-being Under Neuroleptics Scale (SWN)*: This self-rated scale (used in the study by [Machielsen 2014](#)) measures various aspects of self-perceived symptoms, treatment experience and quality of life and functioning over the past 7 days. The SWN (short-version) consists of 20 statements (10 positive and 10 negative) assessing five domains (mental functioning, self-control, emotional regulation, physical functioning, and social integration), with each domain containing four questions. Rating is on a 6-point Likert-type scale yielding total scores varying from 20 to 120 ([de Haan 2002](#); [Naber 1995](#)).

7.4 Craving for substances scales

a. Cocaine and Marijuana Craving Report ([Weddington 1990](#))

This scale measures craving of cocaine or cannabis on a 100-point, 10 cm visual analogue scale with instructions to participants to rate their desire for cocaine or cannabis in the past 24 hours from "not at all" to "more than ever". This scale was used in [Akerle 2007](#).

b. Desires for Drug Questionnaire (DDQ) ([Franken 2002](#))

This instrument measures instantaneous, immediate craving on 14 different items phrased in a positive manner and assessing desires to use, control over using and use to ameliorate negative emotions (negative reinforcement).

c. Marijuana Craving Questionnaire (MCQ) ([Heishman 2009](#))

This instrument measures current cannabis craving on four domains (compulsivity, emotionality, expectancy and purposefulness) containing three questions each using a 7-point Likert type scale.

d. Obsessive-Compulsive Drug Use Scale (OCDUS) ([Dekker 2012](#); [Franken 2002](#))

This instrument measures drug craving over the past 7 days on 12 items containing a 5-point Likert type rating.

7.5 Adverse effects scales

a. Simpson-Angus Scale (SAS)

In one study — [Akerele 2007](#) — the Simpson-Angus Scale was used to measure the presence of parkinsonism ([Simpson 1970](#)). This scale has 10 items and measures bradykinesia, rigidity and tremor in different body regions on a scale of 0 to 4. It has a range of 0 to 28.

7.6 Leaving the study early: Time to leaving

In the study by [Akerele 2007](#) the time to study attrition was measured in weeks.

7.7 Categorical outcomes and time-to-event data

a. Substance use: urine assay for cannabis and cocaine use

In the study by [Akerele 2007](#) urine samples were collected at each of the three meetings per week. Each week over the 10 weeks of follow-up was classified as either positive or negative for drug use for each participant if any one of the three samples tested positive. Urine tests for cannabis were classified as positive if the cannabis concentration was above a cut-off of 100 ng/ml; and for cocaine, if the sample concentration was above the cut-off of 300 ng/ml.

b. Substance use: number of participants with improvement in substance use

In the study by [Noordsy 2010](#) days of cannabis use per week as gathered by the Time-Line Follow-Back method were plotted on graphs at the end of the study. A pair of expert judges were then instructed to rate cannabis use as "improved" or "worsened" if it appeared to be more than 20% better or worse and to rate it as "unchanged" if there was little or no change (less than 20% change). Results were reported as the number of participants per intervention group that had "improved" cannabis use versus "unchanged" or "worsened". [Machielsen 2014](#) reports on the number of participants who continued or stopped using cannabis during the study.

c. Adherence with medication

In the study by [Akerele 2007](#) the proportion of missed doses of all administered doses was reported.

d. Leaving the study early

For six studies the number of participants who did not complete the study was reported ([Akerele 2007](#); [Machielsen 2014](#); [Noordsy 2010](#); [Sevy 2011](#); [Swartz 2008](#); [van Nimwegen 2008](#)).

Excluded studies

We excluded 23 studies from the 37 studies examined for inclusion. [Table 3](#) contains a summary of the various excluded studies. A total of 12 studies were excluded as there was no measure or reporting of substance use comorbidity ([Blin 1996](#); [Gaebel 2010](#); [Harvey 2007](#); [Ikuta 2014](#); [Liemburg 2011](#); [Perlis 2006](#); [Rezayat 2014](#);

[Sachs 2002](#); [Sajatovic 2002](#); [Smulevich 2005](#); [van Nimwegen 2008a](#); [Yatham 2007](#)). Three studies were excluded as they were records of study protocols for which no unpublished data were provided after authors were contacted ([Green 2001](#); [NCT00169026](#); [NCT00498550](#)). Three studies were excluded due to the use of quasi-randomisation ([Rubio 2006a](#); [Rubio 2006b](#); [Zhangyue 2005](#)). One study was excluded as only 8.3% of participants had a severe mental illness ([Nejtek 2008](#)). One study was excluded as it compared risperidone in oral versus depot formulation ([NCT00130923](#)). One study was excluded as it included only mental disorders which were due to alcohol use ([Liu 2008](#)). One study was excluded as it did not contain any data comparing risperidone with other medications but examined the impact of substance use on prognosis ([Kerfoot 2011](#)). Another study was excluded as it was an observational study ([NCT00063349](#)).

Studies awaiting classification

One study appeared to meet inclusion criteria but no results were reported hence it could not be assessed ([NCT00208143](#)). This study is described as an open (no masking), randomised, parallel, superiority trial, comparing the efficacy of quetiapine with risperidone in adults with a diagnosis of schizophrenia or schizoaffective disorder and co-occurring cocaine or methamphetamine abuse or dependence. We contacted the investigators for information and results but received no response. Another study appeared to meet eligibility criteria, but was described only as "double blind" ([Greenspan 2005](#)). Authors were contacted to confirm randomisation but did not respond. A third study appeared to meet eligibility criteria but the authors responded after being contacted that no data for the subgroup with a dual diagnosis are available ([Yatham 2003](#)). It was also not clear how many participants in this study had psychotic bipolar disorders. Two studies contained subgroups of participants with substance use disorders, but no data were provided for the subgroup after authors were contacted ([Johnsen 2010](#); [San 2012](#)).

Ongoing studies

We found one study currently recruiting participants ([NCT01639872](#)). This study is described as a double-blind, randomised, parallel assignment, superiority trial, comparing the efficacy of clozapine with risperidone in people with schizophrenia and a cannabis use disorder. The estimated sample size is 132.

Risk of bias in included studies

We assessed risk of bias for the eight included studies. Overall the risk of bias was unclear across most domains assessed, as reporting of study results lacked particulars of how potential bias was handled and how potential bias could have influenced results. [Figure 4](#) and [Figure 5](#) contains a graphical overview of the risk of bias. The details of the studies are included under [Characteristics of included studies](#).

Figure 4. Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.




Figure 5. Risk of bias summary: review authors' judgements about each risk of bias item for each included study.

	Random sequence generation (selection bias)	Allocation concealment (selection bias)	Blinding of participants and personnel (performance bias)	Blinding of outcome assessment (detection bias)	Incomplete outcome data (attrition bias)	Selective reporting (reporting bias)	Other bias
Akerele 2007	?	?	?	?	-	?	-
Brunette 2011	?	?	-	+	?	+	-
Machielsen 2014	+	+	-	-	?	+	+
Noordsy 2010	?	?	-	?	-	-	?
Sew 2011	+	?	-	+	?	?	?
Smelson 2006	?	?	-	?	+	?	-
Swartz 2008	?	?	?	?	-	?	?
van Nimwegen 2008	?	?	?	?	-	?	-

Allocation

1. Random generation

The method of random sequence generation was unclear in all but two studies for which a description of random sequence generation

was provided and therefore assessed as low risk of bias (Machielsen 2014; Sew 2011).

2. Allocation concealment

The method of allocation concealment was unclear in all the included studies, except for one study for which allocation concealment was adequately described, with low risk of bias (Machielsen 2014).

Blinding

1. Performance bias

There was high risk of performance bias in five of the eight included studies, as many studies were described as open label and both participants and personnel were aware of the medications they received (Brunette 2011; Noordsy 2010; Machielsen 2014; Sevy 2011; Smelson 2006). For Noordsy 2010, Brunette 2011 and Machielsen 2014 we assessed risk of unmasking of participants and personnel as high, as the monitoring requirements for clozapine (weekly blood tests) differs from that of risperidone and no description was given how blinding was maintained. No description of blinding of personnel or participants was provided for the remainder of the included studies and risk of bias was assessed as unclear (Akerlele 2007; Swartz 2008; van Nimwegen 2008).

2. Detection bias

We judged detection bias to be low for two studies where outcome assessors were reported to be blinded and independent of study physicians (Brunette 2011; Sevy 2011). One study was judged as high risk of bias as outcome assessors were not blinded and were aware of allocation (Machielsen 2014). We judged the risk of detection bias as unclear for five of the included studies as no description or an incomplete description of blinding was reported (Akerlele 2007; Noordsy 2010; Smelson 2006; Swartz 2008; van Nimwegen 2008).

Incomplete outcome data

For four studies we judged the risk of attrition bias as being high, due to high levels of attrition (Swartz 2008), unbalanced numbers in leaving between treatments (Akerlele 2007), differing reasons for attrition between medications (Noordsy 2010), the use of only single imputation methods (Swartz 2008; van Nimwegen 2008), and the absence of data on baseline differences in groups that dropped out (van Nimwegen 2008). For one study (Smelson 2006), for which the primary — and only outcome — was attrition, we judged the risk to be low. For three studies (Brunette 2011; Sevy 2011; Machielsen 2014), risk of attrition bias was judged as unclear as the number of participants that failed to complete the study was either not reported across the randomised groups, or only simple imputation methods were used to account for missing data in analyses, or the impact of attrition on the study specific outcomes was not clear.

Selective reporting

Risk of selective reporting was judged to be low for two studies for which a study protocol was available and where there were no changes between the protocol-defined outcomes and outcomes in the study report (Brunette 2011; Machielsen 2014). For five studies risk of selective reporting was judged as unclear as there was either no study protocol available (Akerlele 2007), or outcomes stated in the protocol were not mentioned in the study report (van Nimwegen 2008), or the study was a secondary analysis of an existing parent randomised trial, making it unclear whether the outcome selection could have been influenced by preliminary

results and analysis of the primary study (Sevy 2011; Smelson 2006; Swartz 2008). In the original protocol for the study by Noordsy 2010, the primary outcome was specified as days of substance use as measured by the Time Line Follow Back method. However, changes were made to the protocol prior to the end of the study and substance use outcomes were judged by experts based on graphs derived from data collected by TLFB method and dichotomised into the proportion of participants with an improvement (20% or more reduction in substance use) versus no improvement or unchanged and worsened groups. This process appeared to have occurred following the collection of data and a change to the protocol was added. Risk of selective reporting was judged to be high for Noordsy 2010.

Other potential sources of bias

Four studies were judged as having high risk of other bias due to sponsorship of the study by the pharmaceutical industry (Akerlele 2007; Brunette 2011; Smelson 2006; van Nimwegen 2008). In three studies the risk of other bias was judged as unclear as sponsorship was by academic centres and national funding agencies such as the NIMH but other potential conflicts of interests are not reported and therefore remain unclear, or many authors were supported by the pharmaceutical industry even though the study sponsorship was stated as being independent of industry (Noordsy 2010; Sevy 2011; Swartz 2008). One study was judged to be at low risk of bias as sponsorship was through national funding bodies and university departments with no other potential conflicts of interest declared (Machielsen 2014).

Effects of interventions

See: [Summary of findings for the main comparison RISPERIDONE versus CLOZAPINE - all data short term for people with severe mental illness and co-occurring substance misuse](#); [Summary of findings 2 RISPERIDONE versus OLANZAPINE - short- and long-term data for people with severe mental illness and co-occurring substance misuse](#); [Summary of findings 3 RISPERIDONE versus PERHENAZINE - long-term data for people with severe mental illness and co-occurring substance misuse](#); [Summary of findings 4 RISPERIDONE versus QUETIAPINE - short- and long-term data for people with severe mental illness and co-occurring substance misuse](#); [Summary of findings 5 RISPERIDONE versus ZIPRASIDONE - long-term data \(> 12 months\) for people with severe mental illness and co-occurring substance misuse](#)

See: [Summary of findings for the main comparison](#); [Summary of findings 2](#); [Summary of findings 3](#); [Summary of findings 4](#); [Summary of findings 5](#).

Comparison 1: risperidone versus clozapine

Only two studies containing data on 50 participants contributed data to this comparison (Machielsen 2014; Noordsy 2010). See [Summary of findings for the main comparison](#). All data are short term – up to 6 months.

1.1 Mental state: 1. General: average endpoint scores (PANSS subscale, lower = better)

One trial reported data on these outcomes (Machielsen 2014). There were no clear differences between risperidone and clozapine at study endpoint in general psychopathology symptoms (1 RCT, n = 36, MD 2.70, 95% CI -2.14 to 7.54), [Analysis 1.1](#).

1.2 Mental state: 2. General: any change in general symptoms

Only one study reported results for 'worsening of psychotic symptoms' (non-systematic assessment) as an adverse effect (Noordsy 2010). There were no clear differences between the risperidone and clozapine groups for this outcome (1 RCT, n = 14, RR 0.14, 95% CI 0.01 to 2.34), Analysis 1.2.

1.3 Mental state: 3. Specific: positive, negative symptoms – average endpoint scores (PANSS subscales, lower = better)

One trial reported data on these outcomes (Machielsen 2014). There were no differences between risperidone and clozapine at study endpoint in positive symptoms (1 RCT, n = 36, MD 0.90, 95% CI -2.21 to 4.01). For negative symptoms participants with clozapine had significantly lower scores (1 RCT, n = 36, MD 4.00, 95% CI 0.79 to 7.21), Analysis 1.3.

1.4 Mental state: 4. Specific: anxiety symptoms

The Noordsy 2010 study reported emergence of anxiety symptoms (non-systematic assessment). No clear differences were found between the risperidone and clozapine groups (1 RCT, n = 14, RR 3.00, 95% CI 0.14 to 63.15), Analysis 1.4.

1.5.1 Substance use: 1. Improvement (at least 20% reduction in use, TLFB scale)

One study provided data with this outcome (Noordsy 2010). No significant differences in this measure were demonstrated between the risperidone and clozapine groups (1 RCT, n = 14, RR 1.00, 95% CI 0.30 to 3.35), Analysis 1.5.

1.5.2 Substance use: 2. Discontinued substance use

One study provided data for this outcome (Machielsen 2014). There were no significant differences between risperidone and clozapine in the number of participants who stopped using cannabis (1 RCT, n = 28, RR 1.13, 95% CI 0.41 to 3.12), Analysis 1.5.

1.6 Subjective well-being: average endpoint scores (Subjective Well-being under Neuroleptics scale, SWN scale, higher = better)

One study provided data for this outcome (Machielsen 2014). There were no significant differences in the endpoint scores on the Subjective Well-being under Neuroleptics scale for risperidone compared to clozapine (1 RCT, n = 36, MD -6.00, 95% CI -14.82 to 2.82), Analysis 1.6.

1.7 Craving for substances

1.7.1 Specific: current craving – average endpoint scores (Marijuana Craving Questionnaire, MCQ, lower = better)

One study included data on this outcome (Machielsen 2014). Participants treated with clozapine had significantly lower scores on the Marijuana Craving Questionnaire (MCQ) compared to participants treated with risperidone (1 RCT, n = 28, MD 7.00, 95% CI 2.37 to 11.63, P = 0.003), Analysis 1.7.

1.7.2 Specific: past week craving – average endpoint scores (Obsessive Compulsive Drug Use Scale, OCDUS, lower = better)

One study included data on this outcome (Machielsen 2014). Participants treated with clozapine had significantly lower craving scores on the Obsessive Compulsive Craving Scale (OCDUS), compared to participants treated with risperidone (1 RCT, n = 28, MD 14.20, 95% CI 4.45 to 23.95, P = 0.004), Analysis 1.7.

1.8 Adherence to antipsychotic medication: discontinued medication

One study included data on this outcome (Machielsen 2014). There were no significant differences between risperidone- and clozapine-treated participants in the number of participants who discontinued antipsychotic treatment (1 RCT, n = 36, RR 4.05, 95% CI 0.21 to 78.76), Analysis 1.8.

1.9 Adverse effects: 1. Movement disorders

1.9.1 Any extrapyramidal side-effects

Two studies reported data on extrapyramidal side-effects (Machielsen 2014; Noordsy 2010). There were no significant differences between risperidone- and clozapine-treated participants in terms of the number of participants who experienced any extrapyramidal side-effects (2 RCTs, n = 50, RR 2.71, 95% CI 0.30 to 24.08; $I^2 = 0\%$), Analysis 1.9.

1.9.2 Akathisia

One study provided data for this outcome (Noordsy 2010). There were no statistically significant differences in the risperidone compared to the clozapine groups for akathisia (1 RCT, n = 14, RR 2.00, 95% CI 0.23 to 17.34), Analysis 1.9.

1.10 Adverse effects: 2. Non-movement disorder related side-effects

One study – (Noordsy 2010) – provided data for non-movement disorder-related adverse effects. In all cases no statistically significant differences were found in the proportion of participants with side-effects in the risperidone compared to the clozapine groups. Cardiovascular side-effects: palpitations (1 RCT, n = 14, RR 3.00, 95% CI 0.14 to 63.15); hypotension (1 RCT, n = 14, RR 0.33, 95% CI 0.02 to 7.02). Central nervous system side-effects: headache (1 RCT, n = 14, RR 0.20, 95% CI 0.01 to 3.54); somnolence (1 RCT, n = 14, RR 0.20, 95% CI 0.03 to 1.30). Dermatological side-effects: acne (1 RCT, n = 14, RR 3.00, 95% CI 0.14 to 63.15). Endocrinological side-effects: decreased libido (1 RCT, n = 14, RR 0.33, 95% CI 0.02 to 7.02). Ear and labyrinthine: ear canal blockage (1 RCT, n = 14, RR 3.00, 95% CI 0.14 to 63.15). Gastrointestinal: abdominal pain (1 RCT, n = 14, RR 3.00, 95% CI 0.14 to 63.15); elevated liver function tests (1 RCT, n = 14, RR 3.00, 95% CI 0.14 to 63.15); hypersalivation (1 RCT, n = 14, RR 0.11, 95% CI 0.01 to 1.74). General adverse effects: fatigue (1 RCT, n = 14, RR 0.33, 95% CI 0.02 to 7.02). Injuries: sprain (1 RCT, n = 14, RR 0.33, 95% CI 0.02 to 7.02). Metabolic side-effects: increased appetite (1 RCT, n = 14, RR 0.33, 95% CI 0.02 to 7.02); weight gain (1 RCT, n = 14, RR 1.00, 95% CI 0.19 to 5.24). Musculoskeletal: ankle pain (1 RCT, n = 14, RR 0.33, 95% CI 0.02 to 7.02); knee and foot pain (1 RCT, n = 14, RR 0.33, 95% CI 0.02 to 7.02); muscle twitch (1 RCT, n = 14, RR 3.00, 95% CI 0.14 to 63.15). Renal side-effects: retention (1 RCT, n = 14, RR 0.33, 95% CI 0.02 to 7.02); urgency (1 RCT, n = 14, RR 0.33, 95% CI 0.02 to 7.02) (Analysis 1.10).

1.11 Leaving the study early

1.11.1 Any reason

Two studies reported data on this outcome (Machielsen 2014; Noordsy 2010). There were no statistically significant differences between risperidone and clozapine groups (2 RCT, n = 45, RR 0.49, 95% CI 0.10 to 2.51; $I^2 = 34\%$), Analysis 1.11.

1.11.2 Due to inefficacy

One study provided data for this outcome (Noordsy 2010). There were no participants who left the study due to inefficacy.

Missing outcomes (risperidone versus clozapine)

There were no studies reporting data on mortality or quality of life.

Comparison 2: risperidone versus olanzapine

A total of five studies contributed data to this comparison (Akerele 2007; Sevy 2011; Smelson 2006; Swartz 2008; van Nimwegen 2008). See Summary of findings 2.

2.1 Mental state: 1. Specific: Depression – change scores (HAM-D, higher = better), short term (up to 6 months)

Only Akerele 2007 included data on this outcome. There were no significant differences between the risperidone and olanzapine groups in the reduction of depressive symptoms from baseline to the end of the study (1 RCT, $n = 22$, MD -0.11 , 95% CI -0.78 to 0.56), Analysis 2.1.

2.2 Mental state: 2. Specific: Positive symptoms, total score – average endpoint scores (SADS-C-PD scale, lower = better), short term (up to 6 months)

Only one study provided analysable data for this outcome (Sevy 2011). There were no significant differences between the risperidone and olanzapine groups in positive symptoms scores (1 RCT, $n = 37$, MD -1.50 , 95% CI -3.82 to 0.82), Analysis 2.2.

2.3 Mental state: 3. Specific: Positive symptom subscales – average endpoint scores (SADS-C-PD scale, lower = better), short term (up to 6 months) – skewed data

In addition to total scores for positive symptoms, one study reported on endpoint data for specific types of positive symptoms, namely delusions, hallucinations and thought disorder (Sevy 2011). Data were skewed and best viewed in an additional table (Analysis 2.3). No significant differences between risperidone and olanzapine were reported.

2.4 Mental state: 4. Specific: Negative symptoms, subscales – average endpoint scores (SANS subscales, lower = better), short term (up to 6 months)

Only one study provided analysable data (Sevy 2011). There were no significant differences between the risperidone and olanzapine groups in terms of different subscales for negative symptoms, i.e. affective flattening (1 RCT, $n = 39$, MD 0.50 , 95% CI -0.17 to 1.17); alogia (1 RCT, $n = 39$, MD 0.40 , 95% CI -0.22 to 1.02); avolition apathy (1 RCT, $n = 39$, MD -0.10 , 95% CI -0.73 to 0.53); asociality-anhedonia (1 RCT, $n = 39$, MD -0.10 , 95% CI -0.80 to 0.60), Analysis 2.4.

2.5 Substance use: 1. Substance use: Reduction of cannabis use-change data (number of joints smoked/week, LOCF data, higher = better), short-term data (up to 6 months)

One study provided data (van Nimwegen 2008). There were no significant differences between risperidone and olanzapine in the number of joints smoked (1 RCT, $n = 41$, MD 0.40 , 95% CI -4.72 to 5.52), Analysis 2.5.

2.6 Substance use: 2. Discontinued substance use, short term (up to 6 months)

2.6.1 Substance use: stopped using cannabis (Urine testing and Substance Use Questionnaire)

Only one study provided analysable data (Sevy 2011). There were no significant differences between risperidone and olanzapine in the number of participants who discontinued cannabis (1 RCT, $n = 37$, RR 1.19 , 95% CI 0.68 to 2.08), Analysis 2.6.

2.6.2 Substance use: stopped using alcohol (Substance Use Questionnaire)

One study provided analysable data (Sevy 2011). There were no significant differences between risperidone and olanzapine in the number of participants who discontinued alcohol (1 RCT, $n = 28$, RR 1.31 , 95% CI 0.73 to 2.36), Analysis 2.6.

2.7 Craving for substances: 1. Obsessive Compulsive Drug Use Scale – average endpoint score (OCDUS, lower = better), short term (up to 6 months)

One study provided data for this outcome (van Nimwegen 2008). There were no significant differences between the risperidone and olanzapine groups in craving as measured by this scale (1 RCT, $n = 41$, MD 1.30 , 95% CI -3.51 to 6.11), Analysis 2.7.

2.8 Craving for substances: 2. Desires for Drug Questionnaire – average endpoint scores (DDQ, LOCF data, lower = better), short term (up to 6 months)

One study provided data for this outcome (van Nimwegen 2008). There were no significant differences between the risperidone and olanzapine groups in craving as measured by this scale (1 RCT, $n = 41$, MD 5.00 , 95% CI -4.86 to 14.86), Analysis 2.8.

2.9 Adverse effects

2.9.1 Movement disorders: Parkinsonism – average endpoint score (SAS, high = worse), short term (up to 6 months)

One study provided data on this outcome (Akerele 2007). There were no significant differences in the scores on this scale between the risperidone and olanzapine groups (1 RCT, $n = 16$, MD -0.08 , 95% CI -1.21 to 1.05), Analysis 2.9.

2.9.2 Non-movement disorder related side-effects: weight gain-average endpoint score (BMI, lower = better), short term (up to 6 months)

Only one study provided data on this outcome (Sevy 2011). There were no significant differences in the scores on this scale between the risperidone and olanzapine groups (1 RCT, $n = 37$, MD -1.00 , 95% CI -3.99 to 1.99), Analysis 2.9.

2.10 Leaving the study early: 1. Various reasons

2.10.1 Any reason, short term (up to 6 months)

Two studies provided data for this outcome (Akerele 2007; Sevy 2011). There were no significant differences between risperidone and olanzapine in the number of participants leaving the studies early (2 RCT, $n = 77$, RR 0.68 , 95% CI 0.34 to 1.35 ; $I^2 = 0\%$), Analysis 2.10.

2.10.2 Any reason, long-term data (> 12 months)

One study provided data for this outcome (Swartz 2008). There were no significant differences between risperidone and olanzapine in

the number of participants leaving the study early (1 RCT, $n = 299$, RR 1.07, 95% CI 0.94 to 1.21), [Analysis 2.10](#).

2.10.3 Readmission, short term (up to 6 months)

Only one study provided data on this outcome ([Akerle 2007](#)). In [Akerle 2007](#) participants leaving the study early as a result of readmission to an inpatient unit were similar across the risperidone and olanzapine groups, with no significant differences (1 RCT, $n = 28$, RR 1.00, 95% CI 0.07 to 14.45), [Analysis 2.10](#).

2.10.4 Intolerable adverse effect, short term (up to 6 months)

One study provided data on this outcome ([Akerle 2007](#)). In [Akerle 2007](#) no participants left the study early in either treatment group due to adverse medication effects ([Analysis 2.10](#)).

2.10.5 Participant loss of interest, short term (up to 6 months)

One study provided data on this outcome ([Akerle 2007](#)). In [Akerle 2007](#) there were no significant differences between risperidone and olanzapine in leaving the study early due to lack of interest, although the risperidone group were less likely to drop out due to lack of interest (1 RCT, $n = 28$, RR 0.43, 95% CI 0.14 to 1.33), [Analysis 2.10](#).

2.11 Leaving the study early: 2. Weeks in the study – average endpoint data (high = good), short term (up to 6 months)

Only one study provided data on this outcome ([Akerle 2007](#)). In [Akerle 2007](#) there were no differences in time remaining in the study treatment between the risperidone and olanzapine groups (1 RCT, $n = 28$, MD 0.00, 95% CI -3.35 to 3.35), [Analysis 2.11](#).

2.12 Leaving the study early: 3. Weeks in study – average endpoint data (high = good), short term (up to 6 months) – skewed data

2.12.1 Weeks remained in study – average endpoint data (high = good), short term (up to 6 months) – skewed data

One study provided data for this outcome ([Smelson 2006](#)). Data was skewed so is best inspected in an additional table ([Analysis 2.12](#)).

Comparison 3: risperidone versus perphenazine

3.1 Leaving the study early: all-cause discontinuation, long term (> 12 months)

One study provided data for this outcome ([Swartz 2008](#)). There were no significant differences between risperidone and perphenazine for this outcome (1 RCT, $n = 281$, RR 1.05, 95% CI 0.92 to 1.20), [Analysis 3.1](#).

Comparison 4: risperidone versus quetiapine

4.1 Leaving the study early: all-cause discontinuation, long term (> 12 months)

One study provided data for this outcome ([Swartz 2008](#)). There was no statistically significant difference between risperidone and quetiapine (1 RCT, $n = 294$, RR 0.96, 95% CI 0.86 to 1.07), [Analysis 4.1](#).

Comparison 5: risperidone versus ziprasidone

5.1 Leaving the study early: all-cause discontinuation, long term (> 12 months)

One study provided data for this outcome ([Swartz 2008](#)). There were no significant differences between risperidone and ziprasidone (1 RCT, $n = 240$, RR 0.96, 95% CI 0.85 to 1.10), [Analysis 5.1](#).

6. Missing outcomes (risperidone versus olanzapine)

There were no studies reporting data for general mental state (CGI), anxiety symptoms, subjective well-being, adverse effects such as metabolic syndrome (other than parkinsonism and weight gain), mortality and quality of life.

DISCUSSION

Summary of main results

Comparison 1: risperidone versus clozapine

Only two studies ([Noordsy 2010](#); [Machielsen 2014](#)), containing 50 participants, provided usable data for this comparison ([Summary of findings for the main comparison](#)). A third study, [Brunette 2011](#), met criteria for inclusion but we were unable to extract any usable data from this study. Studies with useable data reported no statistically significant differences between risperidone and clozapine in terms of worsening of general psychotic symptoms, general anxiety symptoms, reduction in substance use, subjective well-being, medication adherence, movement disorder-related side-effects, other side-effects or leaving the study early ([Machielsen 2014](#); [Noordsy 2010](#)). However, in the study by [Machielsen 2014](#), lower negative symptoms were found in the clozapine group as compared to the risperidone-treated group. In addition, lower immediate and 'past 1 week' craving scores were found for participants treated with clozapine as opposed to risperidone ([Machielsen 2014](#)). No results were reported on mortality or quality of life, and side-effects such as weight gain and metabolic syndrome were inconsistently reported. The sample size in this study was very low ($N = 36$), limiting the conclusions that can be drawn from the analysis of data ([Machielsen 2014](#)). Moreover in the study by [Noordsy 2010](#) participants in the clozapine group reported the emergence or worsening of psychotic symptoms and more participants in the risperidone group reported the emergence of anxiety symptoms, although these differences did not reach statistical significance.

Comparison 2: risperidone versus olanzapine

Five studies — [Akerle 2007](#); [Sevy 2011](#); [Smelson 2006](#); [Swartz 2008](#); [van Nimwegen 2008](#) — comprising 997 participants provided data for this comparison ([Summary of findings 2](#)). Overall the quality of evidence was low to very low. Studies differed in terms of design and outcomes measured, precluding pooling of outcome data. In addition sample size was low for most of the individual studies, with [Akerle 2007](#), [Sevy 2011](#) and [van Nimwegen 2008](#) having sample sizes below $N = 50$, limiting the conclusions that can be drawn from them. There were no statistically significant differences between risperidone and olanzapine for a reduction in any mental symptoms (depression, positive or negative symptoms). In one study there was some evidence of significantly fewer days of any substance use for the olanzapine group compared to the risperidone group, whereas the risperidone group showed significantly greater reductions in craving for cannabis use ([Akerle 2007](#)). In turn,

olanzapine-treated participants had a significantly longer time to all-cause antipsychotic treatment discontinuation in one study (Smelson 2006). However, there were no significant differences between the risperidone and olanzapine groups in the proportion of participants with urine-positive weeks for the cannabis and cocaine use subgroups, cocaine craving, parkinsonism, weight gain or leaving the study early. Results for many outcomes were incompletely reported or not suitable for re-analysis and we were only able to report in a qualitative, narrative format. Of note, in many studies authors did not report on any measures relating to metabolic side-effects such as weight gain, abnormalities in glucose or lipid metabolism. For subjective well-being, authors reported only total sample findings and did not report on subgroups who used substances. Furthermore, no results were reported on mortality or quality of life.

Comparison 3: risperidone versus perphenazine

One study (Swartz 2008), with data on 281 participants, reported on leaving the study early, with no differences between risperidone- or perphenazine-treated participants.

Comparison 4: risperidone versus quetiapine

One study (Swartz 2008), with data on 294 participants, provided data for this comparison. There was no significant difference between the risperidone and quetiapine groups in leaving the study early.

Comparison 5: risperidone versus ziprasidone

One study (Swartz 2008), with data on 240 participants, reported on leaving the study early, with no differences between risperidone- or ziprasidone-treated participants.

Overall completeness and applicability of evidence

1. Completeness

The reporting of outcome data was incomplete and generally poor. In addition, some trials often failed to report on outcomes that were mentioned to have been measured in the protocol and Methods sections (Akerle 2007; Noordsy 2010). Primary outcomes of improvement in mental state and substance use were poorly reported, with many studies not reporting on changes in mental state or reporting incompletely (Noordsy 2010; Smelson 2006; van Nimwegen 2008). Substance use was also not reported on in Smelson 2006 and Swartz 2008.

Many studies also failed to report on important outcomes such as weight gain, metabolic changes and endocrinological adverse effects. No outcomes on craving were reported in Noordsy 2010, Sevy 2011, Smelson 2006, and Swartz 2008; and adherence was not reported by Noordsy 2010, Sevy 2011, Swartz 2008 and van Nimwegen 2008. Many studies failed to report on subjective well-being, mortality or quality of life (Akerle 2007, Noordsy 2010; Sevy 2011; Smelson 2006; Swartz 2008).

2. Applicability of evidence

Six of the included trials — Akerle 2007, Brunette 2011, Noordsy 2010, Sevy 2011, Smelson 2006 and Swartz 2008 — were conducted in the USA and two in the Netherlands (Machielsen 2014; van Nimwegen 2008). We found no trials conducted in developing countries. All trials involved comparisons of risperidone with SGAs or clozapine; and only two trials included comparison with

FGAs (Smelson 2006; Swartz 2008), only one with useable data (Swartz 2008). Some SGAs may have lower availability due to cost in middle- and low-income countries, potentially leading to lower applicability of findings to these settings. In most studies males and females were eligible for inclusion, but the study by Akerle 2007 included mostly men and only males were included in Machielsen 2014, potentially limiting applicability to female populations. Moreover, mixed ethnic groups were included in most studies. Noordsy 2010 and Brunette 2011 included only Caucasians (understood to be white participants).

The sample size of many included trials was very low and below $N = 50$ (Akerle 2007; Brunette 2011; Machielsen 2014; Noordsy 2010; Sevy 2011; van Nimwegen 2008). One trial had sample sizes between 100 and 300 (Smelson 2006); and one study had a sample size of more than 400 (Swartz 2008).

Quality of the evidence

1. General

Overall, of the eight studies included in this review, across most studies reporting of results was poor and did not adhere to CONSORT standards (1996). As a result many outcomes yielded unusable data.

2. Specific

From the eight included studies there were five comparisons of risperidone with other antipsychotics. For most studies sample sizes were small. Risk of bias was unclear in most domains across the included studies, however in some instances there was high risk of bias particularly with regards to performance bias, attrition bias, selective outcome reporting and other forms of bias. Moreover, due to heterogeneity in design and poor outcome reporting, pooling of data in meta-analyses was not possible for most outcomes leading to imprecise effect estimates and precluding any meaningful analysis of results and yielding low to very low quality evidence for the main outcomes.

Potential biases in the review process

We conducted a wide search, including a grey literature search, and searches of clinical trial registers and screening of recent relevant conference abstracts. Study selection and data extraction was done in duplicate to minimise the potential for selection and information bias. Our search was conducted within the Cochrane Schizophrenia Group's Trials Register and the Cochrane Depression, Anxiety and Neurosis Controlled Trials Register. We did not include searches of the Drugs and Alcohol group register. This may have led us to miss some studies examining treatments for substance use disorders that contain some participants with serious mental illness, but this is unlikely.

We also contacted authors to clarify reporting of studies and to provide missing data. Following our extensive search we are not aware of any additional studies in this field, but we are open to review the evidence and would call upon authors to contact us should there be any trial that warrant consideration for inclusion.

Agreements and disagreements with other studies or reviews

There have been a number of systematic reviews evaluating the efficacy of antipsychotics in people with a dual diagnosis. In Baker

2010 and Baker 2012 the authors reached similar conclusions regarding the evidence for risperidone versus other antipsychotics. In addition Wobrock 2009 reached conclusions similar to ours, although the methods of grading evidence differed from our review. In Lazary 2012, authors suggest certain agents such as olanzapine and clozapine may be superior to others (including risperidone) but express reservations on the quality of evidence as they based their findings on a mixture of observational and randomised trial evidence. Furthermore, Lazary 2012 used different methods from our review to assess study quality and strength of evidence. In Machielsen 2009 the authors included two studies that we excluded in our review (containing mixed single and dual diagnosis groups and a mixed comparator medication group) and reached a conclusion that clozapine may be superior to risperidone, although they caution against a firm conclusion because of the paucity of well-designed trials. McLoughlin 2014 compared the use of different antipsychotics (classified as antipsychotic A versus B) in people with schizophrenia and co-occurring cannabis disorders and reached similar conclusion to our review, despite different methods and inclusion of different studies.

AUTHORS' CONCLUSIONS

Implications for practice

1. For people with schizophrenia

Although there are theories postulating risperidone to be more efficacious in the treatment of people with a dual diagnosis, all evidence currently available is low in quality and does not favour risperidone over any other antipsychotic medication. We found risperidone did not lead to significantly greater reductions of substance use or improvements in mental state compared to clozapine. In addition, risperidone did not lead to significantly greater reductions in substance use or improvements in mental state compared to olanzapine. Risperidone did not significantly improve study retention compared to perphenazine, quetiapine or ziprasidone. Of note: patient-relevant outcomes such as quality of life were not measured in any of the included studies. Due to the small sample size of the included studies and the overall low quality of evidence, limited conclusions can be drawn regarding these findings.

2. For clinicians

Overall the quality of the existing evidence is very low and includes a very small number of studies with very small sample sizes. We did not find evidence suggesting superiority of risperidone over clozapine, olanzapine, perphenazine, quetiapine or ziprasidone for any of the primary or secondary outcomes in our review. Of note: studies were confined to short-term outcomes and studies with comparisons of risperidone with first-generation antipsychotics were limited. All studies were conducted in a developed world setting.

3. For managers or policy makers

Reviews and pharmacological treatment guidelines for people with a dual diagnosis that suggest that second-generation antipsychotics (SGAs) such as risperidone may be the preferred treatment in this population need to be interpreted with caution. In particular, we found no evidence that risperidone was superior to clozapine, olanzapine, perphenazine, quetiapine or ziprasidone. Due to the paucity of comparisons with first-generation

antipsychotics (e.g. haloperidol and chlorpromazine), little can be said about the treatment effects of risperidone compared to first-generation antipsychotics. Therefore, it may be beneficial to include less expensive medications such as first-generation antipsychotics (such as haloperidol and chlorpromazine) in future in clinical trials in people with a dual diagnosis.

Implications for research

1. General

Future studies should include larger samples and comparisons of risperidone to both first- and second-generation antipsychotics. Investigators should adhere to CONSORT guidelines in reporting results. Adverse effects including those related to weight gain and metabolic disturbances should be reported.

2. Specific

2.1 Reviews

Many of the excluded studies could, perhaps, be included in other reviews; and titles or existing reviews are suggested in Table 3.

2.2 Trials

People with a dual diagnosis are likely to face substantial adversity across clinical, social, legal and financial areas of their lives. Whereas participation in clinical trials investigating the impact of pharmacological treatments is encouraged, it is likely that the recruitment and retention of people with a dual diagnosis in such trials may be difficult at best. The conduct of well-designed, multi-centre randomised adequately powered trials is therefore important. Furthermore it is critical that consistency be maintained in trial design in order to minimize heterogeneity in design, clinical populations studied and methods of outcome assessment. Consistency across studies and adherence to CONSORT guidelines in order to minimise risk of bias should allow for more robust pooling of results in meta-analyses. Engaging with the AllTrials initiative would allow liberation of all relevant data.

In addition, although the mechanisms underlying the differential treatment efficacy of antipsychotics is likely to be complex, and although the role of causal mechanisms is likely to be controversial in evidence-based assessments such as systematic reviews, we would encourage trialists to include a study component that investigates potential underlying neural mechanisms that may underlie the treatment effects of antipsychotics in people with a dual diagnosis. We realise that much care and thought goes into trial design but we also have given this some consideration and, therefore, suggest a design in Table 4.

ACKNOWLEDGEMENTS

The Cochrane Schizophrenia Group Editorial Base in Nottingham produces and maintains standard text for use in the Methods section of their reviews. We have used this text as the basis of what appears here and adapted it as required. We would like to thank Professor Clive Adams, Claire Irving, Jun Xia and Farhad Shokraneh for their patience, editorial assistance and efficient responses to questions.

We would also like to thank Trentham Furness for peer reviewing the protocol and Eleni-Maria Kokkoli, Joseph Wakeman and Zein Hussain for peer reviewing this version of the review.

We also express our gratitude to Juanjuan Ren, who extracted the data from Chinese studies; and to Sarah Dawson, Information

Specialist of Cochrane Common Mental Disorders Group, for developing the search strategies and searching their group's register for this review.

REFERENCES

References to studies included in this review

Akerele 2007 {published data only (unpublished sought but not used)}

* Akerele E, Levin FR. Comparison of olanzapine to risperidone in substance-abusing individuals with schizophrenia. *American Journal on Addictions* 2007;**16**(4):260-8.

Akerele EO, Biderman L, Levin FR. A pilot study of olanzapine/risperidone for the treatment of cocaine/marijuana use disorder in individuals with schizophrenia. 64th Annual Scientific Meeting of the College on Problems of Drug Dependence;2002 Jun 8-13, Quebec, Canada. 2002.

Akerele EO, Gill KB, Vosburg SK, Levin FR. Efficacy of atypical neuroleptics in treatment of substance use among schizophrenic individuals. *Drug and Alcohol Dependence* 2002;**66**(Suppl 1):S4.

Brunette 2011 {published and unpublished data}

Brunette M, Dawson R, O'Keefe CD, Noordsy DL, Green A. Clozapine versus other antipsychotics for schizophrenia and co-occurring cannabis use disorder. *Schizophrenia Bulletin* 2011;**37**(suppl_1):297.

* Brunette MF, Dawson R, O'Keefe CD, Narasimhan M, Noordsy DL, Wojcik J, et al. A randomized trial of clozapine versus other antipsychotics for cannabis use disorder in patients with schizophrenia. *Journal of Dual Diagnosis* 2011;**7**(1-2):50-63.

NCT00149955. Cannabis and schizophrenia: effects of clozapine. www.ClinicalTrials.gov/ct/show/ (Accessed 06 January 2016).

Machielsen 2014 {published data only}

Machielsen M, De Haan L. Differential effect of clozapine and risperidone on craving related brain activity in patients with schizophrenia and cannabis use disorder. *Schizophrenia Bulletin* 2011;**37**(suppl_1):145.

Machielsen MW, Veltman DJ, van den Brink W, de Haan L. Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. www.sciencedirect.com/science/article/pii/S0920996417301688 (accessed prior to 28 November 2017).

* Machielsen MWJ, Veltman DJ, van den Brink W, de Haan L. The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: an fMRI study. *Journal of Psychopharmacology* 2014;**28**(7):633-642.

de Haan L, Machielsen MWJ. Effect of different antipsychotic medications on craving and craving related brain activity in patients with schizophrenia and cannabis abuse or dependence: a randomized controlled study comparing clozapine and risperidone. www.trialregister.nl/trialreg/index.asp (Accessed 06 January 2016).

Noordsy 2010 {published and unpublished data}

NCT00573287. First episode schizophrenia and cannabis-related disorder study. clinicaltrials.gov/ct2/show/NCT00573287 (Accessed 06 January 2016).

Noordsy D. First episode schizophrenia and cannabis abuse: is there a role for clozapine?. Proceedings of the 15th Biennial Winter Workshop in Psychoses; 2009 Nov 15-18; Barcelona, Spain. 2009.

* Noordsy D, Green JA. Clozapine versus risperidone for people with first episode schizophrenia and co-occurring cannabis use disorder. *Schizophrenia Research* 2010;**117**(2-3):165-6.

Noordsy DL. Personal Communication. Personal Communication 2012.

Sevy 2011 {published data only}

Sevy S, Robinson DG, Napolitano B, Gallego J, Patel RC, Soto-Perello JM, et al. Clinical and substance use outcomes of first-episode schizophrenia patients with a lifetime diagnosis of cannabis use disorders randomly assigned to risperidone or olanzapine for 16 weeks. *Schizophrenia bulletin* 2009;**35**(suppl_1):355-6.

* Sevy S, Robinson DG, Sunday S, Napolitano B, Miller R, McCormack J, et al. Olanzapine versus risperidone in patients with first-episode schizophrenia and a lifetime history of cannabis use disorders: 16-week clinical and substance use outcomes. *Psychiatry Research* 2011;**188**(3):310-4.

Smelson 2006 {published data only}

Smelson D, Nyhuis AW, Faries DE, Tunis SL. Impact of substance use on attrition and medication switching in an effectiveness trial for individuals with schizophrenia: implications for relapse prevention. The American Psychiatric Association, 158th Annual meeting, Psychosomatic medicine: Integrating psychiatry and medicine; 2005 May 21-26; Atlanta, Georgia. Arlington, VA: American Psychiatric Association, 2005.

Smelson D, Nyhuis AW, Faries DE, Tunis SL, Ascher-Svanum H, Montgomery WS. Impact of substance use on attrition and medication switching in an effectiveness trial for individuals with schizophrenia. *Australian and New Zealand Journal of Psychiatry* 2005;**39**(2 Suppl):A60.

* Smelson DA, Tunis SL, Nyhuis AW, Faries DE, Kinon BJ, Ascher-Svanum H. Antipsychotic treatment discontinuation among individuals with schizophrenia and co-occurring substance use. *Journal of Clinical Psychopharmacology* 2006;**26**(6):666-7.

Swartz 2008 {published data only}

Swartz MS, Wagner HR, Swanson JW, Stroup TS, McEvoy JP, Reimherr F, et al. The effectiveness of antipsychotic medications in patients who use or avoid illicit substances: results from the CATIE study. *Schizophrenia Research* 2008;**100**(1-3):39-52.

van Nimwegen 2008 {published data only}

Van Nimwegen L, De Haan L, Van Beveren N, Laan W, Van Den Brink W, Linszen D. Subjective well-being and craving

for cannabis in first psychosis, a randomized double blind comparison of olanzapine versus risperidone. *Schizophrenia Research* 2006;**81**(supplement):141.

* van Nimwegen LJ, de Haan L, van Beveren NJM, van der Helm M, van den Brink W, Linszen D. Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial. *Canadian Journal of Psychiatry. Revue Canadienne de Psychiatrie* 2008;**53**(6):400-5.

References to studies excluded from this review

Blin 1996 {published data only}

Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. *Journal of Clinical Psychopharmacology* 1996;**16**(1):38-44.

Gaebel 2010 {published data only}

Gaebel W, Schreiner A, Bergmans P, De Arce R, Rouillon F, Cordes J, et al. Relapse prevention in schizophrenia and schizoaffective disorder with risperidone long-acting injectable vs quetiapine: results of a long-term, open-label, randomized clinical trial [NCT00216476]. *Neuropsychopharmacology* 2010;**35**(12):2367-77.

Green 2001 {published data only}

Green A. Cannabis and schizophrenia-clozapine vs risperidone. www-commons.cit.nih.gov/crisp/index.html (Accessed 19 February 2001).

Harvey 2007 {published data only}

* Harvey PD, Hassman H, Mao L, Gharabawi GM, Mahmoud RA, Engelhart LM. Cognitive functioning and acute sedative effects of risperidone and quetiapine in patients with stable bipolar I disorder: a randomized, double-blind, crossover study. *Journal of Clinical Psychiatry* 2007;**68**(8):1186-94.

Hassman H, Glass S, Krefetz D, Pinho M, Ridolfi E, Engelhardt L, et al. Cognitive function and acute sedative effects of risperidone and quetiapine in patients with stable Bipolar I Disorder: a randomized, double-blind, crossover study. 46th Annual NCDEU (New Clinical Drug Evaluation Unit) Meeting; 2006 June 12-15. Boca Raton, FL., 2006; Vol. 213.

Hassman HA, Glass SJ, Engelhart L, Mao L, Rodriguez S, Gharabawi G, et al. Differences in cognitive function and acute sedative effects of risperidone and quetiapine among individuals with stable Bipolar I Disorder. *Neuropsychopharmacology* 2005;**30**(Suppl 1):S133-4.

Ikuta 2014 {published data only}

Ikuta T, Robinson DG, Gallego JA, Peters BD, Gruner P, Kane J, et al. Subcortical modulation of attentional control by second-generation antipsychotics in first-episode psychosis. *Psychiatry Research* 2014;**221**(2):127-34.

Kerfoot 2011 {published data only}

Kerfoot KE, Rosenheck RA, Petrakis IL, Swartz MS, Keefe RS, McEvoy JP, et al. Substance use and schizophrenia: adverse

correlates in the CATIE study sample. *Schizophrenia Research* 2011;**132**(2-3):177-82.

Liemburg 2011 {published data only}

Liemburg E, Aleman A, Bous J, Hollander K, Knegtering H. An open randomized pilot trial on the differential effects of aripiprazole versus risperidone on anhedonia and subjective well-being. *Pharmacopsychiatry* 2011;**44**(3):109-13.

Liu 2008 {published data only}

Liu ZR, Zhang W, Lin H. A comparative study of risperidone and olanzapine in the treatment of mental disorders due to use of alcohol. *Chinese Magazine of Drug Abuse Prevention and Treatment* 2008;**14**(3):138-9.

NCT00063349 {published data only}

Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. *Schizophrenia Research* 2003;**60**(1):81-5.

* NCT00063349. Clozapine, cannabis and first episode schizophrenia. www.ClinicalTrials.gov/ct/show/ (Accessed 06 January 2016).

NCT00130923 {published data only}

Green AI, Brunette MF, Dawson R, Buckley P, Wallace AE, Hafez H, et al. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. *Journal of Clinical Psychiatry* 2015;**76**(10):1359-65.

NCT00130923. Risperidone long-acting for alcohol and schizophrenia treatment (R-LAST). www.ClinicalTrials.gov/ct/show/ (Accessed 06 January 2016).

NCT00169026 {unpublished data only}

NCT00169026. Alcoholism and schizophrenia: effects of clozapine. www.ClinicalTrials.gov/ct/show/ (Accessed 06 January 2016).

NCT00498550 {published data only}

NCT00498550. Cannabis and schizophrenia: effects of clozapine. www.ClinicalTrials.gov/ct/show/ (Accessed 06 January 2016).

Nejtek 2008 {published data only}

Nejtek VA, Avila M, Chen LA, Zielinski T, Djokovic M, Podawiltz A, et al. Do atypical antipsychotics effectively treat co-occurring bipolar disorder and stimulant dependence? A randomized, double-blind trial. *Journal of Clinical Psychiatry* 2008;**69**(8):1257-66.

Perlis 2006 {published data only}

Perlis RH, Baker RW, Zarate Jr CA, Brown EB, Schuh LM, Jamal HH, et al. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial. *Journal of Clinical Psychiatry* 2006;**67**(11):1747-53.

Rezayat 2014 {published data only}

Rezayat AA, Hebrani P, Behdani F, Salaran M, Marvast MN. Comparison the effectiveness of aripiprazole and risperidone

for the treatment of acute bipolar mania. *Journal of Research in Medical Sciences* 2014;**19**(8):733-8.

Rubio 2006a {published data only}

Rubio G, Marfinez-Gras I, Ponce G, Lopez-Munoz F, Alamo C, Jimenez-Arriero MA, et al. Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long-term controlled study. *European Neuropsychopharmacology* 2005;**15**(Suppl 3):S476.

Rubio G, Martinez I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. Long-acting injectable risperidone compared with zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. *Canadian Journal of Psychiatry* 2006;**51**(8):531-9.

Rubio 2006b {published data only}

Rubio G, Martine I, Recio A, Ponce G, Lopez-Munoz F, Alamo C, et al. Risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity: a long-term randomized, controlled, crossover study. *European Journal of Psychiatry* 2006;**20**(3):133-46.

Rubio G, Martinez-Gras I, Ponce G, Jimenez-Arriero MA, Lopez-Munoz F, Alamo C. Long-acting injectable risperidone versus zuclopenthixol in the treatment of schizophrenia with substance abuse comorbidity. 159th Annual Meeting of the American Psychiatric Association; 2006, May 20-25. Toronto, Canada, 2006.

Sachs 2002 {published data only}

Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. *American Journal of Psychiatry* 2002;**159**(7):1146-54.

Sajatovic 2002 {published data only}

Sajatovic M, Mullen JA, Sweitzer DE. Efficacy of quetiapine and risperidone against depressive symptoms in outpatients with psychosis. *Journal of Clinical Psychiatry* 2002;**63**(12):1156-63.

Smulevich 2005 {published data only}

Smulevich AB, Khanna S, Eerdeken M, Karcher K, Kramer M, Grossman F. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol [NCT00253162]. *European Neuropsychopharmacology* 2005;**15**(1):75-84.

van Nimwegen 2008a {published data only}

van Nimwegen L, de Haan L, van Beveren N, Laan W, van den Brink W, Linszen D. Obsessive-compulsive symptoms in a randomized, double-blind study with olanzapine or risperidone in young patients with early psychosis. *Journal of Clinical Psychopharmacology* 2008;**28**(2):214-8.

Yatham 2007 {published data only}

Yatham LN, Fallu A, Binder CE. A 6-month randomized open-label comparison of continuation of oral atypical antipsychotic therapy or switch to long acting injectable risperidone in

patients with bipolar disorder. *Acta Psychiatrica Scandinavica* 2007;**434**:50-6.

Zhangyue 2005 {published data only}

Zhangyue B, Liu X. Aripiprazole and risperidone in the treatment of schizophrenia. *Chinese Journal of Behavioral Medical Science* 2005;**14**(10):923-5.

References to studies awaiting assessment

Greenspan 2005 {published data only}

Greenspan A, Kosik-Gonzalez C, Bossie C, Zhu Y, McLemore J, Gharabawi G. Atypical antipsychotics in patients with schizophrenia and comorbid substance abuse. 158th Annual Meeting of the American Psychiatric Association; 2005 May 21-26; Atlanta, Georgia, USA. 2005:Nr279.

Johnsen 2010 {published data only}

* Johnsen E, Kroken RA, Wentzel-Larsen T, Jorgensen HA. Effectiveness of second-generation antipsychotics: a naturalistic, randomized comparison of olanzapine, quetiapine, risperidone, and ziprasidone [NCT00932529]. *BMC Psychiatry* 2010;**10**:26.

Kjelby E, Jorgensen H A, Kroken R A, Loberg E M, Johnsen E. Anti-depressive effectiveness of olanzapine, quetiapine, risperidone and ziprasidone: a pragmatic, randomized trial. *BMC Psychiatry* 2011;**11**:145.

NCT00208143 {unpublished data only}

NCT00208143. Seroquel (quetiapine) therapy for schizophrenia and schizoaffective disorders and comorbid cocaine and/or amphetamine abuse/dependence: a comparative study with risperidone. clinicaltrials.gov/show/NCT00208143 (Accessed 06 January 2016).

San 2012 {published data only}

San L, Arranz B, Perez V, Safont G, Corripio I, Ramirez N, et al. One-year, randomized, open trial comparing olanzapine, quetiapine, risperidone and ziprasidone effectiveness in antipsychotic-naive patients with a first-episode psychosis. *Psychiatry Research* 2012;**200**(2-3):693-701.

Yatham 2003 {published data only}

Yatham L N, Beaulieu S, Schaffer A, Kauer-Sant'Anna M, Kapczinski F, Lafer B, et al. Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. *Mol Psychiatry* 2016;**21**(8):1050-6.

* Yatham L, et al. Atypical antipsychotics for continuation and maintenance treatment after an acute manic episode. clinicaltrials.gov/show/NCT01977300 2003.

References to ongoing studies

NCT01639872 {unpublished data only}

NCT01639872. Clozapine for cannabis use in schizophrenia (CLOCS). clinicaltrials.gov/ct2/show/NCT01639872 (Accessed 06 January 2016).

Additional references

Altman 1996

Altman DG, Bland JM. Detecting skewness from summary information. *BMJ* 1996;**313**(7066):1200.

Andreasen 1982

Andreasen NC. Negative symptoms in schizophrenia. Definition and reliability. *Archive of General Psychiatry* 1982;**39**(7):784-8.

Ascher-Svanum 2006

Ascher-Svanum H, Zhu B, Faries D, Lacro JP, Dolder CR. A prospective study of risk factors for nonadherence with antipsychotic medication in the treatment of schizophrenia. *Journal of Clinical Psychiatry* 2006;**67**(7):1114-23.

Baker 2010

Baker AL, Hides L, Lubman DI. Treatment of cannabis use among people with psychotic or depressive disorders: a systematic review. *Journal of Clinical Psychiatry* 2010;**71**(3):247-54.

Baker 2012

Baker AL, Thornton LK, Hides L, Dunlop A. Treatment of cannabis use among people with psychotic disorders: a critical review of randomised controlled trials. *Current Pharmaceutical Design* 2012;**18**(32):4923-37.

Barnes 1989

Barnes TR. A rating scale for drug-induced akathisia. *British Journal of Psychiatry* 1989;**154**:672-6. [PUBMED: 2574607]

Barnett 2007

Barnett JH, Werners U, Secher SM, Hill KE, Brazil R, Masson K, et al. Substance use in a population-based clinic sample of people with first-episode psychosis. *British Journal of Psychiatry* 2007;**190**:515-20.

Baxter 2010

Baxter S, Killoran A, Kelly MP, Goyder E. Synthesizing diverse evidence: the use of primary qualitative data analysis methods and logic models in public health reviews. *Public Health* 2010;**124**(2):99-106.

Bland 1997

Bland JM. Statistics notes. Trials randomised in clusters. *BMJ* 1997;**315**(7108):600.

Boissel 1999

Boissel JP, Cucherat M, Li W, Chatellier G, Gueyffier F, Buyse M, et al. The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use [Aperçu sur la problématique des indices d'efficacité thérapeutique, 3: comparaison des indices et utilisation. Groupe d'Etude des Indices D'efficacité]. *Thérapie* 1999;**54**(4):405-11. [PUBMED: 10667106]

Broderick 2003

Broderick PA, Rahni DN, Zhou Y. Acute and subacute effects of risperidone and cocaine on accumbens dopamine and

serotonin release using in vivo microvoltammetry on line with open-field behavior. *Progress in Neuro-psychopharmacology & Biological Psychiatry* 2003;**27**(6):1037-54.

Buckley 2006

Buckley PF. Prevalence and consequences of the dual diagnosis of substance abuse and severe mental illness. *Journal of Clinical Psychiatry* 2006;**67**(Suppl 7):5-9.

de Haan 2000

de Haan L, Lavalaye J, Linszen D, Dingemans PM, Booij J. Subjective experience and striatal dopamine D(2) receptor occupancy in patients with schizophrenia stabilized by olanzapine or risperidone. *American Journal of Psychiatry* 2000;**157**(6):1019-20.

de Haan 2002

de Haan L, Weisfelt M, Dingemans P M, Linszen D H, Wouters L. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. *Psychopharmacology (Berl)* 2002;**162**(1):24-8.

Deeks 2000

Deeks J. Issues in the selection for meta-analyses of binary data. 8th International Cochrane Colloquium; 2000 Oct 25-28. Cape Town: The Cochrane Collaboration, 2000.

Deeks 2011

Deeks JJ, Higgins JPT, Altman DG editor(s). Chapter 9: Analysing data and undertaking meta-analyses. *Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0* (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org.

Dekker 2012

Dekker N, Koeter M, van den Brink W. Craving for cannabis in patients with psychotic disorder, their non-affected siblings and healthy controls: psychometric analysis of the obsessive compulsive drug use scale. *International Journal of Methods in Psychiatric Research* 2012;**21**(4):286-300.

Demyttenaere 2004

Demyttenaere K, Bruffaerts R, Posada-Villa J, Gasquet I, Kovess V, Lepine JP, et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. *JAMA* 2004;**291**(21):2581-90.

Divine 1992

Divine GW, Brown JT, Frazier LM. The unit of analysis error in studies about physicians' patient care behavior. *Journal of General Internal Medicine* 1992;**7**(6):623-9.

Donner 2002

Donner A, Klar N. Issues in the meta-analysis of cluster randomized trials. *Statistics in Medicine* 2002;**21**:2971-80.

Drevets 2001

Drevets WC, Gautier C, Price JC, Kupfer DJ, Kinahan PE, Grace AA, et al. Amphetamine-induced dopamine release in

human ventral striatum correlates with euphoria. *Biological Psychiatry* 2001;**49**(2):81-96.

Egger 1997

Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;**315**:629-34.

Elbourne 2002

Elbourne D, Altman DG, Higgins JPT, Curtina F, Worthington HV, Vaile A. Meta-analyses involving cross-over trials: methodological issues. *International Journal of Epidemiology* 2002;**31**(1):140-9.

Endicott 1978

Endicott J, Spitzer RL. A diagnostic interview: the schedule for affective disorders and schizophrenia. *Archive of General Psychiatry* 1978;**35**(7):837-44.

Fioritti 1997

Fioritti A, Ferri S, Galassi L, Warner R. Substance use among the mentally ill: a comparison of Italian and American samples. *Community Mental Health Journal* 1997;**33**(5):429-42.

First 1994

First MB, RL Spitzer, M Gibbon, JBW Williams. Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition (SCID-I-P, version 2). American Psychiatric Press, 1994.

Fleischhacker 2003

Fleischhacker WW, Eerdeken M, Karcher K, Remington G, Llorca PM, Chrzanowski W, et al. Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic. *Journal of Clinical Psychiatry* 2003;**64**(10):1250-7.

Fowler 1998

Fowler IL, Carr VJ, Carter NT, Lewin TJ. Patterns of current and lifetime substance use in schizophrenia. *Schizophrenia Bulletin* 1998;**24**(3):443-55.

Franken 2002

Franken IH, Hendriks VM, van den Brink W. Initial validation of two opiate craving questionnaires the obsessive compulsive drug use scale and the desires for drug questionnaire. *Addictive Behaviors* 2002;**27**(5):675-85.

Fukushiro 2007

Fukushiro DF, Alvarez Jdo N, Tatsu JA, de Castro JP, Chinen CC, Frussa-Filho R. Haloperidol (but not ziprasidone) withdrawal enhances cocaine-induced locomotor activation and conditioned place preference in mice. *Progress in Neuro-psychopharmacology & Biological Psychiatry* 2007;**31**(4):867-72.

Fukushiro 2008

Fukushiro DF, Carvalho Rde C, Ricardo VP, Alvarez Jdo N, Ribeiro LT, Frussa-Filho R. Haloperidol (but not ziprasidone) withdrawal potentiates sensitization to the hyperlocomotor effect of cocaine in mice. *Brain Research Bulletin* 2008;**77**(2-3):124-8.

Furukawa 2006

Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. *Journal of Clinical Epidemiology* 2006;**59**(7):7-10.

Gulliford 1999

Gulliford MC. Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994. *American Journal of Epidemiology* 1999;**149**:876-83.

Guy 1976

Guy W. ECDEU Assessment Manual for Psychopharmacology-Revised. Rockville, MD: US Department of Health and Human Services, 1976:534-7. [DHHS Publ No ADM 91-338]

Guyatt 2011

Guyatt G, Oxman A D, Akl E A, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. *J Clin Epidemiol* 2011;**64**:383-94.

Hamilton 1960

Hamilton M. A rating scale for depression. *Journal of Neurology Neurosurgery and Psychiatry* 1960;**23**:56-62.

Hasan 2012

Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. *World Journal of Biological Psychiatry* 2012;**13**(5):318-78.

Hasan 2013

Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthøj B, Gattaz WF, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects. *World Journal of Biological Psychiatry* 2013;**14**(1):2-44.

Hauli 2011

Hauli KA, Ndeti DM, Jande MB, Kabangila R. The prevalence of substance use among psychiatric patients: the case study of Bugando Medical centre, Mwanza (northern Tanzania). *Substance Abuse* 2011;**32**(4):238-41.

Heishman 2009

Heishman SJ, Evans RJ, Singleton EG, Levin KH, Copersino ML, Gorelick DA. Reliability and validity of a short form of the Marijuana Craving Questionnaire. *Drug and Alcohol Dependence* 2009;**102**(1-3):35-40.

Higgins 2003

Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. *BMJ* 2003;**327**:557-60.

Higgins 2011

Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Horacek 2006

Horacek J, Bubenikova-Valesova V, Kopecek M, Palenicek T, Dockery C, Mohr P, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. *CNS Drugs* 2006;**20**(5):389-409.

Hunter 2003

Hunter R, Kennedy E, Song F, Gadon L, Irving CB. Risperidone versus typical antipsychotic medication for schizophrenia. *Cochrane Database of Systematic Reviews* 2003, Issue 2. [DOI: [10.1002/14651858.CD000440](https://doi.org/10.1002/14651858.CD000440)]

Jablensky 2000

Jablensky A, McGrath J, Herrman H, Castle D, Gureje O, Evans M, et al. Psychotic disorders in urban areas: an overview of the Study on Low Prevalence Disorders. *Australian and New Zealand Journal of Psychiatry* 2000;**34**(2):221-36.

Janssen 1988

Janssen PA, Niemegeers CJ, Awouters F, Schellekens KH, Megens AA, Meert TF. Pharmacology of risperidone (R 64 766), a new antipsychotic with serotonin-5₂ and dopamine-D₂ antagonistic properties. *Journal of Pharmacology and Experimental Therapeutics* 1988;**244**(2):685-93.

Kapur 1995

Kapur S, Remington G, Zipursky RB, Wilson AA, Houle S. The D₂ dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. *Life Sciences* 1995;**57**(10):L103-7.

Kapur 1996

Kapur S. 5-HT₂ antagonism and EPS benefits: is there a causal connection?. *Psychopharmacology* 1996;**124**(1-2):35-9.

Kapur 2001

Kapur S, Seeman P. Does fast dissociation from the dopamine D₂ receptor explain the action of atypical antipsychotics?: a new hypothesis. *American Journal of Psychiatry* 2001;**158**(3):360-9.

Katz 2010

Katz G, Durst R, Shufman E, Bar-Hamburger R, Grunhaus L. Cannabis abuse and severity of psychotic and affective disorders in Israeli psychiatric inpatients. *Comprehensive Psychiatry* 2010;**51**(1):37-41.

Kay 1986

Kay SR, Opler LA, Fiszbein A. *Positive and Negative Syndrome Scale (PANSS) Manual*. North Tonawanda, NY: Multi-Health Systems, 1986.

Kay 1987

Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. *Schizophrenia Bulletin* 1987;**13**(2):261-76.

Kelly 2012

Kelly TM, Daley DC, Douaihy AB. Treatment of substance abusing patients with comorbid psychiatric disorders. *Addictive Behaviors* 2012;**37**(1):11-24.

Kessler 2004

Kessler RC. The epidemiology of dual diagnosis. *Biological Psychiatry* 2004;**56**(10):730-7.

Kuhar 1996

Kuhar MJ, Pilotte NS. Neurochemical changes in cocaine withdrawal. *Trends in Pharmacological Sciences* 1996;**17**(7):260-4.

Kuroki 2008

Kuroki T, Nagao N, Nakahara T. Neuropharmacology of second-generation antipsychotic drugs: a validity of the serotonin-dopamine hypothesis. *Progress in Brain Research* 2008;**172**:199-212.

Lacro 2002

Lacro JP, Dunn LB, Dolder CR, Leckband SG, Jeste DV. Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature. *Journal of Clinical Psychiatry* 2002;**63**(10):892-909.

Lambert 2005

Lambert M, Conus P, Lubman DI, Wade D, Yuen H, Moritz S, et al. The impact of substance use disorders on clinical outcome in 643 patients with first-episode psychosis. *Acta Psychiatrica Scandinavica* 2005;**112**(2):141-8.

Lazary 2012

Lazary J. Psychopharmacological boundaries of schizophrenia with comorbid cannabis use disorder: a critical review. *Current Pharmaceutical Design* 2012;**18**(32):4890-6.

Lehman 2004

Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. *American Journal of Psychiatry* 2004;**161**(2 Suppl):1-56.

Leucht 2005a

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. *British Journal of Psychiatry* 2005;**187**:366-71. [PUBMED: 16199797]

Leucht 2005b

Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel RR. What does the PANSS mean?. *Schizophrenia Research* 2005;**79**(2-3):231-8. [PUBMED: 15982856]

Leucht 2007

Leucht S, Engel RR, Bauml J, Davis JM. Is the superior efficacy of new generation antipsychotics an artifact of LOCF?. *Schizophrenia Bulletin* 2007;**33**(1):183-91. [PUBMED: 16905632]

Leucht 2009

Leucht S, Davis JM, Engel RR, Kissling W, Kane JM. Definitions of response and remission in schizophrenia: recommendations for their use and their presentation. *Acta Psychiatrica Scandinavica* 2009;**438**:7-14.

Lieberman 2005

Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. *New England Journal of Medicine* 2005;**353**(12):1209-23.

Lukoff 1986

Lukoff D, Nuechterlein KH, Ventura J. Manual for expanded Brief Psychiatric Rating Scale. *Schizophrenia Bulletin* 1986;**12**:594-602.

Machielsen 2009

Machielsen MW, de Haan L. Differences in efficacy on substance abuse between risperidone and clozapine supports the importance of differential modulation of dopaminergic neurotransmission. *Psychopharmacology Bulletin* 2009;**42**:40-52.

Marshall 2000

Marshall M, Lockwood A, Bradley C, Adams C, Joy C, Fenton M. Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia. *British Journal of Psychiatry* 2000;**176**:249-52.

Mattick 2014

Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. *Cochrane Database of Systematic Reviews* 2014, Issue 2. [DOI: [10.1002/14651858.CD002207.pub4](https://doi.org/10.1002/14651858.CD002207.pub4)]

McIntyre 2007

McIntyre RS, Soczynska JK, Woldeyohannes HO, Alsuwaidan M, Konarski JZ. A preclinical and clinical rationale for quetiapine in mood syndromes. *Expert Opinion on Pharmacotherapy* 2007;**8**(9):1211-9.

McLellan 1980

McLellan AT, Luborsky L, Woody GE, O'Brien CP. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. *Journal of Nervous and Mental Disease* 1980;**168**:26-33.

McLellan 1992

McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, et al. The Fifth Edition of the Addiction Severity Index. *J.Subst.Abuse Treat.* 1992;**9**(0740-5472 (Print)):199-213.

McLoughlin 2014

McLoughlin BC, Pushpa-Rajah JA, Gillies D, Rathbone J, Variend H, Kalakouti E, et al. Cannabis and schizophrenia.

Cochrane Database of Systematic Reviews 2014, Issue 10. [DOI: [10.1002/14651858.CD004837.pub3](https://doi.org/10.1002/14651858.CD004837.pub3)]

Menezes 1996

Menezes PR, Johnson S, Thornicroft G, Marshall J, Prosser D, Bebbington P, et al. Drug and alcohol problems among individuals with severe mental illness in south London. *British Journal of Psychiatry* 1996;**168**(5):612-9.

Modestin 1997

Modestin J, Nussbaumer C, Angst K, Scheidegger P, Hell D. Use of potentially abusive psychotropic substances in psychiatric inpatients. *European Archives of Psychiatry and Clinical Neuroscience* 1997;**247**(3):146-53.

Moller 2005

Moller HJ. Risperidone: a review. *Expert Opinion on Pharmacotherapy* 2005;**6**(5):803-18.

Moller 2007

Moller HJ. Long-acting injectable risperidone for the treatment of schizophrenia: clinical perspectives. *Drugs* 2007;**67**(11):1541-66.

Naber 1995

Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. *International Clinical Psychopharmacology* 1995;**10**(Suppl 3):133-8.

National Institute of Mental Health 1988

National Institute of Mental Health Psychopharmacology Research Branch. Abnormal Involuntary Movement Scale (AIMS). *Psychopharmacology Bulletin* 1988;**24**:781-3.

Newcomer 2007

Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. *Journal of Clinical Psychiatry* 2007;**68**(Suppl 1):20-7.

NICE 2009

National Collaborating Centre for Mental Health (UK). Schizophrenia: Core Interventions in the Treatment and Management of Schizophrenia in Primary and Secondary Care (Update). (NICE Clinical Guidelines, No. 82). Leicester: British Psychological Society, 2009.

NICE 2011

National Collaborating Centre for Mental Health (UK). Psychosis with Coexisting Substance Misuse: Assessment and Management in Adults and Young People. (NICE Clinical Guidelines, No. 120). Leicester: British Psychological Society, 2011.

Overall 1962

Overall JE, Gorham DR. The Brief Psychiatric Rating Scale. *Psychological Reports* 1962;**10**:799-812.

Owen 1996

Owen RR, Fischer EP, Booth BM, Cuffel BJ. Medication noncompliance and substance abuse among patients with schizophrenia. *Psychiatric Services* 1996;**47**(8):853-8.

Perkins 2002

Perkins DO. Predictors of noncompliance in patients with schizophrenia. *Journal of Clinical Psychiatry* 2002;**63**(12):1121-8.

Perkins 2006

Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrino F, et al. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. *Schizophrenia Research* 2006;**83**(1):53-63.

Potvin 2009

Potvin S, Blanchet P, Stip E. Substance abuse is associated with increased extrapyramidal symptoms in schizophrenia: a meta-analysis. *Schizophrenia Research* 2009;**113**(1573-2509 (Electronic), 2-3):181-8.

Regier 1990

Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL, et al. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiologic Catchment Area (ECA) Study. *JAMA* 1990;**264**(19):2511-8.

Robins 1988

Robins LN, Wing J, Wittchen HU, Helzer JE, Babor TF, Burke J, et al. The Composite International Diagnostic Interview. An epidemiologic instrument suitable for use in conjunction with different diagnostic systems and in different cultures. *Archives of general psychiatry* 1988;**45**(12):1069-77. [PUBMED: 2848472]

Robinson 2006

Robinson DG, Woerner MG, Napolitano B, Patel RC, Sevy SM, Gunduz-Bruce H, et al. Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. *American Journal of Psychiatry* 2006;**163**(12):2096-102.

Rosenberg 2009

Rosenberg H. Clinical and laboratory assessment of the subjective experience of drug craving. *Clinical Psychology Review* 2009;**29**(6):519-34.

Ruggeri 2000

Ruggeri M, Leese M, Thornicroft G, Bisoffi G, Tansella M. Definition and prevalence of severe and persistent mental illness. *British Journal of Psychiatry* 2000;**177**:149-55.

Salyers 2001

Salyers MP, Mueser KT. Social functioning, psychopathology, and medication side effects in relation to substance use and abuse in schizophrenia. *Schizophrenia Research* 2001;**48**(1):109-23.

Schünemann 2011

Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S (editors), *Cochrane*

Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.

Seeman 2002

Seeman P. Atypical antipsychotics: mechanism of action. *Canadian Journal of Psychiatry* 2002;**47**(1):27-38.

Shokraneh 2017

Shokraneh F, Adams CE. Study-based registers of randomized controlled trials: Starting a systematic review with data extraction or meta-analysis. *BioImpacts* 2017;**InPress**:InPress.

Simpson 1970

Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. *Acta Psychiatrica Scandinavica* 1970;**212**(0065-1591):11-9.

Sinha 2006

Sinha R, Garcia M, Paliwal P, Kreek MJ, Rounsaville BJ. Stress-induced cocaine craving and hypothalamic-pituitary-adrenal responses are predictive of cocaine relapse outcomes. *Archives of General Psychiatry* 2006;**63**(3):324-31.

Sinha 2011

Sinha R. New findings on biological factors predicting addiction relapse vulnerability. *Current Psychiatry Reports* 2011;**13**(5):398-405.

Siris 1990

Siris SG. Pharmacological treatment of substance-abusing schizophrenic patients. *Schizophrenia Bulletin* 1990;**16**(1):111-22.

Smelson 1997

Smelson DA, Roy A, Roy M. Risperidone diminishes cue-elicited craving in withdrawn cocaine-dependent patients. *Canadian Journal of Psychiatry* 1997;**42**(9):984.

Smelson 2002

Smelson DA, Losonczy MF, Davis CW, Kaune M, Williams J, Ziedonis D. Risperidone decreases craving and relapses in individuals with schizophrenia and cocaine dependence. *Canadian Journal of Psychiatry* 2002;**47**(7):671-5.

Sobell 1992

Sobell LC, Sobell MB. Timeline follow-back: a technique for assessing self-reported ethanol consumption. In: J Allen RZ Litten editor(s). *Measuring Alcohol Consumption: Psychosocial and Biological Methods*. Totowa NJ: Humana Press, 1992:41-72.

Soyka 1993

Soyka M, Albus M, Kathmann N, Finelli A, Hofstetter S, Holzbach R, et al. Prevalence of alcohol and drug abuse in schizophrenic inpatients. *European Archives of Psychiatry and Clinical Neuroscience* 1993;**242**(6):362-72.

Stroup 2003

Stroup TS, McEvoy JP, Swartz MS, Byerly MJ, Glick ID, Canive JM, et al. The National Institute of Mental Health clinical antipsychotic trials of intervention effectiveness (CATIE)

project: schizophrenia trial design and protocol development. *Schizophrenia Bulletin* 2003;**29**(1):15-31.

Stuyt 2006

Stuyt EB, Sajbel TA, Allen MH. Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders. *American Journal on Addictions* 2006;**15**(2):166-73.

Sun 2007

Sun SX, Liu GG, Christensen DB, Fu AZ. Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States. *Current Medical Research and Opinion* 2007;**23**(10):2305-12.

Sun 2014

Sun X, Ioannidis JP, Agoritsas T, Alba AC, Guyatt G. How to use a subgroup analysis: users' guide to the medical literature. *JAMA* 2014;**311**(4):405-11.

Swofford 1996

Swofford CD, Kasckow JW, Scheller-Gilkey G, Inderbitzin LB. Substance use: a powerful predictor of relapse in schizophrenia. *Schizophrenia Research* 1996;**20**(1-2):145-51.

Tort 2006

Tort AB, Souza DO, Lara DR. Theoretical insights into the mechanism of action of atypical antipsychotics. *Progress in Neuro-psychopharmacology & Biological Psychiatry* 2006;**30**(4):541-8.

Tsibulsky 1998

Tsibulsky VL, Grocki S, Dashevsky BA, Kehne JH, Schmidt CJ, Sorensen SM, et al. Mixed D2/5-HT2A antagonism of cocaine-induced facilitation of brain stimulation reward. *Pharmacology, Biochemistry, and Behavior* 1998;**59**(2):275-80.

Tunis 2006

Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R. Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. *Value Health* 2006;**9**(2):77-89.

Ukoumunne 1999

Ukoumunne OC, Gulliford MC, Chinn S, Sterne JAC, Burney PGJ. Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review. *Health Technology Assessment* 1999;**3**(5):1-75.

van Mastrigt 2004

van Mastrigt S, Addington J, Addington D. Substance misuse at presentation to an early psychosis program. *Social Psychiatry and Psychiatric Epidemiology* 2004;**39**(1):69-72.

Volkow 1997

Volkow ND, Wang GJ, Fowler JS, Logan J, Gatley SJ, Hitzemann R, et al. Decreased striatal dopaminergic responsiveness in detoxified cocaine-dependent subjects. *Nature* 1997;**386**(6627):830-3.

Volkow 2006

Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Childress AR, et al. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. *Journal of Neuroscience* 2006;**26**(24):6583-8.

Volkow 2007

Volkow ND, Wang GJ, Telang F, Fowler JS, Logan J, Jayne M, et al. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. *Journal of Neuroscience* 2007;**27**(46):12700-6.

Volkow 2011

Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. *Proceedings of the National Academy of Sciences of the United States of America* 2011;**108**(37):15037-42.

Vothknecht 2011

Vothknecht S, Schoevers RA, de Haan L. Subjective well-being in schizophrenia as measured with the Subjective Well-Being under Neuroleptic Treatment scale: a review. *Australian and New Zealand Journal of Psychiatry* 2011;**45**(3):182-92.

Wade 2006

Wade D, Harrigan S, Edwards J, Burgess PM, Whelan G, McGorry PD. Substance misuse in first-episode psychosis: 15-month prospective follow-up study. *British Journal of Psychiatry* 2006;**189**:229-34.

Wang 2007

Wang R, Lagakos SW, Ware JH, Hunter DJ, Drazen JM. Statistics in medicine - reporting of subgroup analyses in clinical trials. *New England Journal of Medicine* 2007;**357**(21):2189-94.

Weddington 1990

Weddington WW, Brown BS, Haertzen CA, Cone EJ, Dax EM, Herning RI, et al. Changes in mood, craving, and sleep during short-term abstinence reported by male cocaine addicts. A controlled, residential study. *Archives of General Psychiatry* 1990;**47**(9):861-8.

Weich 2009

Weich L, Pienaar W. Occurrence of comorbid substance use disorders among acute psychiatric inpatients at Stikland Hospital in the Western Cape, South Africa. *African Journal of Psychiatry* 2009;**12**(3):213-7.

Wobrock 2009

Wobrock T, Soyka M. Pharmacotherapy of patients with schizophrenia and substance abuse. *Expert Opinion in Pharmacology* 2009;**10**:353-67.

Xia 2009

Xia J, Adams CE, Bhagat N, Bhagat V, Bhoopathi P, El-Sayeh H, et al. Loss to outcomes stakeholder survey: the LOSS study. *Psychiatric Bulletin* 2009;**33**(7):254-7.

Yatham 2005

Yatham LN, Goldstein JM, Vieta E, Bowden CL, Grunze H, Post RM, et al. Atypical antipsychotics in bipolar depression:

potential mechanisms of action. *Journal of Clinical Psychiatry* 2005;**66**(Suppl 5):40-8.

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies [ordered by study ID]

Akerele 2007

Methods	Allocation: randomised. Blindness: not described. Duration: 14 weeks, 4-week medication taper and 10-week follow-up. Design: superiority, parallel group, randomised trial, single site. Setting: outpatients attending day treatment, USA.
Participants	Diagnosis: Structured Clinical Interview for DSM (SCID-I) schizophrenia or schizoaffective disorder and either current cannabis or cocaine abuse or dependence. N = 28. All with co-occurring substance use disorders. Age: mean ~36 years. Sex: 25 M, 3 F. History: cannabis use at least twice/week or cocaine once/week in 3 months prior to enrolment. Ethnicity: 54% African American, 32% Hispanic, 14% Caucasian Exclusion: pregnant, unstable psychiatric or medical condition, current physiological dependence on alcohol or another substance for which had experienced significant withdrawal symptoms in past (caffeine, nicotine dependence was acceptable), history of seizures or neuroleptic malignant syndrome, enzyme levels 3 times upper normal limit, violent crime committed in past 2 years, non-response to either olanzapine or risperidone in the past, score of more than 30 on PANSS positive and negative subscales.
Interventions	1. Risperidone: fixed dose escalation of 3 mg/day for 3 days followed by 6 mg for 4 days and then 9 mg for remainder of study. N = 14 2. Olanzapine: fixed dose escalation of 5 mg/day for 3 days then 10 mg/day for 4 days and then 15 mg/day for 5 days followed by 20 mg/day for remainder of study. N = 14 All participants received weekly psychotherapy over the study period and were asked to nominate a "significant other" to assist with attendance and follow-up.
Outcomes	Mental state: change scores HAM-D scale Adverse effects: parkinsonism endpoint score SAS. Leaving the study early: any reason <i>Unable to use:</i> Mental state: PANSS positive and PANSS negative subscales (no means or SD, longitudinal data), CGI (no data reported). Substance use: proportion of positive urine tests for cannabis and cocaine weekly over 10-week study period (no means or SD, longitudinal data), days of self-reported substance use (no SD); Quantitative Substance Use Inventory (psychometric properties of instrument not validated). Craving for substances: Marijuana Craving Report, Cocaine Craving Report (no means or SD, longitudinal data). Adherence to antipsychotic medication: number of medication doses missed (no means or SD). Adverse effects: tardive dyskinesia (AIMS)(not reported by group), sedation (no data provided).

Akerele 2007 (Continued)

Notes

Funding: support for this study was provided in part by grants from the National Institute on Drug Abuse and the National Alliance for Research on Schizophrenia and Depression (NARSAD, currently known as The Brain and Behavior Research Foundation) and Eli Lilly and Co.

Declarations of interest made by researchers conducting this study include support from a number of pharmaceutical companies, i.e. Ortho-McNeil Pharmaceuticals, Eli Lilly & Company, UCB Pharma and consultancy to Shire, Pharmaceuticals Inc, AstraZeneca Pharmaceutical, Eli Lilly and Company.

Contact of authors: we contacted the study primary and co-authors by e-mail to clarify items of study design and to obtain study data. The authors did not respond to these attempts.

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised but there was insufficient information on the method used to randomise the participants. Quote: "Randomization was not stratified, but was a 50=50 uniform distribution of groups of 4".
Allocation concealment (selection bias)	Unclear risk	There was insufficient information provided to determine if study medication allocation was concealed.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	No description of blinding is provided in the study report.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No mention is made of whether the outcome assessors were indeed blinded and independent.
Incomplete outcome data (attrition bias) All outcomes	High risk	Twice as many people withdrew from the olanzapine group (8/14; 57%) compared to the risperidone group (4/14; 29%). The most common reasons for withdrawal were that the participants were not interested (N = 10) or that they were admitted to inpatient units (N = 3). There were no other significant differences between the groups with respect to demographic and baseline clinical characteristics.
Selective reporting (reporting bias)	Unclear risk	The study protocol was not available for this study. Subgroups are reported as primary outcomes.
Other bias	High risk	Funding for study provided in part by industry (Eli Lilly and Co). No other sources of bias were identified.

Brunette 2011

Methods	Allocation: randomised Blindness: single-blind (outcome assessor) Duration: 12 weeks Design: superiority, parallel group, randomised trial Setting: outpatients, two treatment sites: New Hampshire and South Carolina, USA Funding: National Institute on Drug Abuse
Participants	Diagnosis: Structured Clinical Interview for DSM (SCID-I) diagnosis of schizophrenia or schizoaffective disorder and a current cannabis use disorder (abuse or dependence). N = 31. All with co-occurring substance use disorders.

Brunette 2011 (Continued)

Age: range 18 to 65 years; mean ~36 years.

Sex: 24 M, 7 F

History: cannabis use on at least 5 days in the 3 weeks prior to screening.

Ethnicity: 26 (83.9%) were Caucasian.

Inclusion: outpatient status prior to randomisation and on current antipsychotic treatment other than clozapine.

Exclusion: patients with serious, active medical illness, suicidality, severe psychiatric instability, on treatment with medications that could affect alcohol use such as naltrexone, topiramate, disulfiram, low white cell counts ($< 3.500/\text{mm}^3$), seizure disorder.

Interventions	<p>Clozapine: titrated to 400 mg daily in 4 weeks. n = 15</p> <p>Treatment as usual (TAU): i.e. continue on existing antipsychotic treatment. n = 16; (n = 5 on risperidone)</p> <p>All participants received weekly individual substance abuse and mental health counselling and attend weekly Alcoholics Anonymous meetings.</p>
Outcomes	<p><i>Unable to use:</i></p> <p>Mental state: (BPRS, CGI, SANS) (no data reported)</p> <p>Substance use: cannabis use (TLFB) number of "average joints" used per week, assessed weekly for 12 weeks; (no data on subgroup with risperidone)</p> <p>Substance Abuse Treatment Scale (SATS) (1 to 8) measuring treatment involvement, Single-Item Contemplation ladder (0 to 10) motivation to stop using cannabis (no data on subgroup with risperidone)</p> <p>Adverse effects: SAS scale, BARS scale, AIMS scale (no data reported)</p>
Notes	<p>Further data requested. Author responded and indicated that 5/16 patients in TAU group were on risperidone. Authors decided not to provide requested data as they were advised by their methodological consultant that using subgroup data will in effect interfere with the randomisation given the specific design of this study.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomisation was blocked by site. No description of how sequence was generated.
Allocation concealment (selection bias)	Unclear risk	Randomisation was blocked by site. No description of how sequence was generated or how allocation concealment was maintained.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Unblinded clinicians prescribed and adjusted study medications weekly.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Blinded raters assessed patients weekly, independent of study physicians.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Longitudinal random-effects modelling was used that could have accounted for missing data; however no indication as to the extent of missing data;

Brunette 2011 (Continued)

Selective reporting (reporting bias)	Low risk	Study outcomes are identical to protocol-defined outcomes.
Other bias	High risk	Protocol indicates study was sponsored by Janssen, Novartis.

Machielsen 2014

Methods	<p>Allocation: randomised. Blindness: no description. Duration: 4 weeks. Design: superiority, parallel group, randomised trial. Setting: Inpatients and outpatients recruited from the Early Psychosis Department of The Academic Medical Centre of the University of Amsterdam between April 2009 and June 2012. Funding: Dutch Health Research Council.</p>
Participants	<p>Diagnosis: DSM-IV diagnosis of schizophreniform, schizophrenia or schizoaffective disorder. CIDI diagnosis of cannabis use disorder (abuse or dependence, N = 35). N = 39 randomised, N = 31 with co-occurring substance use disorders. Age: range 18 to 50 years; mean ~22.4 years (risperidone), mean ~22.3 years (clozapine). Sex: all participants were male. Ethnicity: not stated. Inclusion: males, aged 18 to 30 with DSM-IV diagnosis of schizophreniform, schizophrenia or schizoaffective disorder. Exclusion: previous contraindication or unsuccessful treatment with risperidone or clozapine, depot antipsychotic use in the 3 months prior to recruitment, treatment with medication or than biperiden or benzodiazepines.</p>
Interventions	<p>Risperidone: titrated to initial dose of 3.5 mg/day, then according to treatment response. N = 16 Clozapine: titrated to initial dose of 350 mg/day, then according to treatment response. N = 15 Participants had "supportive treatment as usual".</p>
Outcomes	<p>Mental state: positive psychotic symptoms (average endpoint score, PANSS positive sub-scale), negative symptoms (average endpoint score, PANSS negative sub-scale), general psychopathology (average endpoint score, PANSS general sub-scale). Substance use: number discontinuing cannabis use. Subjective well-being: Subjective well-being under neuroleptics scale (SWN scale) Craving for substances: Marijuana Craving Questionnaire (MCQ), Obsessive Compulsive Drug Use Scale (OCDUS). Adherence to medication: discontinuing medication. Adverse effects: any extrapyramidal side-effects (no data for subgroups with specific extrapyramidal side-effects). Leaving the study early.</p>
Notes	<p>Authors e-mailed for additional information: response was given to questions about randomisation, and a flow diagram of study attrition was provided.</p>

Risk of bias

Machielsen 2014 (Continued)

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Random number generator software was used through the ALEA program: randomisation has been performed on-line via a secure internet facility by the TENALEA Clinical Trial Data Management System. Randomisation has been performed in a 1:1 ratio, using randomly permuted blocks with maximum blocksize of 4, within strata formed by use of drugs (Cannabis use, no drugs use).
Allocation concealment (selection bias)	Low risk	The physician states the patient's date of birth and the stratification factor and receives treatment allocation when submitting this information to the website from central trial office.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Due to feasibility and ethical considerations this was an open label study over a relatively short period of time in which dosage of medication could be adjusted in case of side-effects or lack of efficacy. Clozapine required blood monitoring which differs from risperidone requirements.
Blinding of outcome assessment (detection bias) All outcomes	High risk	Outcome assessment was not blinded.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Authors provided flow diagram on request reporting differential drop-out (with reasons stated) in two treatment arms (20%, 3/15 cannabis users in clozapine arm, 0/16 in risperidone arm). The impact of not including these participants in the endpoint analysis is unclear.
Selective reporting (reporting bias)	Low risk	Outcomes in pre-published protocol are identical to study reported outcomes.
Other bias	Low risk	No clear evidence for bias.

Noordsy 2010

Methods	<p>Allocation: randomised</p> <p>Blindness: single-blind (outcome assessor)</p> <p>Duration: 24 weeks</p> <p>Design: superiority, parallel group, randomised trial</p> <p>Setting: New Hampshire, United States including: New Hampshire Hospital (Concord), Dartmouth-Hitchcock Medical Center (Lebanon), West Central Behavioral Health (Lebanon), Mental Health Center of Greater Manchester (Manchester), Center for Psychiatric Advancement & Community Council of Nashua (Nashua).</p> <p>Funding: Sponsors and collaborators stated as Dartmouth-Hitchcock Medical Center and National Institute of Mental Health.</p>
Participants	<p>Diagnosis: Structured Clinical Interview for DSM (SCID-I) schizophrenia or schizoaffective disorder and either current cannabis abuse or dependence.</p> <p>N = 14. All with co-occurring substance use disorders.</p> <p>Age: 17 to 45 years. Mean ~ 22.4 years. 4 participants were 17 years old.:(see amendments to protocol).</p> <p>Sex: 8 M, 6 F</p> <p>History: first episode of schizophrenia, cannabis use within the five weeks prior to recruitment</p> <p>Ethnicity: Caucasian</p> <p>Exclusion:</p>

Noordsy 2010 (Continued)

Medical contraindications to treatment with clozapine or risperidone, including previous paralytic ileus.

Cumulative treatment with antipsychotic medication in excess of 16 weeks prior to hospital admission (or case identification if an outpatient), unless waived by the medication adjustment group (MAG).

History of allergic reaction to clozapine or risperidone.

History of seizure disorder or blood dyscrasia. Note: if participants had a history of seizures, but not a diagnosed seizure disorder, they could be admitted to the study if approved by the medication adjustment group.

Current treatment with clozapine.

Currently pregnant, planning to become pregnant, or unwilling to use an acceptable form of birth control.

Currently residing in a residential programme designed to treat substance use disorders.

Participants who required treatment at baseline with a psychotropic agent proposed to curtail substance use (e.g. disulfiram, naltrexone, valproic acid, topiramate, acamprosate or benzodiazepines) were reviewed by the medication adjustment group before entering into the study.

Participants who, in the opinion of the investigator, are judged unsuitable to participate in the study (for example, are actively homicidal or have a pending incarceration that would prevent them from participating in the study).

History of, or current breast cancer.

People who are doing well on current therapy.

Lack of an identifiable primary family/support person, and unable to come to a study site for weekly visits.

Treatment with serotonin re-uptake inhibitors did not mean exclusion but required a review by the MAG prior to randomisation.

Participants with current cocaine dependence required review by the MAG to determine stability for the study. Treatment with multiple antipsychotics or long-acting injectable antipsychotic at baseline not excluded, but reviewed by the MAG to assess appropriateness for the study.

Interventions

1. Clozapine: tablets – 12.5 mg to maximum 100 mg daily for 24 weeks. N = 7

2. Risperidone: tablets – 0.5 mg to maximum 5 mg daily for 24 weeks. N = 7

All participants received a Lifestyle Intervention to manage metabolic side-effects and to assist with recovery.

Outcomes

Mental state: worsening of psychotic symptoms, emergence of anxiety symptoms reported as trial adverse events.

Substance use: cannabis use (TLFB), urine tests, collateral reports, and monthly clinician ratings, final expert clinician rating – dichotomised

Adverse effects: movement disorder, various adverse effects.

Leaving the study early.

Unable to use:

Mental state: (BPRS, CGI, SANS – no data reported).

Notes

Contact of authors: no response from authors to e-mails sent requesting clarification on study design and to obtain missing data.

Noordsy 2010 (Continued)

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No details given as to how sequence was generated.
Allocation concealment (selection bias)	Unclear risk	No details given as to whether allocation was concealed.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Study described as single-blind with outcome assessors blind. Knowledge of treatment allocation and monitoring procedures of clozapine could have influenced participants or personnel.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Outcome assessors described as masked, but no mention is made of whether the outcome assessors were indeed blinded and independent.
Incomplete outcome data (attrition bias) All outcomes	High risk	One participant in both groups did not receive treatment but were randomised and were not included in the outcome report. "About half of participants in the clozapine group have discontinued treatment early, a rate similar to previous first episode schizophrenia studies in the US. There were no discontinuations due to lack of efficacy in either group, but several discontinuations due to inability to tolerate medication side-effects in clozapine group". It is also mentioned that 2 participants in risperidone group terminated early and 2 study completers in the risperidone group elected to discontinue medication and 1 to switch to a different antipsychotic at the end of the study.
Selective reporting (reporting bias)	High risk	The manner in which the primary outcome was determined changed in later versions of the protocol (from 2007 to following completion of data collection in 2011, with a change in 2013). The initial outcome was marijuana use measured weekly by means of TLFB method, but this changed to improvement as judged by experts at a particular cut-point of 20% improvement and then dichotomised, assessed at the end of the study.
Other bias	Unclear risk	Study did not receive funding from pharmaceutical industry and principal Investigators are not employed by the organization sponsoring the study. Declarations of interest made by researchers conducting this study: "Principal Investigators are not employed by the organization sponsoring the study".

Sevy 2011

Methods	Allocation: randomised. Blindness: single-blind (outcome assessor). Duration: 4 months' acute treatment phase of 32 month study. Design: secondary data analysis of existing superiority, parallel group, randomised trial. Setting: all new patients referred to acute care at the Zucker Hillside, Bronx Lebanon Hospital were screened. Funding: National Institutes for Health, Feinstein Institute for Medical Research
---------	---

Sevy 2011 (Continued)

Participants	<p>Diagnosis: Structured Clinical Interview for DSM (SCID-I) diagnosis of current schizophrenia, schizophreniform disorder, or schizoaffective disorder and a lifetime or current 3 months' history of cannabis abuse or dependence.</p> <p>N = 49 (post-hoc analysis of a subgroup of 49 patients with co-occurring substance use disorders from larger study of 120 participants).</p> <p>Age: range 16 to 40 years; mean ~21.7 years (risperidone), mean ~21.7 years (olanzapine).</p> <p>Sex: 40 (81.6%) M, 9 (18.4%) F.</p> <p>Ethnicity: not stated.</p> <p>Inclusion criteria:</p> <p>Less than 12 weeks of lifetime antipsychotic medication treatment.</p> <p>Current positive symptoms evidenced by a rating of 4 or more on the severity of delusions, hallucinations, or thought disorder items of the Schedule for Affective Disorders and Schizophrenia Change Version with psychosis and disorganization items (SADS-C+PD) or current negative symptoms demonstrated by a rating of 4 or more on the affective flattening, avolition, or anhedonia global items of the Hillside Clinical Trials version of the Scale for Assessment of Negative Symptoms (SANS).</p> <p>For women, a negative pregnancy test and agreement to use a medically accepted method of birth control.</p> <p>Competent and willing to sign informed consent.</p> <p>Exclusion criteria: 1) meeting DSM-IV criteria for a current substance-induced psychotic disorder, psychotic disorder due to a general medical condition, or mental retardation; 2) medical condition/treatment known to affect the brain; 3) any medical condition requiring treatment with a medication with psychotropic effects; 4) medical contraindications to treatment with olanzapine or risperidone; or 5) significant risk of suicidal or homicidal behaviour.</p>
Interventions	<p>Risperidone: mean modal daily dose 4 mg. N = 21</p> <p>Olanzapine: mean modal daily dose 15 mg. N = 28</p> <p>All participants received psychoeducation about schizophrenia, were seen on a regular basis by allocated social workers and also had access to the ancillary treatment service available from 2 large departments of psychiatry.</p>
Outcomes	<p>Mental state: positive psychotic symptoms – average endpoint scores (SADS-C-PD scale, lower = better), negative symptoms (SADS-C-PD scale, lower = better).</p> <p>Substance use: stopped using cannabis (Urine testing and Substance Use Questionnaire).</p> <p>Substance use: stopped using alcohol (Substance Use Questionnaire).</p> <p>Leaving the study early.</p>
Notes	<p>Authors e-mailed for additional data and information: no response.</p>

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Computer pre-generated block randomization list provided by the department of biostatistics and only accessible to the biostatisticians and dedicated research coordinators.
Allocation concealment (selection bias)	Unclear risk	Unclear whether "research coordinators" were involved in patient recruitment.

Sevy 2011 (Continued)

Blinding of participants and personnel (performance bias) All outcomes	High risk	Open label, both patients and staff were aware of treatments received.
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Diagnosis and psychopathology assessments were performed by masked ("blind") assessors.
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Although attrition was equal across groups (approximately 25%) no method of accounting for missing outcomes was present, i.e. ITT analysis with imputation.
Selective reporting (reporting bias)	Unclear risk	Secondary data analysis directed by analysis of primary study. Not clear if this could have influenced selection of outcomes.
Other bias	Unclear risk	Several authors have ties to drug companies; however unclear whether this could have an impact on the results as the parent study was supported by NIH grants K23 DA015541 (SS), MH60004 (DR), MH41960, and RR018535. It is stated that the NIH had no further role in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the paper for publication.

Smelson 2006

Methods	Allocation: randomised. Blindness: open-label trial, not blinded Duration: 12 months Design: secondary data analysis of subgroup with substance use from existing superiority, parallel group, randomised trial. Setting (parent study): academic and community treatment settings mainly outpatient clinics, USA. Multicenter trial.
Participants	Diagnosis: DSM-IV diagnosis of schizophreniform, schizophrenia or schizoaffective disorder, illicit drug or alcohol use 30 days prior to study entry as measured by the quantity/frequency sub-scale of the Addiction Severity Index. N = 664 (236 with analysable data were substance users). Age: > 18 years; mean age ~ 43 years. Sex (parent study): 420 (63%) M, 244 (37%) F Ethnicity (parent study): Caucasian 361 (54%), African American 224 (34%), Other 79 (12%) Inclusion: psychotic symptom threshold of 18 or more on the Brief Psychiatric Rating Scale (BPRS). Individuals recently experiencing an adverse event attributable to current antipsychotic treatment (unless olanzapine or risperidone) were also eligible, although the vast majority met symptom criteria. Exclusion criteria: patients with very serious, unstable physical illnesses and other medical conditions or histories contraindicating use of any study medication.
Interventions	Risperidone: suggested initiating dose 1 mg twice daily with flexible dosing and titration by study clinicians. N = 76 Olanzapine: suggested initiating dose 10 mg daily with flexible dosing and titration by study clinicians. N = 85

Smelson 2006 (Continued)

Conventional antipsychotics: 2 conventional agents (from: perphenazine, loxapine, haloperidol, fluphenazine, thiothixene) for minimum of 8 weeks consecutively as decided by study physicians based on prior history. N = 75

It is unclear what psychosocial interventions participants received.

Outcomes	Unable to use: Time to discontinuation (skewed data) Numbers discontinuing treatment (no data)
Notes	Authors e-mailed for additional data and information: no response received

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No description of how sequence was generated.
Allocation concealment (selection bias)	Unclear risk	No description of how allocation sequence was concealed.
Blinding of participants and personnel (performance bias) All outcomes	High risk	Treatment was described as open-label.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No description of blinding of outcome assessors.
Incomplete outcome data (attrition bias) All outcomes	Low risk	Primary outcome and only outcome reported is time to all-cause medication discontinuation, including leaving study for any reason.
Selective reporting (reporting bias)	Unclear risk	Secondary data analysis of existing trial. Analysis for primary trial not fully reported so unclear if this informed the aims and hypothesis of the secondary data analysis.
Other bias	High risk	Several authors have relationships with the pharmaceutical industry. Parent study funded by Eli Lilly.

Swartz 2008

Methods	Allocation: randomised Blindness: double-blind Duration: 18 months Design: secondary data-analysis of subgroup with and without substance use from an existing superiority, parallel group, randomised trial. Setting (parent study): multicenter trial, 57 sites in USA.
Participants	Diagnosis: Structured Clinical Interview for DSM (SCID-I) diagnosis of schizophrenia, with past history of more than one episode. Alcohol and illicit drug use was determined by a combination of self-reported use, SCID-I interviews, urine and hair samples, ratings on Clinician Alcohol and Drug Use Scale.

Swartz 2008 (Continued)

N = 1432 cases available from the parent study for analysis; 643 were substance users.

Age: 18 to 65 years; substance user group mean age ~38.1 years, non-substance user group mean age ~42.6 years.

Sex: 1062 (74.1%) M, 370 (25.8%) F.

Ethnicity: White 722 (50.4%), Non-white 710 (49.5%).

Inclusion: multi-episode schizophrenia with or without illicit substance use disorder.

Exclusion criteria:

People with schizoaffective disorder, mental retardation or other cognitive disorders.

A history of serious adverse reactions to the proposed treatments.

Patients with only 1 schizophrenic episode or a history of treatment resistance, including non-response to one of the proposed treatments or prior treatment with clozapine.

Pregnant, breast-feeding or presence of an unstable medical condition.

Interventions	<p>Risperidone: flexible dosing, allowable daily dose 1.5 mg to 6 mg, mean dose 3.8 mg/day. N = 157</p> <p>Olanzapine: flexible dosing, allowable daily dose 7.5 mg to 30 mg, mean dose 20.0 mg/day. N = 142</p> <p>Perphenazine: flexible dosing, allowable daily dose 8 mg to 32 mg, mean dose 20.4 mg/day. N = 124</p> <p>Quetiapine: flexible dosing, allowable daily dose 200 mg to 800 mg, mean dose 515.1 mg/day. N = 137</p> <p>Ziprasidone: flexible dosing, allowable daily dose 40 mg to 160 mg, mean dose 113.3 mg/day. N = 83</p> <p>The investigators did not account for substance abuse treatments received, but they noted that very few were actively engaged in such treatments.</p>
---------------	---

Outcomes	<p>Leaving the study early (any reason)</p> <p><i>Unable to use:</i></p> <p>Mental state: psychotic symptoms, positive psychotic symptoms, negative symptoms and general psychopathology (PANSS total and sub-scales) (N and SD not available)</p> <p>Clinical Global Impression of Severity of illness (CGI-severity) (N and SD not available)</p> <p>Readmission rate (no data)</p> <p>Adherence to antipsychotic medication (no SD)</p> <p>Adverse events: weight gain (no data), neurological side-effects (no data)</p>
----------	--

Notes

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Described as randomised but no details given as to how the sequence was generated.
Allocation concealment (selection bias)	Unclear risk	No description of how sequence was kept concealed.
Blinding of participants and personnel (performance bias)	Unclear risk	Study described as double blind with identically appearing capsules. Different medications had different side-effect profiles and some overlap in side-effect

Swartz 2008 (Continued)

All outcomes		profiles for some medications (i.e. weight gain and sedation). Unclear if this could have favoured one or more medications over others.
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	No clear description of how blinding was maintained. Different side-effect profiles may have unblinded medication and symptom severity ratings could have been influenced by this. Nevertheless, outcomes such as discontinuation would unlikely have been affected by blinding.
Incomplete outcome data (attrition bias) All outcomes	High risk	High attrition rates with up to 69% of risperidone patients discontinuing treatment and high numbers (56% to 81%) in other treatment groups. Simple imputation with LOCF was used which could have biased results given such a large attrition rate. This would however not have affected the outcome of time to medication all-cause discontinuation (as all patients were counted for medication discontinuation outcome), but could have impacted on measurement of mental state (i.e. LOCF imputations).
Selective reporting (reporting bias)	Unclear risk	The results from earlier analysis directed the current hypothesis in this study. Nevertheless the outcomes (time to all-cause discontinuation), were similar to the original study protocol. It is unclear how earlier analyses could have directed results.
Other bias	Unclear risk	Several pharmaceutical companies provided medication for the study. A number of authors had ties to the pharmaceutical industry. The NIMH was responsible for the study was design, data collection, analysis, writing up and decision to publish the study.

van Nimwegen 2008

Methods	Allocation: randomised Blindness: double-blind Duration: 6 weeks Design: subgroup with substance (cannabis) reported, superiority, parallel group, randomised trial. Setting: outpatients. Multisite across 4 sites in the Netherlands. (Academic Medical Centre University of Amsterdam, Erasmus Medical Centre Rotterdam, Panassia Psychomedical Centre in the Hague, Mediant in Enschede).
Participants	Diagnosis: Structured Clinical Interview for DSM (SCID-I) diagnosis of schizophreniform disorder, schizophrenia or schizoaffective disorder, cannabis self-report and urine testing for cannabis. N = 138 (subgroup of 41 (29.7%) used cannabis). Age: 18 to 30 years, mean age ~25 years Sex: 80% male. Ethnicity: not reported Exclusion criteria: pregnant or lactating, no adequate contraception, known hypersensitivity to any ingredient of olanzapine or risperidone. Concomitant use of any other antipsychotic drug than olanzapine or risperidone. Use of depot anti-psychotics for a period of at least three months prior to the study or the use of other psychotropic medication other than oxazepam or biperiden. Narrow-angle glaucoma, neurological or endocrine disease.
Interventions	Risperidone: flexible dosing, 1.25 mg, 2.5 mg, 3.75 mg, 5 mg, titrated to a fixed dose within the first week. N = 21 Olanzapine: flexible dosing, 5 mg, 10 mg, 15 mg, 20 mg, titrated to fixed dose within first week. N = 20

van Nimwegen 2008 (Continued)

Outcomes	Substance use: cannabis use self-report scores – change data (joints per week) Craving for substances: Obsessive Compulsive Drug Use Scale (OCDUS), Desires for Drug Questionnaire (DDQ) – endpoint data. Leaving the study early <i>Unable to use:</i> Subjective Well-being: Subjective Well-being Under Neuroleptics (SWN) score (no subgroup mean, SD or N)
----------	---

Notes

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No description of how sequence was generated.
Allocation concealment (selection bias)	Unclear risk	No description of where sequence was kept and who allocated participants. Nevertheless tablets were described as identical-looking.
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Study described as "double blind" with identically appearing capsules, although no description is given as to how blinding was achieved. Different side-effect profiles of the two medications could have lead to unblinding
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Described as "double blind" with identically appearing capsules, although no description is given as to how outcome assessors were kept masked from treatment. Different side-effect profiles of the two medications could have lead to unblinding.
Incomplete outcome data (attrition bias) All outcomes	High risk	ITT analysis with single imputation method (LOCF). Although attrition was comparable across groups it is unclear if groups differed with regards to other factors such as symptoms severity and other baseline measures.
Selective reporting (reporting bias)	Unclear risk	Only some outcomes stated in protocol are reported. Unclear how some factors, such as symptom severity that was not reported, could have impacted on reported outcomes of SWN and craving.
Other bias	High risk	Study funded by Eli-Lilly

Characteristics of excluded studies [ordered by study ID]

Study	Reason for exclusion
Blin 1996	Allocation: randomised Participants: people with schizophrenia who do not have co-occurring substance misuse.
Gaebel 2010	Allocation: randomised Participants: people with schizophrenia, schizoaffective disorder; people with schizophrenia who do not have co-occurring substance misuse.

Study	Reason for exclusion
Green 2001	Allocation: randomised. Participants: patients with both schizophrenia and a cannabis use disorder. Intervention: risperidone vs. clozapine. Outcomes: cannabis use, negative symptoms, psychotic symptoms, neuropsychological function and quality of life. No data available: only published as study protocol, authors contacted for unpublished data: no response.
Harvey 2007	Allocation: randomised. Participants: people with bipolar I disorder who do not have co-occurring substance misuse.
Ikuta 2014	Allocation: randomised Participants: people with schizophrenia, schizophreniform, or psychosis not otherwise specified who do not have co-occurring substance misuse.
Kerfoot 2011	Allocation: randomised. Participants: schizophrenia with and without co-occurring substance use. Intervention: risperidone versus quetiapine versus perphenazine versus olanzapine versus ziprasidone. Outcomes: psychotic symptoms, depression, quality of life, neurocognition No data available comparing risperidone with other medications. Study examined the impact of substance use on prognosis.
Liemburg 2011	Allocation: randomised. Participants: people with schizophrenia who do not have co-occurring substance misuse.
Liu 2008	Allocation: randomised. Participants: not people with dual diagnosis – people with 'mental disorders due to alcohol use'.
NCT00063349	Allocation: trial suspended, reported as non-randomised, retrospective observational study. Participants: schizophrenia, schizoaffective disorder, cannabis and/or alcohol use disorder Intervention: risperidone, clozapine. Outcomes: cessation of substance use.
NCT00130923	Allocation: randomised Participants: schizophrenia, schizoaffective disorder and alcohol use disorder (abuse or dependence) Intervention: risperidone oral formulation compared to risperidone long-acting injectable formulation (RLAI). Not risperidone versus another antipsychotic.
NCT00169026	Allocation: randomised Participants: schizophrenia, schizoaffective disorder and alcohol or substance use disorder. Intervention: clozapine, conventional antipsychotics, atypical antipsychotics. Outcomes: substance and alcohol use (breathalyzer, urine tests, TLFB, Alcohol and Drug Use Scale), mental state (BPRS), SANS, CGI, neurological side-effects, cognitive function, quality-of-life measure No data available. study protocol of terminated study.
NCT00498550	Allocation: randomised Participants: schizophrenia, schizoaffective disorder and cannabis use disorder Intervention: clozapine, conventional antipsychotics, atypical antipsychotics.

Study	Reason for exclusion
	<p>Outcomes: substance use measures (urine testing, breathalyzer), medication side-effects, physical and psychological symptoms, substance use, treatment services received, and living situation, quality of life.</p> <p>Study protocol only, authors contacted but no data provided.</p>
Nejtek 2008	<p>Allocation: randomised</p> <p>Participants: bipolar I and II disorder, recent manic or mixed episode with or without psychosis and with co-occurring cocaine- or methamphetamine-use disorder. Only 8.3% of total sample had psychotic features and 15.9% had bipolar type II disorder.</p>
Perlis 2006	<p>Allocation: randomised</p> <p>Participants: bipolar I disorder with mania or mixed states. Patients with psychosis excluded. Patients with recent substance use excluded.</p>
Rezayat 2014	<p>Allocation: randomised</p> <p>Participants: acute mania (bipolar disorder). Study excludes participants with drug or alcohol use in past 3 months</p>
Rubio 2006a	<p>Allocation: quasi-randomisation (participants allocated "alternately").</p>
Rubio 2006b	<p>Allocation: quasi-randomisation (participants allocated "alternately").</p>
Sachs 2002	<p>Allocation: randomised</p> <p>Participants: bipolar with current manic or mixed episode. Study excludes participants with drug or alcohol in past 1 months.</p>
Sajatovic 2002	<p>Allocation: randomised</p> <p>Participants: psychotic disorders: schizoaffective disorder, bipolar I disorder, major depressive disorder, delusional disorder, Alzheimer's dementia, schizophreniform disorder, vascular dementia, and substance abuse dementia.</p> <p>Intervention: risperidone, quetiapine</p> <p>Outcomes: psychotic symptoms (PANSS), depression (HAM-D), extrapyramidal symptoms (ESRS)</p> <p>No subgroups with substance use reported, authors contacted for unpublished data, no response.</p>
Smulevich 2005	<p>Allocation: randomised</p> <p>Participants: bipolar I disorder who do not have recent drug or alcohol use.</p>
van Nimwegen 2008a	<p>Allocation: randomised</p> <p>Participants: schizophrenia, schizophreniform, schizoaffective disorder. No co-occurring substance use disorders.</p> <p>Intervention: haloperidol, risperidone, placebo</p> <p>Outcomes: Obsessions and compulsions (Y-BOCS), PANSS scores, CDSS scores.</p> <p>Authors contacted to determine if there were participants with co-occurring substance use disorders. Authors clarified that there were no participants with co-occurring substance use disorders.</p>
Yatham 2007	<p>Allocation: randomised</p> <p>Participants: bipolar I and II. Excludes participants with drug or alcohol use in past 3 months.</p>
Zhangyue 2005	<p>Allocation: quasi-randomisation (allocation based on admission order)</p>

Characteristics of studies awaiting assessment [ordered by study ID]

Greenspan 2005

Methods	Allocation: described as "double-blind" * Blindness: described as "double-blind" * Duration: 6 weeks, 2-week monotherapy phase Design: "double-blind" efficacy study Setting: unclear
Participants	Patients with schizophrenia and co-occurring alcohol, cocaine, amphetamine, marijuana, opiate use disorder. N = 111 with substance use disorders
Interventions	Risperidone; (dose and delivery method unclear) N = 51. Quetiapine; (dose and delivery method unclear) N = 40. Placebo. N = 20**
Outcomes	Mental state: psychotic symptoms, PANSS scale
Notes	* Randomisation could not be confirmed from authors, no response to e-mails sent. ** Data from placebo group not used for this review.

Johnsen 2010

Methods	Allocation: randomised, rater blinded, prospective head-to-head trial
Participants	Participants: schizophrenia, schizoaffective disorder, delusional disorder, affective psychosis (supplementary data with sample characteristics indicate that 3.8% of risperidone group had alcohol use disorder at baseline and 21.2% of risperidone group had drug misuse at baseline).
Interventions	risperidone, clinician determined dose, N = 53 (2 alcohol misuse in past 6 months, 11 drug misuse in past 6 months) olanzapine, clinician determined dose, N = 52 (5 alcohol misuse in past 6 months, 9 drug misuse in past 6 months) quetiapine, clinician determined dose, N = 50 (10 alcohol misuse in past 6 months, 7 drug misuse in past 6 months) ziprasidone, clinician determined dose, N = 58 (5 alcohol misuse in past 6 months, 11 drug misuse in past 6 months)
Outcomes	Outcomes: time to antipsychotic discontinuation, discharge and readmission. Improvement in PANSS, Calgary Depression Scale for Schizophrenia, CGI-S, GAF, adverse effects, UKU Side Effect Rating Scale (UKU-SERS). Baseline, 6 weeks, 3-, 6-, 12- and 24-month measures.
Notes	Authors contacted for any subgroup data or analysis, no response to e-mails sent.

NCT00208143

Methods	Open (no masking), randomised, parallel assignment, superiority trial
Participants	Adults age 19 to 65 years with a diagnosis of schizophrenia or schizoaffective disorder and co-occurring cocaine or methamphetamine abuse or dependence as diagnosed by Structured Clinical Interview for DSM-IV.
Interventions	quetiapine or risperidone oral formulation
Outcomes	<p>Primary: 50% or greater decrease in the drug use determined by the Time Line Follow Back (TLFB) method versus baseline</p> <p>Secondary: psychiatric symptoms assessed with the CGI, PANSS, BPRS, HAM-D, and HAM-A. Safety and tolerability assessed by patient- and physician-reported adverse events and AIMS. Quality of life assessed with QoLI.</p>
Notes	Authors were contacted via e-mail but no response received.

San 2012

Methods	Allocation: randomised
Participants	Participants: schizophrenia, schizophreniform, schizoaffective, bipolar, psychotic disorder NOS. Substantial subgroup used substances (cannabis: N = 64, 56.1%; alcohol: N = 87, 76.3%; cocaine: N = 24, 21.1%).
Interventions	<p>Open-label flexible-doses of antipsychotic treatment with the following dose ranges:</p> <p>haloperidol 1.5 mg to 8.5 mg, N = 21 (cannabis = 14, alcohol = 17, cocaine = 7)</p> <p>olanzapine 7.5 mg to 40 mg, N = 25 (cannabis = 15, alcohol = 19, cocaine = 4)</p> <p>risperidone 1.5 mg to 7.0 mg, N = 25 (cannabis = 14, alcohol = 17, cocaine = 5)</p> <p>quetiapine 100 mg to 1500 mg, N = 23 (cannabis = 11, alcohol = 17, cocaine = 2)</p> <p>ziprasidone 40 mg to 240 mg, N = 20 (cannabis = 10, alcohol = 17, cocaine = 6)</p>
Outcomes	Time to medication discontinuation, PANSS scores, CDSS scores, Adverse effects
Notes	No data provided for substance misuse subgroup – authors contacted and responded, no data provided.

Yatham 2003

Methods	<p>Allocation: multicentre, randomised, placebo-controlled trial</p> <p>Blindness: described as "double blind"</p> <p>Duration: 52 weeks</p> <p>Setting: Canadian and Brazilian academic centres</p>
Participants	Bipolar I disorder in remission from recent manic or mixed episode on treatment with mood stabiliser (valproate or lithium) and either risperidone or olanzapine (N = 159, not clear how many had psychotic features). Total of 39% (62/159) of total sample had co-occurring alcohol or substance use disorder.

Yatham 2003 (Continued)

Interventions	Discontinuation of risperidone or olanzapine at either 0 weeks, 24 weeks or 52 weeks and substitution with placebo.
Outcomes	Time to any mood episode, YMRS, HAMD-21, MADRS, CGI-BP, CGI-S, Side-effects UKU scale, ESRS, weight, metabolic measures (glucose, lipid profile).
Notes	Authors contacted. Responded that no data or analyses available at present for subgroups. No information provided on how many participants had bipolar type I with psychotic features.

Characteristics of ongoing studies [ordered by study ID]

NCT01639872

Trial name or title	Clozapine for Cannabis Use in Schizophrenia (CLOCS)
Methods	Double blind (subject, caregiver, investigator, outcomes assessor), randomised, parallel assignment, superiority trial, comparing the efficacy of clozapine with risperidone, Estimated recruitment target N = 132
Participants	Adults 18 to 55 years, males and females, clinical diagnosis of schizophrenia and a co-occurring cannabis use disorders (abuse or dependence)
Interventions	clozapine with target dose of 400 mg/day and maximum of 550 mg/day; risperidone with target dose of 4 mg/day and maximum of 6 mg/day
Outcomes	Primary: intensity (amount of cannabis used); frequency (number of days in past week) Secondary: symptoms of schizophrenia as measured by the BPRS, SANS, CGI; neuropsychological function by means of MATRICS Consensus Cognitive Battery; and reward responsiveness by means of a computerised Probabilistic Reward Task.
Starting date	April 2013
Contact information	alan.i.green@dartmouth.edu; christopher.okeefe@dartmouth.edu
Notes	Estimated completion in Oct 2016 (recruitment); Oct 2017 (results)

DATA AND ANALYSES
Comparison 1. RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months)


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mental state: 1. General: average end-point scores (PANSS subscale, lower=better)	1	36	Mean Difference (IV, Fixed, 95% CI)	2.70 [-2.14, 7.54]
2 Mental state: 2. General: any change in general symptoms:	1	14	Risk Ratio (M-H, Random, 95% CI)	0.14 [0.01, 2.34]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3 Mental state: 3. Specific: positive, negative symptoms - average endpoint scores (PANSS subscales, lower = better):	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
3.1 Mental state: Positive symptoms - average endpoint score (PANSS positive subscale, lower=better)	1	36	Mean Difference (IV, Random, 95% CI)	0.90 [-2.21, 4.01]
3.2 Mental state: Negative symptoms - average endpoint score (PANSS negative subscale, lower=better)	1	36	Mean Difference (IV, Random, 95% CI)	4.0 [0.79, 7.21]
4 Mental state: 4. Specific: anxiety symptoms	1	14	Risk Ratio (M-H, Random, 95% CI)	3.0 [0.14, 63.15]
5 Substance use	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
5.1 Substance use: Improvement (at least 20% reduction in use, TLFB scale)	1	14	Risk Ratio (M-H, Random, 95% CI)	1.0 [0.30, 3.35]
5.2 Substance use: Discontinued substance use	1	28	Risk Ratio (M-H, Random, 95% CI)	1.13 [0.41, 3.12]
6 Subjective Well-being: average endpoint scores (Subjective Well-being under Neuroleptics scale, SWN scale, higher=better)	1	36	Mean Difference (IV, Random, 95% CI)	-6.0 [-14.82, 2.82]
7 Craving for substances	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
7.1 Craving for substances: 1. Specific: current craving- average endpoint scores (Marijuana Craving Questionnaire, MCQ, lower=better)	1	28	Mean Difference (IV, Random, 95% CI)	7.00 [2.37, 11.63]
7.2 Craving for substances: 2. Specific: past week craving- average endpoint scores (Obsessive Compulsive Drug Use Scale, OCDUS, lower=better)	1	28	Mean Difference (IV, Random, 95% CI)	14.20 [4.45, 23.95]
8 Adherence to antipsychotic medication: discontinued medication	1	36	Risk Ratio (M-H, Random, 95% CI)	4.05 [0.21, 78.76]
9 Adverse effects. 1. Movement disorders	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
9.1 any extrapyramidal side-effects	2	50	Risk Ratio (M-H, Random, 95% CI)	2.71 [0.30, 24.08]
9.2 akathisia	1	14	Risk Ratio (M-H, Random, 95% CI)	2.0 [0.23, 17.34]


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10 Adverse effects: 2. Non-movement disorder related side-effects	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
10.1 Cardiovascular: palpitations	1	14	Risk Ratio (M-H, Random, 95% CI)	3.0 [0.14, 63.15]
10.2 Cardiovascular: hypotension	1	14	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 7.02]
10.3 Central nervous system: headache	1	14	Risk Ratio (M-H, Random, 95% CI)	0.2 [0.01, 3.54]
10.4 Central Nervous System: somnolence	1	14	Risk Ratio (M-H, Random, 95% CI)	0.2 [0.03, 1.30]
10.5 Dermatological: acne	1	14	Risk Ratio (M-H, Random, 95% CI)	3.0 [0.14, 63.15]
10.6 Endocrinological: decreased libido	1	14	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 7.02]
10.7 Ear and labarynthine: ear canal blockage	1	14	Risk Ratio (M-H, Random, 95% CI)	3.0 [0.14, 63.15]
10.8 Gastrointestinal: abdominal pain	1	14	Risk Ratio (M-H, Random, 95% CI)	3.0 [0.14, 63.15]
10.9 Gasstrointesinal: elevated liver function tests	1	14	Risk Ratio (M-H, Random, 95% CI)	3.0 [0.14, 63.15]
10.10 Gastrointestinal: hypersalivation	1	14	Risk Ratio (M-H, Random, 95% CI)	0.11 [0.01, 1.74]
10.11 General adverse effects: fatigue	1	14	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 7.02]
10.12 Injuries: sprain	1	14	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 7.02]
10.13 Metabolic: increased appetite	1	14	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 7.02]
10.14 Metabolic: weight gain	1	14	Risk Ratio (M-H, Random, 95% CI)	1.0 [0.19, 5.24]
10.15 Musculoskeletal: ankle pain	1	14	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 7.02]
10.16 Musculoskeletal: knee and foot pain	1	14	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 7.02]
10.17 Musculoskeletal: muscle twitch	1	14	Risk Ratio (M-H, Random, 95% CI)	3.0 [0.14, 63.15]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
10.18 Renal: urinary retention	1	14	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 7.02]
10.19 Renal: urinary urgency	1	14	Risk Ratio (M-H, Random, 95% CI)	0.33 [0.02, 7.02]
11 Leaving the study early	2		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
11.1 any reason	2	45	Risk Ratio (M-H, Random, 95% CI)	0.49 [0.10, 2.51]
11.2 due to inefficacy	1	14	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]


Analysis 1.1. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 1 Mental state: 1. General: average endpoint scores (PANSS subscale, lower=better).




Analysis 1.2. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 2 Mental state: 2. General: any change in general symptoms:.




Analysis 1.3. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 3 Mental state: 3. Specific: positive, negative symptoms - average endpoint scores (PANSS subscales, lower = better):.




Analysis 1.4. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 4 Mental state: 4. Specific: anxiety symptoms.




Analysis 1.5. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 5 Substance use.







Analysis 1.6. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 6 Subjective Well-being: average endpoint scores (Subjective Well-being under Neuroleptics scale, SWN scale, higher=better).




Analysis 1.7. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 7 Craving for substances.




Analysis 1.8. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 8 Adherence to antipsychotic medication: discontinued medication.





Analysis 1.9. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 9 Adverse effects. 1. Movement disorders.




Analysis 1.10. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 10 Adverse effects: 2. Non-movement disorder related side-effects.










Analysis 1.11. Comparison 1 RISPERIDONE versus CLOZAPINE - all data short term (up to 6 months), Outcome 11 Leaving the study early.




Comparison 2. RISPERIDONE versus OLANZAPINE


Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Mental state: 1. Specific: Depression-change scores (HAM-D, higher = better), short term (up to 6 months)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
1.1 short-term (up to 6 months)	1	22	Mean Difference (IV, Random, 95% CI)	-0.11 [-0.78, 0.56]
2 Mental state: 2. Specific: Positive symptoms, total score- average endpoint scores (SADS-C-PD scale, lower=better), short term (up to 6 months)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
2.1 short term, up to 6 months)	1	37	Mean Difference (IV, Random, 95% CI)	-1.5 [-3.82, 0.82]
3 Mental state: 3. Specific: Positive symptom subscales- average endpoint scores (SADS-C-PD subscores, lower=better), short term (up to 6 months)- skewed data			Other data	No numeric data
4 Mental state: 4. Specific: Negative symptoms, subscales- average endpoint scores (SANS subscales, lower=better), short term (up to 6 months)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
4.1 Negative symptoms: Affective flattening	1	39	Mean Difference (IV, Random, 95% CI)	0.5 [-0.17, 1.17]
4.2 Negative symptoms: alogia	1	39	Mean Difference (IV, Random, 95% CI)	0.40 [-0.22, 1.02]
4.3 Negative symptoms: avolition-apathy	1	39	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.73, 0.53]
4.4 Negative symptoms: asociality-anhedonia	1	39	Mean Difference (IV, Random, 95% CI)	-0.10 [-0.80, 0.60]
5 Substance use: 1. Reduction of cannabis use-change data (number of joints smoked/week, LOCF data, higher =better)- short term data (up to 6 months)	1	41	Mean Difference (IV, Random, 95% CI)	0.40 [-4.72, 5.52]
6 Substance use: 2. Discontinued substance use, short term (up to 6 months)	1		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
6.1 Substance use: 2. Stopped using cannabis (Urine testing and Substance Use Questionnaire)	1	37	Risk Ratio (M-H, Random, 95% CI)	1.19 [0.68, 2.08]
6.2 Substance use: 2. Stopped using alcohol (Substance Use Questionnaire)	1	37	Risk Ratio (M-H, Random, 95% CI)	1.31 [0.73, 2.36]
7 Craving for substances: 1. Obsessive Compulsive Drug Use Scale- average endpoint	1		Mean Difference (IV, Random, 95% CI)	Subtotals only

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
score (OCDUS, lower=better)-short term (up to 6 months)				
7.1 short-term (up to 6 months)	1	41	Mean Difference (IV, Random, 95% CI)	1.30 [-3.51, 6.11]
8 Craving for substances: 2. Desires for Drug Questionnaire- average endpoint scores (DDQ, LOCF data, lower=better), short term (up to 6 months)	1		Mean Difference (IV, Random, 95% CI)	Subtotals only
8.1 Short-term (up to 6 months)	1	41	Mean Difference (IV, Random, 95% CI)	5.0 [-4.86, 14.86]
9 Adverse effects	2		Mean Difference (IV, Random, 95% CI)	Subtotals only
9.1 Movement disorders: Parkinsonism- average endpoint score (SAS, high = worse)- short-term (up to 6 months)	1	16	Mean Difference (IV, Random, 95% CI)	-0.08 [-1.21, 1.05]
9.2 Non-movement disorder related side-effects: Weight gain- average endpoint score (BMI, lower=better)- short term (up to 6 months)	1	37	Mean Difference (IV, Random, 95% CI)	-1.0 [-3.99, 1.99]
10 Leaving study early: 1. Various reasons	3		Risk Ratio (M-H, Random, 95% CI)	Subtotals only
10.1 any reason, short term (up to 6 months)	2	77	Risk Ratio (M-H, Random, 95% CI)	0.68 [0.34, 1.35]
10.2 any reason, long term (> 12 months)	1	299	Risk Ratio (M-H, Random, 95% CI)	1.07 [0.94, 1.21]
10.3 readmission, short term (up to 6 months)	1	28	Risk Ratio (M-H, Random, 95% CI)	1.0 [0.07, 14.45]
10.4 intolerable adverse effects, short term (up to 6 months)	1	28	Risk Ratio (M-H, Random, 95% CI)	0.0 [0.0, 0.0]
10.5 participant loss of interest, short term (up to 6 months)	1	28	Risk Ratio (M-H, Random, 95% CI)	0.43 [0.14, 1.33]
11 Leaving study early: 2. Weeks in the study- average endpoint data (high=good), short term (up to 6 months)	1	28	Mean Difference (IV, Random, 95% CI)	0.0 [-3.35, 3.35]
12 Leaving study early: 3. Weeks in study- average endpoint data (high=good), short term (up to 6 months)- skewed data			Other data	No numeric data

Analysis 2.1. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 1 Mental state: 1. Specific: Depression- change scores (HAM-D, higher = better), short term (up to 6 months).



Analysis 2.2. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 2 Mental state: 2. Specific: Positive symptoms, total score- average endpoint scores (SADS-C-PD scale, lower=better), short term (up to 6 months).





Analysis 2.3. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 3 Mental state: 3. Specific: Positive symptom subscales- average endpoint scores (SADS-C-PD subscores, lower=better), short term (up to 6 months)- skewed data.

Mental state: 3. Specific: Positive symptom subscales- average endpoint scores (SADS-C-PD subscores, lower=better), short term (up to 6 months)- skewed data


Study	Intervention	Outcome (symp-tom subscore)	Mean	SD	N
Sevy 2011	Risperidone	Delusions	2.6	1.7	16
Sevy 2011	Olanzapine		2.7	1.6	21
Sevy 2011	Risperidone	Hallucinations	1.8	1.2	16
Sevy 2011	Olanzapine		2	1.6	21
Sevy 2011	Risperidone	Thought disorder	3.6	0.8	16
Sevy 2011	Olanzapine		4.5	2.6	21

Analysis 2.4. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 4 Mental state: 4. Specific: Negative symptoms, subscales- average endpoint scores (SANS subscales, lower=better), short term (up to 6 months).







Analysis 2.5. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 5 Substance use: 1. Reduction of cannabis use-change data (number of joints smoked/week, LOCF data, higher =better)- short term data (up to 6 months).




Analysis 2.6. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 6 Substance use: 2. Discontinued substance use, short term (up to 6 months).







Analysis 2.7. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 7 Craving for substances: 1. Obsessive Compulsive Drug Use Scale- average endpoint score (OCDUS, lower=better)-short term (up to 6 months).




Analysis 2.8. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 8 Craving for substances: 2. Desires for Drug Questionnaire- average endpoint scores (DDQ, LOCF data, lower=better), short term (up to 6 months).





Analysis 2.9. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 9 Adverse effects.






Analysis 2.10. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 10 Leaving study early: 1. Various reasons.





Analysis 2.11. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 11 Leaving study early: 2. Weeks in the study- average endpoint data (high=good), short term (up to 6 months).




Analysis 2.12. Comparison 2 RISPERIDONE versus OLANZAPINE, Outcome 12 Leaving study early: 3. Weeks in study- average endpoint data (high=good), short term (up to 6 months)- skewed data.

Leaving study early: 3. Weeks in study- average endpoint data (high=good), short term (up to 6 months)- skewed data					
Study	Intervention	Mean (number of weeks)	SD		N
Smelson 2006	Risperidone	207	142.9		76
Smelson 2006	Olanzapine	267.9	127.4		85

Comparison 3. RISPERIDONE versus PERPHENAZINE

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Leaving the study early: all cause discontinuation, long term (>12 months)	1	281	Risk Ratio (M-H, Random, 95% CI)	1.05 [0.92, 1.20]


Analysis 3.1. Comparison 3 RISPERIDONE versus PERPHENAZINE, Outcome 1 Leaving the study early: all cause discontinuation, long term (>12 months).



Comparison 4. RISPERIDONE versus QUETIAPINE

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Leaving the study early: all cause discontinuation, long term (>12 months)	1	294	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.86, 1.07]


Analysis 4.1. Comparison 4 RISPERIDONE versus QUETIAPINE, Outcome 1 Leaving the study early: all cause discontinuation, long term (>12 months).



Comparison 5. RISPERIDONE versus ZIPRASIDONE

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Leaving the study early: all cause discontinuation, long term (>12 months)	1	240	Risk Ratio (M-H, Random, 95% CI)	0.96 [0.85, 1.10]

Analysis 5.1. Comparison 5 RISPERIDONE versus ZIPRASIDONE, Outcome 1 Leaving the study early: all cause discontinuation, long term (>12 months).



ADDITIONAL TABLES

Table 1. Assessment of risk of bias

Sequence generation	<ul style="list-style-type: none"> • Low: investigators described a random component in the sequence generation process such as the use of random number table, coin tossing, cards or envelope shuffling etc. • High: investigators described a non-random component in the sequence generation process such as the use of odd or even date of birth, algorithm based on the day/date of birth, hospital or clinic record number. • Unclear: insufficient information to permit judgment of the sequence generation process.
Allocation concealment	<ul style="list-style-type: none"> • Low: participants and the investigators enrolling participants cannot foresee assignment, e.g. central allocation; or sequentially numbered, opaque, sealed envelopes. • High: participants and investigators enrolling participants can foresee upcoming assignment, e.g. an open random allocation schedule (e.g. a list of random numbers); or envelopes were unsealed or nonopaque or not sequentially numbered. • Unclear: insufficient information to permit judgment of the allocation concealment or the method not described.
Blinding of participants and personnel	<ul style="list-style-type: none"> • Low: blinding of the participants, key study personnel, and unlikely that the blinding could have been broken, or lack of blinding unlikely to introduce bias. No blinding in the situation where non-blinding is not likely to introduce bias. • High: no blinding, incomplete blinding and the outcome is likely to be influenced by lack of blinding. Blinding of participants and key study personnel attempted but likely that blinding could have been broken and the outcome is likely to be influenced by lack of blinding. • Unclear: insufficient information to permit judgment of 'low risk' or 'high risk', or otherwise the study did not address this outcome.
Blinding of outcome assessment	<ul style="list-style-type: none"> • Low: no blinding of the outcome assessment but the review authors judge that the outcome measurement is not likely to be influenced by lack of blinding, or blinding of outcome assessment ensured and unlikely that blinding could have been broken. • High: no blinding of outcome assessment and outcome measurement is likely to be influenced by lack of blinding, or blinding of outcome assessment but likely that blinding could have been broken and outcome measurement is likely to be influenced by lack of blinding. • Unclear: insufficient information to permit judgement of 'low risk' or 'high risk', or the study did not address this outcome.
Incomplete outcome data	<ul style="list-style-type: none"> • Low: no missing outcome data, reasons for missing outcome data unlikely to be related to true outcome, or missing outcome data balanced in number across groups. • High: reason for missing outcome data likely to be related to true outcome, with either imbalance in number across groups or reasons for missing data. • Unclear: insufficient reporting of attrition or exclusions.
Selective reporting	<ul style="list-style-type: none"> • Low: a protocol is available which clearly states the primary outcome as the same as in the final trial report. • High: the primary outcome differs between the protocol and final trial report. • Unclear: no trial protocol is available or there is insufficient reporting to determine if selective reporting is present.
Other forms of bias	<ul style="list-style-type: none"> • Low: there is no evidence of bias from other sources. • High: there is potential bias present from other sources (e.g. fraudulent activity, extreme baseline imbalance or bias related to specific study design). • Unclear: insufficient information to permit judgment of adequacy or otherwise of other forms of bias.

Table 2. Scales, diagnostic instruments and other outcome measures used in included studies

<i>Diagnostic tools</i>	Abbreviation	Source of scale/ instrument	Study using in- strument	Results reported or usable data for re-analysis/ quantitative synthesis or qualitative results/data only
Structured Clinical Interview for DSM Disorders	SCID-I	First 1994	Akerele 2007; Sevy 2011; Swartz 2008; van Nimwegen 2008	Not an outcome measure
Mental state scales				
Brief Psychiatric Rating Scale	BPRS	Lukoff 1986	Noordsy 2010	No results or usable data reported or obtained
Clinical Global Impression scale	CGI	Guy 1976	Akerele 2007; Noordsy 2010	No results or usable data reported or obtained
Hamilton Depression Rating Scale	HAM-D	Hamilton 1960	Akerele 2007	Results reported; usable data for quantitative synthesis
Positive and Negative Syndrome Scale	PANSS	Kay 1986	Akerele 2007; Greenspan 2005; Machielsen 2014; Swartz 2008	Results reported; usable data for quantitative synthesis
Schedule for Affective Disorders and Schizophrenia – Change Version with Psychosis and Disorganization items	SADS-C-PD	Endicott 1978	Sevy 2011	Results reported; usable data for quantitative synthesis
Schedule for the Assessment of Negative Symptoms	SANS	Andreasen 1982	Noordsy 2010	No results or usable data reported or obtained
Substance use scales				
Addiction Severity Index	ASI	McLellan 1980; McLellan 1992	Akerele 2007	No results or usable data reported or obtained
Composite International Diagnostic Interview	CIDI	Robins 1988	Machielsen 2014	Not an outcome measure
Substance Use Questionnaire	SUQ	Sevy 2011, Locally derived instrument/ non-validated	Sevy 2011	Results reported, used together with urine testing; usable data for quantitative synthesis
Time-Line Follow-Back	TLFB	Sobell 1992	Noordsy 2010	Results reported in dichotomised format for quantitative synthesis
Quantitative Substance Use Inventory		Locally derived instrument/ non-validated	Akerele 2007	Non-validated scale
Subjective-Wellbeing Scales				

Table 2. Scales, diagnostic instruments and other outcome measures used in included studies (Continued)

Subjective Well-being Under Neuroleptics Scale	SWN	de Haan 2002; Naber 1995	Machielsen 2014; van Nimwegen 2008	Results reported; usable data for quantitative synthesis
Craving for substances measures				
Cocaine Craving Report		Weddington 1990	Akerele 2007	No usable data for quantitative synthesis
Desires for Drug Questionnaire	DDQ	Franken 2002	van Nimwegen 2008	Results reported; usable data for quantitative synthesis
Marijuana Craving Report		Weddington 1990	Akerele 2007	No usable data for quantitative synthesis
Marijuana Craving Questionnaire	MCQ	Heishman 2009	Machielsen 2014	Results reported; usable data for quantitative synthesis
Obsessive Compulsive Drug Use Scale	OCDUS	Dekker 2012	Machielsen 2014;van Nimwegen 2008	Results reported; usable data for quantitative synthesis
Adverse effect scales				
Abnormal Involuntary Movement Scale	AIMS	National Institute of Mental Health 1988	Akerele 2007	No results or usable data reported or obtained
Barnes Akathisia Rating Scale	BARS	Barnes 1989	Brunette 2011	No results or usable data reported or obtained
Simpson Angus Scale	SAS	Simpson 1970	Akerele 2007	Results reported; usable data for quantitative synthesis
Other measures (categorical or time to event)				
Urine assay for cannabis and cocaine use (proportion of treatment group positive per week)			Akerele 2007	No usable data for quantitative synthesis
Number of participants with improvement in substance use (categorised as improved or not-improved versus unchanged)			Noordsy 2010	Results reported; usable data for quantitative synthesis (dichotomised)
Days of self-reported drug use in past week			Akerele 2007	No usable data for quantitative synthesis
Weeks in treatment			Akerele 2007; Smelson 2006	Results reported; usable data for quantitative synthesis
Number of participants not completing the study			Akerele 2007; Machielsen 2014; Noordsy	Results reported, usable data for quantitative synthesis

Table 2. Scales, diagnostic instruments and other outcome measures used in included studies (Continued)

 2010; Sevy 2011;
 Swartz 2008

Compliance with medication (missed doses)	Akerele 2007	No usable data for quantitative synthesis
---	--------------	---

Table 3. Excluded randomised and quasi randomised studies and their relevant comparisons

Study tag	Participants			Comparison	Relevant review
	Primary problem	Co-morbidity	Note (reasons for exclusion)		
Blin 1996	schizophrenia	Excludes participants with alcohol or drug abuse in past year	Excludes comorbidity	risperidone, haloperidol, methotrimeprazine	-
Gaebel 2010	schizophrenia, schizoaffective disorder	Excludes participants with alcohol or drug abuse in past year	Excludes comorbidity	risperidone, olanzapine, conventional antipsychotics vs. risperidone long-acting injectable (RLAI), or quetiapine	-
Green 2001	schizophrenia	cannabis use disorder	Excluded as this was a study protocol, authors contacted for unpublished data, no response	risperidone vs. clozapine	-
Harvey 2007	bipolar type I disorder	No measure of substance use	Excludes comorbidity	risperidone, quetiapine	-
Ikuta 2014	schizophrenia, schizophreniform, psychosis not otherwise specified	No measure of substance use	Excludes comorbidity	risperidone, aripiprazole	-
Kerfoot 2011	schizophrenia	Co-occurring substance use in subgroup of 44.9%	No comparison of study medication, mainly a prognostic study of the impact of substance use	risperidone, quetiapine, perphenazine, olanzapine, ziprasidone	-
Liemburg 2011	schizophrenia	No measure of substance use	Excludes comorbidity	risperidone, aripiprazole	-
Liu 2008	mental disorders due to alcohol use	substance induced mental disorders	Exclusion criterion	risperidone, olanzapine	Suggested review: risperidone versus other antipsychotics for substance induced psychosis

Table 3. Excluded randomised and quasi randomised studies and their relevant comparisons (Continued)

NCT00063349	schizophrenia	Co-occurring cannabis use disorder	Study protocol, authors contacted for unpublished data no response	risperidone, clozapine	
NCT00130923	schizophrenia, schizoaffective disorder	Co-occurring alcohol use disorder (abuse or dependence)	Comparison of same medication (risperidone) in different preparations (oral vs depot)	oral risperidone, depot risperidone	-
NCT00169026	schizophrenia, schizoaffective disorder	Co-occurring alcohol and substance use disorder	Study protocol, study terminated, authors contacted for unpublished data no response	clozapine, conventional antipsychotics, atypical antipsychotics	-
NCT00498550	schizophrenia, schizoaffective disorder	Co-occurring cannabis use disorder	Study protocol, authors contacted no data provided	clozapine, conventional antipsychotics, atypical antipsychotics	-
Nejtek 2008	bipolar I and II disorder, recent manic or mixed episode with or without psychosis	co-occurring cocaine or methamphetamine use disorder	Only 8.3% of total sample had psychotic features and 15.9% had bipolar type II disorder.	risperidone, quetiapine	Suggested review: Risperidone versus other antipsychotics in bipolar disorder with co-occurring substance use disorders
Perlis 2006	bipolar I disorder with mania or mixed states	Excludes participants with recent substance use	Excludes comorbidity. Excludes bipolar disorder with psychotic features.	risperidone or olanzapine	-
Rezayat 2014	bipolar disorder, acute mania	Excludes participants with drug or alcohol use in past 3 months	Excludes comorbidity	aripiprazole, risperidone	-
Rubio 2006a	schizophrenia	Co-occurring substance use disorders	Quasi-randomisation	risperidone long-acting depot, zuclopendthixol long-acting depot	-
Rubio 2006b	schizophrenia	Co-occurring substance use disorders	Quasi-randomisation	risperidone (oral), zuclopendthixol (oral), zuclopendthixol long acting depot	-
Sachs 2002	bipolar with current manic or mixed episode	Study excludes participants with drug or alcohol in past 1 months	Excludes comorbidity	mood stabiliser augmentation with risperidone, haloperidol or placebo	-

Table 3. Excluded randomised and quasi randomised studies and their relevant comparisons (Continued)

Sajatovic 2002	psychotic disorders: schizoaffective disorder, bipolar I disorder, major depressive disorder, delusional disorder, Alzheimer's dementia, schizophreniform disorder, vascular dementia, and substance abuse dementia	No subgroups with substance use reported	Excludes comorbidity. Authors contacted for unpublished data, no response.	risperidone, quetiapine	-
Smulevich 2005	bipolar I disorder	Excludes participants with recent substance use	Excludes comorbidity	haloperidol, risperidone, placebo	-
van Nimwegen 2008a	schizophrenia, schizophreniform, schizoaffective disorder	No measure of substance use	Excludes comorbidity	haloperidol, risperidone, placebo	-
Yatham 2007	bipolar I and II	Excludes participants with drug or alcohol use in past 3 months.	Excludes comorbidity	continuation of oral risperidone, olanzapine, quetiapine or switch to long-acting injectable LAI risperidone	-
Zhangyue 2005	schizophrenia or schizophrenia-like illnesses	Excludes participants with alcohol or substance dependence	Quasi-randomisation. Excludes comorbidity.	aripiprazole versus risperidone	-

Table 4. Suggested design for future trial

Methods	Allocation: centralised sequence generation with table of random numbers or computer-generated code, stratified by severity of illness, sequence concealed till interventions assigned. Blinding: could be optional, depending on choice of outcome. Duration: 12 months.
Participants	Diagnosis: schizophrenia and co-occurring ongoing substance misuse (clinical criteria). N = 300*. Age: adults. Sex: men and women. Setting: any.
Interventions	1. Risperidone: clinically indicated dose. N = 150. 2. Olanzapine: clinically indicated dose. N = 150.
Outcomes	Global state: CGI-I and CGI-S. Substance use: pragmatic binary/continuous measure. Well-being: pragmatic binary/continuous measure.

Table 4. Suggested design for future trial (Continued)

	Craving: pragmatic binary/continuous measure. Service outcomes: re-hospitalisation, days in hospital, time attending psychiatric outpatient clinic. Quality of life: important change. Adverse effects: including mortality, weight change and extrapyramidal symptoms. Satisfaction with care: patients/carers. Leaving the study early. Economic data. Other routine data, such as incidents with the police,
Notes	* size of study to detect a 10% difference in improvement with 80% certainty. For all outcomes there should be binary cut-off points of clinically important improvement, defined before the study starts.

APPENDICES

Appendix 1. Previous Searches

1.1 Search in 2014

1.1.1 Electronic searches

On April 25, 2014, we searched the Cochrane Schizophrenia Review Group's Register with the phrase: "[(*rispe* or *9-OH-risperid* or *r 64766* in abstract, index terms of REFERENCE] or [*rispe* in interventions of STUDY] AND [(polydrug* or *substanc* or *alcoh* or *tranquiliz* or *narcot* or *abus* or *opiat* or *street drug* or *intoxi*) in REFERENCE) and (substance abus* or drug abus* or *alcohol* or dual* and diagnos*) in STUDY]"

The Schizophrenia Review Group's trials register is based on regular searches of: BIOSIS Inside; CENTRAL; CINAHL; EMBASE; MEDLINE and PsycINFO; the hand searching of relevant journals and conference proceedings; and searches of several key grey literature sources. A full description is given in the [Group's module](#).

1.1.2 Searching other resources

1.1.2.1 Reference searching

We inspected reference lists of all included studies for further relevant studies.

1.1.2.2 Personal contact

We contacted the first author of each included study for information regarding unpublished trials. In addition we contacted pharmaceutical companies regarding unpublished trials.

WHAT'S NEW

Date	Event	Description
6 February 2018	Amended	Addition of affiliations for review author Nandi Siegfried.

CONTRIBUTIONS OF AUTHORS

Henk Temmingh: protocol development, searching, study selection, data extraction, data analysis, report writing.

Taryn Williams: protocol development, study selection, data extraction, comments and editing of final report.

Nandi Siegfried: protocol development, study selection, data extraction, comments and editing of final report.

Dan Stein: protocol development, comments and editing of final report.

DECLARATIONS OF INTEREST

Henk Temmingh has received a speaker honorarium from Pharma Dynamics and was a recipient of the Harry Crossley Clinical Fellowship that provided support for travel and subsistence during his sabbatical.

Taryn Williams has no known conflicts of interest outside her employment by the MRC Unit on Anxiety and Stress Disorders.

Nandi Siegfried provides technical consultation on the efficacy of drugs at the request of a managed care organization, and receives an honorarium. Nandi has not appraised risperidone in this work.

Dan Stein has received research grants or consultancy honoraria (or both) from AstraZeneca, Eli Lilly, GlaxoSmithKline, Lundbeck, Orion, Pfizer, Pharmacia, Roche, Servier, Solvay, Sumitomo, and Wyeth.

SOURCES OF SUPPORT

Internal sources

- South African Cochrane Centre, South Africa.

For their assistance and support during the protocol development

- Department of Psychiatry and Mental Health, University of Cape Town, South Africa.

Dr Temmingh is a lecturer on joint University of Cape Town and Western Cape Department of Health conditions of employment. Dr Siegfried, Dr Amos and professor Stein are supported by the Department of Psychiatry and Mental Health, University of Cape Town.

- Western Cape Department of Health, Valkenberg hospital, Cape Town, South Africa.

Dr Temmingh is on joint University of Cape Town and Department of Health conditions of employment and is salaried by the Western Cape Department of Health

- Harry Crossley Foundation, South Africa.

Dr Temmingh is the recipient of the 2013 Harry Crossley Senior Clinical Research Fellowship. He received support from this fellowship for travel and subsistence during his sabbatical leave.

- Goldman Trust, South Africa.

Dr Temmingh received a travel grant to attend the Cochrane workshop at the London School of Hygiene and Tropical medicine in 2011

External sources

- No sources of support supplied

DIFFERENCES BETWEEN PROTOCOL AND REVIEW

The search revealed very few studies that met inclusion criteria as per the original protocol. This was due to the original protocol requiring that all participants randomised had to have both a severe mental illness and a substance use disorder and that the primary pre-specified study aims should be to examine the efficacy of risperidone against a comparator drug. Studies that included subgroup and post hoc, secondary data analyses were also excluded.

Our original protocol followed this approach due to a concern that amongst studies that randomised mixed populations (single and dual diagnosis patients), the analysis of a subgroup with particular characteristics may lead to the selection of participants with certain prognostic features that could potentially effectively undo the effect of balancing prognostic factors between the intervention groups during randomisation. This may be of particular concern where allocation concealment was not ensured, leading to selection bias in the allocation of interventions where some participants but not others were using substances.

In the case of subgroup analysis in individual studies or secondary data analysis of subgroups in existing trials, we initially aimed to exclude all such studies as secondary analyses may have potentially been motivated by data-driven post hoc hypothesis testing of non-prespecified subgroups, leading to potentially spurious results, effectively selecting groups with specific prognostic features, interfering with randomisation and rendering such studies observational in nature (Sun 2014; Wang 2007).

Therefore, due to the paucity of studies in this area and because the implications of including such studies in reviews have not been empirically tested (it could be argued that randomisation still applies to participants in studies using subgroups and secondary analyses), we decided to include studies with a mixed population and subgroup and secondary analyses using a set of modified inclusion criteria.

1. To include RCTs reporting on outcomes where 100% of participants have BOTH a severe mental illness AND co-occurring substance use disorder.
2. For studies that specifically examined the efficacy of risperidone in dual diagnosis, but that included mixed populations in randomisation: to include RCTs where $\geq 70\%$ of participants had BOTH a severe mental illness AND co-occurring substance use disorder. For these studies we used data from all participants as if they had a dual diagnosis.
3. In those RCTs where outcomes are reported for sub-groups (i.e. secondary data analyses of existing data) with both severe mental illness and co-occurring substance use, we reported on these and added only the relevant sub-group into the meta-analysis if possible.

In addition we will note the following.

1. In case RCTs randomising mixed populations, we highlighted whether such studies reported adequate allocation concealment procedures.
2. For secondary and subgroup analyses, we systematically recorded whether participants were randomised to risperidone or comparator following stratification into groups with and without co-occurring substance use disorder either in the study or parent study.
3. In case of studies conducting subgroup analyses or secondary data analyses of subgroups, we recorded whether this analysis was pre-specified in the original study protocol, and if not, rated these studies at potential high risk of selective outcome reporting by virtue of their design.

For data extraction of studies of mixed populations and subgroups or secondary analysis of subgroups, we extracted categorical or continuous data at study endpoint or change data within subgroups for risperidone and comparator drugs.

Should meta-analyses have been possible, we would have examined the impact of excluding "lower quality studies" from the analysis.

Other minor changes

One minor change was the inclusion of one study that included a few participants younger than 18 years (age inclusion criteria 17 to 45 years).

We also included participants if they happened to be smokers, despite the protocol stating we would exclude nicotine dependence. We did, however, exclude studies where the substance use disorder under study was nicotine dependence or where investigators looked at the impact of antipsychotic treatments on smoking in particular.

As the review yielded only few studies with even lower numbers of studies providing data for different outcomes we were unable to conduct any planned funnel plots to detect publication bias, subgroup analyses, or sensitivity analyses.

Cochrane guidelines now recommend fewer primary outcomes and at least one primary outcome to be an adverse effect. We specified fewer mental state outcomes as primary outcomes and added incidence of adverse effect to be a primary outcome. We have reworded outcomes such as 'significant improvement' or 'significant response' to current wording of 'clinically important change'. The types of outcome specified as important have not changed.

INDEX TERMS

Medical Subject Headings (MeSH)

Antipsychotic Agents [*therapeutic use]; Benzodiazepines [therapeutic use]; Clozapine [therapeutic use]; Diagnosis, Dual (Psychiatry); Mental Disorders [*drug therapy]; Olanzapine; Patient Dropouts [statistics & numerical data]; Perphenazine [therapeutic use]; Piperazines [therapeutic use]; Quetiapine Fumarate [therapeutic use]; Randomized Controlled Trials as Topic; Risperidone [*therapeutic use]; Schizophrenia [drug therapy]; Substance-Related Disorders [*drug therapy] [psychology]; Thiazoles [therapeutic use]

MeSH check words

Humans